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Abstract 
VARIATION AND MODULATION OF MICRORNAS IN PROSTATE CANCER AND 
BIOLOGICAL FLUIDS  
By Sarah Joy Seashols, Ph.D. 
A dissertation) submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy in Biochemistry at Virginia Commonwealth University. 
Virginia Commonwealth University, 2013 
Major Director: Zendra Elizabeth Zehner, PhD.  Professor, Department of Biochemistry 
& Molecular Biology 
   
Prostate cancer is the second-most diagnosed and fatal carcinoma for males in 
the United States, and better diagnostic markers and potential therapies are needed.  
microRNAs are small, single-stranded RNA molecules that affect protein expression at 
the translational level, and dysregulation can dramatically affect cell metabolism.  
Comparison of 736 microRNA expression levels between the poorly metastatic SV40T 
immortalized prostate epithelial cell line P69 to its highly tumorigenic and metastatic 
subline M12 identified 231 miRs that were overexpressed and 150 miRs that showed 
loss of expression in the M12 cell line.  Further evaluation of fourteen identified miRs 
was accomplished using other prostate cell lines as well as laser-capture 
microdissected prostate samples.  Inhibition of miR-147b was found to affect 
proliferative, migratory and invasive capabilities of M12 cells, and reduced tumour 
xxv 
 
 
 
growth in nude athymic mice.  AATF, an activator of the cell-cycle inhibitor p21, was 
identified as a target.  Overexpression of miR-9 was found to affect the epithelial to 
mesenchymal transition through suppression of e-cadherin, a protein characterized as 
lost in EMT, as well as suppression of SOCS5, an attenuator of JAK-STAT signaling.  
Inhibition of miR-9 resulted in reduction of migratory and invasive potential, and 
significant reduction of tumorigenesis and metastases in male nude athymic mice.   
miR-17-3p was previously identified as down-regulated in prostate cancer and 
loss of miR-17-3p shown to cause vimentin transcriptional activation.  Reverse phase 
microarray analysis (RPMA) identified c-KIT as a potential second mRNA target for 
miR-17-3p.  miR-17-3p was shown to modulate not only protein levels, but also 
messenger RNA levels of c-KIT.  Four miR-17-3p binding sites in the c-KIT mRNA were 
identified.  Thus, a number of microRNAs involved in prostate cancer were identified, 
and their targets found to be highly relevant to tumour progression and could potentially 
be used as targets for therapy or diagnostics. 
Stability of microRNAs in forensically relevant biological fluids was evaluated 
through heat treatment, ultraviolet radiation, and chemical treatment.  The dried body 
fluids showed some susceptibility to harsh treatment, but in most cases microRNAs 
were still detectable in the samples.  microRNAs could represent a highly stable species 
for body fluid identification methods in forensic science. 
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I. The prostate and incidence of cancer 
 The prostate is an exocrine organ located at the bladder-urethral junction that 
serves to secrete an alkaline fluid that makes up 50-70% of seminal fluid.  This fluid is 
composed of nutrients and other compounds that facilitate spermatozoa activation, 
survival and genomic integrity1.  As a ductal gland, the prostate consists of multiple 
lobes in which epithelial cells secrete their expressed products into glandular lumens, 
and are compressed by the pelvic floor muscles during ejaculation to secrete the 
prostatic fluid along with spermatozoa stored in the ejaculatory ducts into the urethra. 
 Prostate cancer (CaP) is the most common cancer for men in the United States 
other than skin cancer, and the second leading cause of cancer deaths in the US, with 
over 29,000 fatalities each year2.  While two-thirds of the prostate cancers diagnosed 
are indolent, wherein the tumour grows so slowly that the diagnosed male will likely die 
of other causes before the carcinoma develops to a dangerous level, the other one-third 
of diagnosed prostatic neoplasias are highly aggressive and metastasize readily to bone 
and brain3,4. 
Diagnosis of Prostate Cancer 
 The current standard for diagnosis of a potential prostate cancer diagnosis is use 
of the prostate-specific antigen (PSA) test as a screening test, followed by manual 
examination and ultrasound-guided transrectal biopsy5.  PSA is a protein that is 
produced in the prostate, and is normally found in high levels in seminal fluid, with lower 
levels in male urine, and also in ultra-low levels in breastmilk, amniotic fluid, 
cerebrospinal fluid, and other minor fluids6.  Identification of PSA in the bloodstream has 
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been shown to be indicative of abnormal prostate growth2,3,6-8.  Mechanistically, PSA 
leaks into the bloodstream as the tumour both increases PSA production, and perturbs 
the glandular form of the prostate, resulting in leakage of the overexpressed PSA into 
the bloodstream9.   
 Before the implementation of PSA testing in the US in 1979, prostate cancer 
diagnosis was made via a prostate examination only.  Diagnosis using physical 
examination often was only positive after the tumour was well-advanced, and thus 
prostate cancer was often progressed to the point that chemotherapeutics were not 
significantly effective.  PSA level analysis was first used for monitoring therapeutic 
outcomes10.  However, further research showed that it could also be used for diagnosis, 
and upon implementation of PSA screening, death rates for prostate cancer have 
dropped 4% per year.   
 A blood PSA level of 4.0 ng/mL is considered to be abnormal in the United 
States.  PSA screening is not recommended for men of limited life expectancy, which is 
typically classified as men 75 years or older, due to the nature of the very common 
indolent form of prostate cancer8.  In a 5-year DOD study, of 295,645 men included in 
the analysis, 8.5% of the men evaluated had an abnormally high PSA level.  Of the 67% 
who did not have a biopsy, 0.1% died of prostate cancer.  Of the 33% that had a biopsy 
performed, 5220 (62.8%) were diagnosed with high-risk prostate cancer and were 
treated.  3.5% of the 1161 diagnosed with low-risk CaP died from prostate cancer, an 
average death rate for cohorts with or without treatment8.  Thus, this and multiple 
additional studies have shown that the intervention rate is well above that which is 
necessary4.   
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 Interventions tend to have drastic consequences for the diagnosed male; radical 
prostatectomies, cryosurgery, and androgen ablation therapy significantly affect patient 
quality of life through high levels of incontinence, psychological, and sexual side 
effects3.  Thus, the identification of new screening practices is critical to diagnosing not 
only prostate cancer, but also differentiating between the aggressive and indolent forms 
of the disease.   
Transmission of genetic predisposition for prostate cancer 
 While high incidences of prostate cancer are common in those of Northern 
European and African American descent, native Africans do not suffer such high 
incidences, although it could also be underestimated due to lack of surveillance7.  
Additional evidence indicates that the susceptibility is Northern European in origin, 
specifically of Swedish and/or Scandinavian origin, and follows the historical migration 
routes of the Scandinavian people, with a higher incidence on the coasts of continents.  
The high incidence seen in African Americans as compared to their native African 
counterparts is most likely due to low levels of Northern European inter-breeding7, but 
diet could also have an additive effect11.  Likewise, men of Asian descent do not 
develop malignancies at high rates7. 
 As may be expected from the observed ethnic disparities, monozygotic twin 
studies have shown that inheritance of the predisposition for prostate cancer is real12.  
Additionally, evaluation of paternal and maternal histories show similar inheritance 
patterns, which indicates autosomal transmission4,13,14.  Recent genome-wide 
association studies (GWAS) have identified forty-six SNPs that show enhanced 
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susceptibility to CaP; studies are currently underway to evaluate both diagnostic 
possibilities as well as treatment protocols based on those loci13.   
Prostate Cancer tumorigenesis & histopathology 
 Protate cancer, like breast cancer, is the tumorigenesis of a glandular tissue.  As 
such, the carcinoma begins in the ducts of the gland, with small lesions gradually 
building up over time and collecting additional mutations that allow the tumour to 
progress to the invasive stage.  At this point, the neoplastic cells are able to disrupt the 
periglandular basement membrane and migrate into the surrounding stromal tissue15. 
Tumour progression is scored using the Gleason scoring model, wherein the average 
and maximum observed tumour grade are evaluated by a pathologist (Figure 1-1)16. 
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Figure 1-1:  Schematic diagram of histological progression of Prostate Cancer 
using Gleason scoring.  In the progression of CaP, (GS-1) normal prostate epithelium 
begins to become hyperplastic (GS-2), and progression into a tumour with smooth 
round edges (GS-3).  As the tumour becomes invasive, the edges of the tumour 
becomes ragged and glandular fusion is observed (GS-4).  A GS-5 score is made when 
the tumour has progressed to the point that the tumour core has necrosed, due to the 
need for oxygen and blood flow (Adapted from Epstein et al.16). 
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Treatment of Prostate Cancer 
 Treatment of newly diagnosed prostate cancer typically involves a multi-modal 
approach.  Tumour removal can be accomplished through radical prostatectomy or 
cryosurgery, which entails laparoscopic liquid nitrogen ablation of tumour cells.  When 
necessary, pelvic lymphadenectomy is performed as well to determine the invasiveness 
of the carcinoma.  Surgical removal is then usually followed by radiation therapy using 
external beam therapy, brachytherapy, and/or proton beam therapy.  Traditional 
chemotherapeutics and diet modification are also commonly implemented3.
 Treatment of early prostate cancer also typically involves attacking the hormone-
dependent nature of the early tumour.  As it is androgen-dependent for growth, early 
success in tumour treatment typically involves hormonal ablatement through the use of 
androgen chelating agents, or even as extreme as surgical castration3,8.  However, this 
treatment is only effective in the short-term, as the neoplasias that survive then become 
hormone-independent, and can metastasize readily throughout the body.  At that point, 
treatment options are limited, and the cancer is usually terminal.  Prostate cancer cells 
exhibiting androgen insensitivity still have active androgen receptor (AR) pathways.  
Thus, recent work has shown that androgen-independence of the tumour cell has been 
shown to be not so much “independence” of androgens per se, but a bypass of the 
need for external androgen activation of those same pathways17-19. 
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II. Tumour progression through the epithelial to mesenchymal transition, 
angiogenesis, and metastasis 
 All epithelial tumours that eventually metastasize go through the epithelial to 
mesenchymal transition (EMT), wherein the cells develop a phenotype that is no longer 
polar, stationary and adherent, and assume a mesenchymal phenotype, which is motile.  
This change allows for invasion through the basement membrane into the lymphatic 
system, and eventually the bloodstream.  The circulating tumour cells can then exit the 
bloodstream, and undergo the reverse phenomenon, mesenchymal to epithelial 
transition (MET), for clonal growth at the metastatic site9.  The EMT transition is marked 
by changes in cytoskeletal protein expression and matrix metalloproteinase induction. 
Changes in cytoskeletal protein expression 
 Changes in cytoskeleton protein expression are required for EMT, and 
canonically used as a marker of the EMT state of the cancer cell.  The early tumour 
epithelial cell must suppress e-cadherin and develop a concomitant increase in vimentin 
expression.  E-cadherin is a transmembrane adherens protein that anchors epithelial 
cells to each other in a calcium-dependent manner, and ultimately through interaction 
cytoplasmically with β-catenin, to the actin cytoskeleton20-22.  Loss of e-cadherin results 
in dissociation from the epithelial sheet, and allows for extravasation through the 
basement membrane.  Likewise, increased expression of vimentin, an intermediate 
filament protein that imparts stability to the motile cell, is a canonical marker of the 
mesenchymal cell and has been shown to be expressed in poorly differentiated prostate 
cancer tumours23-25.  Additionally, siRNA inhibition of vimentin expression has been 
shown to significantly impact motility of PC-3 prostate cancer cells, although the 
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complete mechanism is unknown26.  Matrix metalloproteinase enzymes are shown to 
cleave the cadherins (E-, N-, and P-), contributing to release of cell-cell contact, 
increased cell migration, and loss of epithelial cell polarization27-29. 
Angiogenesis of the prostate tumour 
 A microtumour can develop to the size of 2-3 mm with no requirement for 
angiogenesis, as that is the diffusion limit of oxygen and nutrients from surrounding 
capillaries.  As the tumour grows larger, the core of the tumour necroses (Figure 1-1), 
and the surrounding tumour cells adapt to induce angiogenesis.  Key proteins induced 
in the angiogenic process include vascular endothelial growth factor (VEGF), epidermal 
growth factor (EGF), platelet derived growth factor (PDGF), and tumor necrosis factor 
alpha (TNF-α) (reviewed in Amankwah et al.30), all of which act to stimulate the 
proliferation and migration of endothelial cells in microvasculature formation31.   
Metastases in Prostate Cancer 
 Metastases in CaP typically travel through the lympathic system first to lymph 
nodes, then move into the bloodstream and home to bone and brain.  Bone metastases 
commonly occur in the vertebrae, sternum, pelvic bone, ribs, and femurs32.  During the 
malignant transformation of prostate cells to metastatic neoplasias, it has been 
commonly observed that the cells switch from an epithelial to a osteomimetic, or bone-
like expression, with initiated expression of bone matrix noncollagenous proteins such 
as osteopontin (OPN), Osteocalcin (OC), and bone sialoproetin (BSP).  These proteins 
are essential in that OPN assists in osteoclast adhesion, BSP stimulates osteoblast 
differentiation, and OC is secreted as a chemoattractant for osteoclast remodeling.  This 
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change in expression has been postulated to allow for integration of the neoplasia into 
the bone.   
III. microRNAs and their role in cancer progression 
 microRNAs are a class of small RNAs that were described in C. Elegans in 
199333, and have since emerged as major regulators of protein levels through 
attenuation of translation at the ribosome34-37.  microRNAs, or miRs, are 19-22 
nucleotide single-stranded RNA sequences that are guided by a protein complex to their 
mRNA targets, typically in the 3’-UTR of the mRNA.  miRs are present in all animals 
and plants, as well as chromalveolata, slime molds, viruses, and yeast38,39.  Over 2578 
mature microRNAs have been described in humans40,41.   microRNA genes are found 
throughout the genome, and can be alone, part of another gene within or without exonic 
regions, or in a multicistron of multiple microRNAs in tandem.   
miR transcription and processing 
 microRNA transcription is often driven by standard transcription factor activation, 
including c-Myc, Sp1, Ets-1, STAT1α, and NF-kB42-44, and most miRs are transcribed by 
RNA Polymerase II45.  The immature microRNA anneals onto itself in the form of a 
hairpin loop, whether transcribed solo, within a gene, or in a polycistron.  The hairpin 
loop is cleaved from the surrounding message within the nucleus by the RNase III 
enzyme Drosha microprocessor complex, which requires the DGCR8 protein as a 
cofactor46-48.  The resultant 65-100 nt hairpin pre-miRNA is then exported from the 
nucleus via Exportin V, which recognizes the double-stranded stem and short single-  
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Figure 1-2:  Biogenesis of microRNAs.  The microRNA is transcribed by Pol II, and 
the pre-miRNA is excised from the transcript by Drosha.  Export from the nucleus is 
active and assisted by Exportin V, and upon exit into the cytoplasm, the pre-miRNA is 
bound and cleaved into the mature single-stranded form by the DICER complex.  The 
RISC complex then guides the mature miR to its target mRNA for translational 
suppression and cleavage in some cases.  (Adapted from Davis-Dusenbery et al.46) 
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stranded overhang created by Drosha cleavage49,50, and further processed into a 
mature, 19-21 nucleotide single strand in one of two ways (Figure 1-2).  Typical 
processing occurs by Dicer, an RNase type III protein, along with its cofactors, but in 
some cases, Argonaute 2 (Ago2) itself has been shown to perform cleavage without 
need for Dicer46,51.  At this point, the selected strand of the pre-miR hairpin is retained in 
the RNA-Induced Silencing Complex (RISC) and the passenger strand is ejected from 
the complex.  Both strands of the immature microRNA can be active in mRNA 
translation suppression.  Strand selection of the Ago protein that receives the mature 
miR has not yet been resolved, although it appears that while some miRs can be 
processed and used for repression using all Ago proteins, some miRs are Ago-specific 
51. 
 The RISC is a complex that is primarily composed of Argonaute, an RNA-binding 
protein, along with the mature miR strand and several co-factor proteins50,52,53.There are 
four Argonaute proteins that are capable of forming the RISC and interacting with 
microRNAs for translational repression of targets.    
mIR action 
 The RISC enfolds around the mature microRNA such that the single-stranded 
RNA is bound within the protein, with both 5’ and 3’ ends protected from RNase 
degradation, and nucleobases 2-9 on the 5’-end of the miR in optimal position for 
binding to complementary sequences54. The RISC complex then travels along the 
mRNA, the miR binds to the complementary portion, and this  
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Figure 1-3:  Mechanism of action on mRNA targets of the microRNA-RISC 
complex.  Most microRNA binding events result in binding to the mRNA target and 
translational suppression.  However, in the presence of Argonaute 2, which has been 
shown to have Slicer activity, a perfect seed-region match (nt 2-9 of the mature 
microRNA) to a complementary sequence of the mRNA results in message cleavage 
and subsequent degradation. 
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binding can cause translational repression, or when the seed-mRNA match is exact and 
Ago2 is present, cleavage of the mRNA and subsequent degradation34,51,55 (Figure 1-3). 
Secreted miRs 
 microRNAs can be secreted from the cell for signaling in a paracrine, endocrine 
or autocrine manner.  microRNAs can be bound in microvesicles, in protein complexes, 
or encapsulated in HDL particles in association with ApoB56-59.  The miRs present in 
vesicles appear to be miRs secreted for a purpose such as communication, as the 
relative abundance levels of miRs found in exosomes of a particular cell type are not 
representative of the miR abundance levels found in those cells59.  Indeed, cell-cell 
communication and resultant changes in protein expression of receiving cells have been 
shown in recent reports44. 
 microRNAs that have been shown to be found in vesicles fuse with the plasma 
membrane through the multivesicular bodies (MVBs).  They display the same general 
characteristics observed in other secreted vesicles, with similar size and shape, as well 
as the presence of CD63 antigens when secreted by dendritic, B and T cells59.  miRs 
contained in vesicles and released into the extracellular environment have been shown 
to be resistant to RNase as well as trypsin, indicating that the miRs are neither free-
floating in media, nor anchored on the outside of the vesicle.59  miRs have also been 
found to be protected from RNase digestion while associated with free protein 
complexes, including nucleophosmin 1 (NPM1)57. 
miRs as tumour suppressors and oncomiRs 
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microRNAs can bind either perfectly or imperfectly to an mRNA target, thus 
making it possible for one miR to attenuate the translation of tens to hundreds of 
different targets.  Additionally, miRs have been shown to impact all aspects of the 
proteome, from cell proliferation and apoptosis to mitochondrial and metabolic 
processes, to cytoskeleton and secreted products.  Thus, microRNAs have recently 
been subject to intense scrutiny as modulators of protein levels in cancer, as they are 
increasingly being shown to influence carcinogenesis and tumour progression.  Since 
the target protein level has an inverse relationship to its regulating microRNA, an 
overexpressed microRNA is known as an oncomiR, and causes excessive suppression 
of its tumour suppressor target mRNA.  A tumour suppressor microRNA is one that has 
reduced or lost expression, and thus an oncogene that it should regulate is translated 
and expressed in an unchecked manner. 
IV. The laboratory’s research objectives and models in use 
 The objective of our laboratory’s research is to identify potential biomarkers or 
therapeutic targets for prostate cancer.  We use a combination of in-vitro, in-vivo, and 
human prostate cancer samples for validation and verification of our findings. 
 The P69 cell line is the foundation for a unique progression model for prostate 
cancer. The cell line was created from human non-neoplastic prostate epithelial cells 
isolated from a transurethral resection of a 63-year old African American male.  The 
cells were isolated from the extracellular matrix using collagenase and then 
immortalized by transfection with the SV40 large T antigen gene60.  They retain 
epithelial, and specifically basal epithelial cytokeratin markers60 (basal identification 
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unpublished data from ZEZ), and are poorly tumorigenic (2/18 mice injected 
subcutaneously developed tumours after a long latent period, no metastases). 
 Metastatic sublines were created by injecting P69 cells subcutaneously into nude 
athymic mice. Tumours that developed were excised, analyzed for histopathological 
origin, and placed into culture.  They were then grown up and subsequently injected 
subcutaneously into additional nude athymic mice.  This cycle was repeated two 
additional times.  Each successive injection resulted in faster and more frequent 
tumorigenesis61,62.  The M2182 cell line was derived from a tumour derived from the 
second series of injections, and the M12 cell line, a highly tumorigenic, highly metastatic 
cell line63, was derived from the tumour excised from a mouse from the third series of 
injections.  The M12 cell line produces metastases in lung and diaphragm when injected 
subcutaneously, intraperitoneally, and intraprostatically60.  Thus, the P69, M2182, and 
M12 cell lines represent a progressively tumorigenic model of prostate cancer (Figure 1-
4). 
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Figure 1-4:  Generation of metastatic sublines from the poorly tumorigenic normal 
prostate epithelial SV40T immortalized P69 cell line.  Injection of P69 cells resulted 
in tumours in only 2 of 18 mice after a long latent period.  An excised tumour was then 
placed into culture, and the subsequent cells injected into a second nude athymic mice.  
This process was repeated one more time, resulting in the highly metastatic and 
tumorigenic M12 cell line, which develops tumours in 100% of mice within 12 days, and 
produces metastatic sites in the diaphragm and lung. 
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 Cytogenetic analysis of the M12 cell line revealed deletion of the p-arm and a 
portion of the proximal arm of chromosome 19 (19q13.1  19pter), as well as loss of 
the Y-chromosome60.  Serendipitously, identification of this deletion sparked the 
laboratory’s initial interest in microRNAs as chromosome 19 contains a large cluster of 
microRNAs known to be crucial to development.  Additionally, the miR-17-92 cluster on 
chromosome 13 is known to be highly regulated, activated by c-Myc, and dysregulation 
has been shown to be associated with cancer42,64,65.  Eight of the 21 miRs known to 
translationally modulate p21, a cell-cycle inhibitor proten and known effector of multiple 
tumour suppressor pathways, are found in the chromosome 13 miRNA cluster37.  
Chromosome 19 was reintroduced into the M12 cell lines using microcell-mediated 
chromosome transfer (MMCT), and injection of this F6 cell line showed that 
reintroduction of chromosome 19 resulted in poor tumorigenesis, loss of metastatic 
potential, and increased adhesion of the resultant cells66. 
 The P69, M12, M2182, and F6 lines are pseudodiploid, which makes the model 
appropriate to study early pre-aneuplodic prostatic carcinomas.  In contrast, the 
canonical prostate cell lines PC-3, DU145, and LnCaP cell lines were derived from 
metastatic sites (reviewed in Chapter 3), and are known to have high chromosomal 
numbers60,61, an observation commonly made of late stage carcinomas. 
Dysregulated miRs identified through the P69-M12 progressive model 
 Previous work in the laboratory has shown that miR-17-3p, a microRNA found in 
the miR-17-92 cluster on chromosome 19, is downregulated in the M12 cells as 
compared to the P69 cell line.  This loss of expression was shown to have a positive 
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effect on vimentin expression through direct targeting by miR-17-3p on vimentin.  Thus, 
loss of miR-17-3p resulted in an increased level of vimentin, which was then shown to 
be reversed upon stable transformation with miR-17-3p, along with reduced 
tumorigenicity (Figure 1-5)25.   
 Recent work has focused on miR-125b as a tumour suppressor miR that was lost 
in M12 cells as compared to P69.  Analysis of benign and tumour tissue captured 
through laser-captured microdissection of prostate biopsies showed a similar pattern.  
Restoration of miR-125 through stable transformation resulted in reduced migratory and 
invasive potential of M12 cells (Figure 1-6)67.  miR-125b has been well characterized as 
a suppressor of ERBB2 & 3, receptor tyrosine kinase hormone receptors known to be 
upregulated in some carcinomas68-71 
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Figure 1-5:  miR-17-3p directly binds and modulates vimentin mRNA, an 
intermediate filament key to the EMT transition.  A:  Vimentin mRNA expression is 
increased through the P69 progression line, and B: miR-17-3p is decreased 
concomitantly.  C:  miR-17-3p directly binds to a portion of the vimentin 3’-UTR, and D: 
mutation of the 3’-UTR binding site results in loss of vimentin suppression.  From Zhang 
et al25. 
C D 
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Figure 1-6:  miR-125b is downregulated in prostate cancer, which allows for 
activated transcription of ERBB2/3 and activation of the AKT pathway.  A:  miR-
125b was shown to be down-regulated in M12 cells as compared to P69 cells, as well 
as in prostate cancer tumour tissue captured via laser capture microdissection.  B 
Restoration of miR-125b resulted in reduced migratory and invasive capability of M12 
cells C: through postulated inhibition of the AKT pathway.  From Budd et al67. 
A 
B 
C 
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V. Scope of this thesis 
Identification of dysregulated microRNAs in prostate cancer and their target mRNAs 
 Our laboratory is focused on identifying microRNAs that are modulated in cancer 
along with their mRNA targets, thus providing not only a microRNA, but to further 
elucidate the modified pathway and its contribution to progression of the prostate 
carcinoma.  The work in Chapter 3 details a panel-wide analysis of dysregulated miRs 
in the M12 cell line, and confirmation of oncomiR or tumour suppressor expression 
through additional prostate cell line analysis along with human prostate samples.
 Chapters 2, 4, and 5 investigate specific miRs shown to be modulated in prostate 
cancer through the multifaceted analysis such as used in Chapter 3.  c-KIT, an RTK 
growth factor receptor, is identified and confirmed as an additional target of miR-17-3p; 
thus loss of that miR results in increased levels of c-KIT and activation of proliferative 
pathways.  Chapter 4 focused on the identification of miR-9 as an oncomiR, and 
evaluates proven targets e-cadherin, NF-kB, and SOCS5 for modulation in the prostate 
cancer model.  Chapter 5 identifies miR-147b as a novel oncomiR in cancer, and 
specifically evaluates modulation and consequent impact on tumour growth and 
invasive capabilities.  AATF is identified as a novel target for miR-147b through protein 
and mRNA expression analysis. 
 This work culminates in an analysis that, as expected, illustrates that no one 
microRNA is responsible for the progression of a prostate tumour.  Rather, the 
compilation of the work of this laboratory has identified multiple microRNAs that each 
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contributes to the progression of the tumour, and their individual contributions result in 
an overwhelming activation of proliferative pathways and repression of terminal ones. 
Stability of microRNAs in forensically relevant biological fluids 
 Dr. Zehner’s and my work began with a question of whether microRNAs could be 
used for body fluid identification in forensic samples.  As a forensic scientist and a 
researcher, body fluid identification has long been my passion, and being well familiar 
with the limitations of the currently accepted and researched techniques, she and I were 
curious as to whether her interest, microRNAs, could be used in a forensic context.  
This collaboration began at the cusp of the exploratory literature of microRNAs in the 
forensic biology field, and thus our interest in using miRs as a potential molecular 
method of body fluid identification must first be tested through an evaluation of the 
stability of miRs in forensically relevant body fluids.  Thus, while wildly different from the 
rest of the thesis, this stability evaluation also holds a place in our research, and 
answers some unresolved questions in the forensic science field about the utility of 
miRs for forensic science.   
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Chapter 2 
 Identification of c-KIT as a novel target for miR-17-3p in prostate cancer 
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Our laboratory uses the previously described SV40T immortalized human 
prostate cancer cell line progression model, initiated with P69.  The P69 line is 
analogous to and derived from normal prostatic tissue and is poorly tumorigenic in nude 
athymic mice, whereas the subline M12 is highly tumorigenic and highly metastatic.  
This unique model in prostate cancer research permits the identification of additional 
players required for the progression of prostate tissue from benign to tumour.  Thus, 
both microRNAs and their protein targets that are in fact driving the change in 
neoplastic potential between the two cell lines can be elucidated.   
Previous work had identified vimentin mRNA as differentially expressed between 
the P69 and M12 cell lines25 (Figure 2-1a), in correlation with the change in EMT 
between the related cell lines and acquired invasive potential of the M12 subline.  
Investigation into the source of this differential expression revealed a highly conserved 
3’-UTR with a binding site for miR-17-3p in the human vimentin mRNA.  Evaluation of 
miR-17-3p levels in the P69 to M12 progression model showed a gradual loss of miR-
17-3p (Figure 2-1b), with a concomitant increase in vimentin expression.  Restored 
expression of miR-17-3p in the M12 cell line by stable transformation resulted in a five-
fold increase in miR-17-3p expression, causing reduced tumour growth in subcutaneous 
injection in mice and reversion of vimentin message and protein expression (Figure 2-
1c). 
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Figure 2-1:  miR-17-3p is lost in the P69-M12 progression model, which affects 
vimentin expression.  A:  Vimentin mRNA levels increase through the P69 to M12 
progression model.  B.  The increase in vimentin is inversely correlated to a loss of miR-
17-3p in this progression.  C.  Stable reintroduction of miR-17-3p results in suppression 
of vimentin (from Zhang et al25). 
 
 
 
 
C 
Zhang et al. 
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As part of the miR-17-92 cluster on chromosome 13q31.3, miR-17 (5p and 3p), 
as well as the other members of the cluster (miRs-18a, -19a&b, -20a, and -92a) are all 
transcribed by Pol II in the same polycistronic RNA, cleaved to individual precursor 
miRs, and exported and processed to mature miRNAs in the cytoplasm65.  Transcription 
of the cluster is activated through c-Myc and the protooncogene Pim-142, and thus the 
miR-17-92 cluster is commonly described as overexpressed in cancer.  miR-17-3p is 
not well researched, while the other strand, miR-17-5p, has been well-established as an 
oncomiR.  Thus, it is postulated that during tumorigenesis, activation of the miR-17-92 
cluster results in overexpression of certain members of the cluster, with strand selection 
for miR-17-5p and concomitant loss of miR-17-3p.  This could result in not only loss of 
tumour suppressor protein expression by miR-17-5p, but also loss of regulation of 
oncogenes by miR-17-3p. 
In an effort to identify additional proteins that may be modulated through the loss 
and subsequent re-expression of miR-17-3p in M12 cells, a collaboration was formed 
with Dr. Emanuel Petricoin, of George Mason University, who along with Dr. Lance 
Liotta, first described the Reverse phase Protein Microarray, or RPMA15.  The RPMA is 
a method in which a cell or tissue lysate, containing the entire proteome of that sample, 
is spotted at a concentration of 250 µM onto glass-backed nitrocellulose slides, and 
then fluorescently tagged antibodies are washed across the slides.  This allows for rapid 
analysis of hundreds of individual samples, with demonstrated use in therapeutic 
proteomics72-75.  Spotting the same lysate onto hundreds of slides can make for rapid 
immunohistochemical analysis of a large set of proteins that could be implicated in 
tumorigenesis.  RPMA analysis and comparison between the P69, M12, and M12 cells 
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+ miR-17-3p identified the phosphorylated version of the V-Kit Hardy-Zuckerman 4 
Feline Sarcoma Viral Oncogene Homolog, also known as c-KIT, CD117, and/or Stem 
Cell Factor Receptor (SCFR), as differentially phosphorylated between the M12 and 
P69 cell lines67.  In fact, c-KIT was the most dramatic differentially expressed protein 
between the two cell lines, warranting further investigation (Table 2-1). 
Interestingly, reintroduction of miR-17-3p to the M12 cell line also resulted in total 
ablation of the p-c-KIT signal in the proteomics analysis (Figure 2-2).  phospho-c-KIT 
levels were undetected in the benign prostatic cell line P69, and highly detectable in the 
tumorigenic and metastatic M12 cell line.  Reintroduction of miR-17-3p resulted in total 
loss of the p-c-KIT signal. 
 Given these dramatic changes in c-KIT levels between the P69 and M12 cell 
lines with complete ablation in the M12 + miR-17-3p transformant, it was important to 
determine the mechanism of c-KIT modulation, as well as investigating which signaling 
pathway(s) were subject to the tumour suppressor activity of miR-17-3p. 
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Table 2-1 – Significant differences in key proteins in M12 versus P69 cell lines as 
determined by RPMA proteomic analysis. p = phospho-specific antibody 
Protein Fold Change (M12 to P69) 
p-c-KIT 700 
p-ErbB3 2 
p-ErbB2 1.8 
p-Androgen Receptor 1.7 
p-BAD 1.7 
Caspase 7 1.5 
p-PI3 kinase 1.4 
p-GSK3A/B 1.2 
BCL2 1.2 
p-p27 0.7 
Cyclin B1 0.6 
 *adapted from Budd dissertation
67 
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Figure 2-2:  Re-Introduction of miR-17-3p into M12 cells ablates p-c-KIT levels.  
RPMA analysis was conducted on 3 sequential passages of each cell line.  Serial 
dilutions of each replicate were probed for phospho-c-KIT, and expression normalized 
against the global protein expression mean. 
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c-KIT is a 145 kDa transmembrane receptor tyrosine kinase, identified 
immunologically as CD117.  It is typically only expressed in high levels in hematopoietic 
stem cells, mast cells, melanocytic cells, germ cells, and interstitial cells of Cajal, and 
functions to promote cell proliferation and survival through interaction with its ligand 
stem cell factor (SCF)76.  SCF can be either membrane-bound for an autocrine function, 
or secreted from the cell for a paracrine effect77 .  Activation of c-KIT through ligand 
binding by SCF induces homodimerization, intermolecular tyrosine phosphorylation, and 
immediate internalization and rapid degradation via the ubiquitination pathway77,78.  
Upon binding and internalization, c-KIT protein is very slow to recover to previous 
levels, on the order of >24 hours78.  Levels are also heavily influenced by translational 
and transcriptional repression, further confirming a short half-life for the cell-surface 
protein78.  
The c-KIT gene is located in the white spotting locus 4q11-12, and has also been 
associated with piebaldism in both human and mouse77,79.  Transcriptional activation is 
accomplished through a variety of common transcription factors, including multiple Sp1, 
Ets, AP-2, and MyB binding sites80.  The signal transduction pathways activated by c-
KIT include MAPKinase, PI3-Kinase, JAK/STAT, Src, and phospholipase C pathways 
(Figure 2-3, reviewed in Reber et al., Lennartsson et al.77,81).  As the majority of these 
pathways are pro-survival and/or pro-proliferation, activation of c-KIT in neoplasias is 
unsurprising, and consequently it is the target of several chemotherapeutic approaches.   
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Figure 2-3:  c-KIT activation induces signal transduction in a variety of 
proliferative pathways (adapted from Reber et al.77) 
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Mutation causing a constitutively active c-KIT results in uncontrolled proliferation 
and has been found to be a primary tumorigenic cause of gastrointestinal stromal 
tumours (GIST)82.  This mutation is typically a ligand-independent RTK activity, resulting 
in constant stimulation of downstream proliferative pathways.   
In normal prostatic tissue, c-KIT expression historically has been found only in 
mast cells83, but recent studies have shown increasing c-KIT expression as tumour 
progression increases, with c-KIT positive tumours leading to disease relapse and bone 
metastasis76,84.   
In this study, we evaluated the potential of miR-17-3p as a modulator of c-KIT 
expression in a prostate cancer model.  Proteomic analyses showed that c-KIT 
expression, while absent in the poorly-tumorigenic P69 cell line, was highly expressed 
in the M12 cell line, and reintroduction of miR-17-3p to the same cell line resulted in 
complete loss of c-KIT signal and reduced tumorigenesis and metastases.   
Project Aims: 
1. Confirm c-KIT modulation between the P69, M12, and M12 with stably expressed 
miR-17-3p cell lines through mRNA and protein expression analysis. 
2. Identify miR-17-3p binding sites within the c-KIT message, and determine if they 
contribute to message suppression. 
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METHODS AND MATERIALS 
Cell Culture 
 Adherent cells were cultured in 75 cm2 flasks using RPMI 1640 supplemented 
with L-Glutamine (Caisson Labs, North Logan, UT), 5% fetal bovine serum, 5 µg/mL 
insulin, 5 µg/mL transferrin, 5 µg/mL selenium (ITS, Collaborative Research, Bedford, 
MA).  Gentamycin (0.05 mg/mL) was used to prevent bacterial contamination. M12 cells 
previously stably transformed with pSIREN:miR-17-3p vector (Clontech Laboratories, 
Inc., Mountain View, CA) were maintained using puromycin25 (100 ng/mL).  Cells were 
passaged when 50-65% confluent, and maintained for no longer than 20 passages.  
Passaging was accomplished by incubating with 0.25% Trypsin-EDTA (Gibco-Life 
Technologies, Carlsbad, CA) for 5 minutes at 37°C, after which the trypsin was 
inactivated by washing the cells in serum-containing media.  The cells were then 
pelleted through centrifugation at 1500xg for 5 minutes and either passaged, plated, or 
pellets preserved.  Cell pellets for analysis were produced by washing the pellet in 10 
mL PBS, centrifugation at 1500xg for 5 minutes, removal of the supernatant, and flash 
freezing in liquid nitrogen.  Pellets were stored at -80°C for at least 24 hours. 
RNA Isolation 
 RNA was isolated from cell pellets using the miRVanaTM RNA isolation method 
according to the manufacturer’s protocol (Ambion-Life Technologies, Carlsbad, CA), 
eluted in 50 µL of Elution Buffer, and stored at -80°C.  RNA concentration was 
estimated using either the Smart SpecTM 3000 Spectrophotometer (Bio-Rad 
34 
 
Laboratories, Hercules, CA) or the NanoDrop ND-2000 Spectrophotometer (Thermo-
Fisher Scientific, Inc., Waltham, MA). 
Messenger RNA Analysis 
Messenger RNA was quantified using reverse transcription-quantitative PCR 
(RT-qPCR).  Reverse transcription was accomplished using the iScriptTM cDNA 
Synthesis kit (Bio-Rad Laboratories).  Briefly, 50 ng of RNA was mixed with 4 µL of the 
5X iScript reaction mix, 1 µL of the iScript Reverse Transcriptase, and the volume 
brought to 20 µL with nuclease-free water.  The reaction mixture was incubated for 5 
minutes at 25°C, followed by 30 minutes at 42°C, and heat inactivation for 5 minutes at 
85°C.  Reactions were stored at -20°C until analysis.  The qPCR reactions were 
prepared by adding 3 µL of the prepared cDNA, 10 µM primer pairs for the relevant 
mRNA target (GAPDH:  Forward:  5’-ACCACAGTCCATGCCATCAC; Reverse: 5’-
TCCACCACCCTGTTGCTGTA.  c-KIT:  Forward:  5’-ATGAGAGGCGCTCGCGGCGC; 
Reverse: 5’-AGCTTGGCAGGATCTCTAAC), 1X FastStart Universal SYBR Green 
Master Mix (Roche Diagnostics, Indianapolis, IN), and brought to 20 µL volume with 
nuclease-free water.  qPCR was conducted in an Applied Biosystems 7300 real-time  
PCR instrument (Life Technologies) using the following conditions:  50°C for 2 minutes, 
95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 55°C for 35 
seconds, and 68°C for 35 seconds.  Data was analyzed using SDS software v1.3.1 (Life 
Technologies), using automatic threshold and baseline settings.  Each mRNA evaluated 
was analyzed in triplicate using a minimum of three separate cell passage RNA 
extractions.  GAPDH was used as a normalization control, and relative expression was 
calculated using the comparative CT method85. 
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Western Blotting 
Cultured cell pellets were lysed in 4% sodium dodecyl sulfate (SDS) in 
phosphate-buffered saline (PBS) with 1X PhosSTOP phosphatase inhibitor (Roche 
Diagnostics) and COMplete protease inhibitor (Roche Diagnostics), followed by 
sonication for five minutes at 4°C.  Protein concentration was calculated using the Dc 
Protein Assay (Bio-Rad Laboratories), and absorbance read at 750 nm on the Smart 
SpecTM 3000 Spectrophotometer (Bio-Rad Laboratories). 
For western blotting, equal quantities of cell lysate (30-40 µg) were loaded onto a 
Novex® 4-12% Tris-Glycine SDS polyacrylamide gel (Life Technologies), under 
denaturing conditions using a loading buffer with 2% SDS, 5% β-Mercaptoethanol, 20% 
glycerol and 0.004% bromophenol blue in 0.125M Tris-HCl, and electrophoresed in a 25 
mM Tris, 190 nM glycine, 0.1% SDS running buffer for approximately 90 minutes at 140 
volts.  The samples were transferred onto a Trans-Blot® nitrocellulose membrane (Bio-
Rad Laboratories) for 90 minutes at 200 mA and 4°C in a 48 mM Tris, 39 mM glycine, 
0.04% SDS transfer buffer.  Nonspecific binding was prevented by washing the blot for 
30 minutes at room temperature in 5% nonfat dry milk in Tris-buffered saline with 0.05% 
Tween-20 (TBST).    The blot was rinsed briefly in TBST, and incubated overnight (14-
20 hours) at 4°C in primary IgG antibody in 5% BSA in TBST.  Primary antibodies used 
were 1:1000 α-β-actin (C4) produced in mouse (Santa Cruz Biotechnologies, Inc., 
Santa Cruz, CA) and 1:500 α-CD117 produced in rabbit (Dako, Glostrup, Denmark),.  
After incubation in primary antibody, the blot was washed with TBST four times for 5 
minutes, followed by incubation in secondary antibody (1:1000 α-mouse IgG-HRP 
produced in goat (Santa Cruz Biotechnologies) and/or 1:1000 α-rabbit IgG-HRP 
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produced in goat (Cell Signalling Technology, Danvers, MA),  for 1 hour at room 
temperature.  The blot was again washed with TBST four times for 5 minutes, and 
luminol reaction developed using the Western Lightning® chemiluminescent reagents 
(Perkin Elmer, Boston, MA).  Western blots were exposed and bands quantified using 
the ODYSSEY® Fc Imaging System (LI-COR Biosciences, Lincoln, NE). 
Cloning of 3’-UTR constructs 
A 612 base pair portion of the 3’-UTR of c-KIT containing both potential miR-17-
3p binding sites was amplified from a cDNA plasmid containing the c-KIT 3’-UTR (gift 
from Dr. Jeff Krystal, Veteran’s Administration Hospital), and inserted into the XbaI 
restriction site in the MCS downstream from the luciferase gene in the pmiR-Glo vector 
(Promega Corporation, Madison, WI) using standard cloning techniques.  This cloning 
reaction resulted in not only the desired insert in the correct orientation, but also 2 
tandem copies of the 612 bp fragment.   
Wild type and mutated fragments of the c-KIT 3’-UTR were synthesized through 
Invitrogen for oriented cloning into pmiR-Glo.  The Wild type fragments were 63 and 64 
nucleotides long (sites 2 and 1, respectively), and mutations at the seed region (Table 
2-2) were synthesized as indicated.  Failure of these mutations to bind miR-17-3p was  
verified through RNAHybrid86,87. 
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Table 2-2:  c-KIT 3’-UTR fragment constructs.  miR-17-3p binding site is highlighted 
in yellow, the seed region is highlighted in green, and mutated nucleotides are 
highlighted in red. 
Clone ID Size Sequence 
Site-1 WT 64  
AATGGATTTGATGCTGTTTGACAAAGTTACTGATTCACTGCATGGCTCCCACAGGAGTGGGAAA 
Site-1 Mut 64  
AATGGATTTGATGCTGTTTGACAAAGTTACTGATTCGGACAATGGCTCCCACAGGAGTGGGAAA 
   
Site-2 WT 63  
GTAGCAGGAAATAAAGTATAGGTTTAGCCTCCTTCGCAGGCATGTCCTGGACACCGGGCCAGT 
Site-2 Mut 63 
GTAGCAGGAAATAAAGTATAGGTTTAGCCTCCTAGTGAGCGTTGTCCTGGACACCGGGCCAGT 
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Transfection & Luciferase Activity Analysis 
 Transient transfections of the 3’-UTR fragments cloned into a firefly 
luciferase/renilla reporter vector were performed using TransIT®-LT1 Transfection 
Reagent (Mirus BIO LLC, Madison, WI, USA).  Briefly, cells were plated to achieve 50% 
density in appropriate serum-containing media after 24 hours (1x105 cells/well for a 6-
well plate, or 2.5x104 cells/well for a 24-well plate).   The cells were allowed to adhere 
for 24 hours, rinsed with 0.5 mL PBS, and media replaced (2 mL for 6-well plate, 0.5 mL 
for 24-well plate).  For 6-well plate transfections, 2.5 µg of the cloned 3’-UTR:vector was 
mixed with 250 µL of RPMI media with no serum or additives plus 7.5 µL of TransIT®-
LT1 reagent at room temperature for 15 minutes.  For 24-well plate transfections, 0.5 µg 
of the cloned UTR:vector was mixed with 50 µL of RPMI media with no serum or 
additives and 2.0 µL of TransIT®-LT1 reagent at room temperature for 15 minutes.  The 
solution was added dropwise to each well, and gently rocked back and forth.  The 
transfections were incubated for 24 hours under standard cell culture conditions.   
 Cell lysis and luciferase assays were conducted using the Dual-Luciferase 
Reporter Assay System (Promega Corporation).  The transfection media in each well 
was suctioned off, wells rinsed in PBS, and 1X Passive Lysis Buffer (Promega 
Corporation) (500 µL – 6 well plates; 100 µL – 24 well plates) was pipetted into each 
well.  The samples were rocked for 15 minutes at room temperature, and the lysate 
transferred to 1.5 mL microcentrifuge tubes and frozen at -20°C until analysis.  
Luciferase and Renilla measurements were taken in a GloMax® 20/20 luminometer 
(Promega Corporation).  Lysate (20 µL) was added to a new 1.5 mL microcentrifuge 
tube, and 30 µL of firefly Luciferase Assay Reagent II added to the lysate and luciferase 
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activity measured at a wavelength of 560 nm.  Subsequently, 30 µL of Stop & Glo was 
added, the solution mixed, and renilla luciferase activity was measured at the 480 nm 
wavelength. 
Data Analysis 
 Statistical analyses were conducted in the Microsoft® Excel software platform, 
using the independent Student's t-test, assuming equal variance between the two 
groups. Statistical significance was defined as p < 0.05. 
RESULTS  
 Western blot analysis of c-KIT protein in cell lysates corresponded with the 
RPMA analysis data, showing that while c-KIT was minimally detectable in P69 cells, it 
was highly expressed in the metastatic M12 cell line, and introduction of miR-17-3p 
resulted in total loss of the c-KIT protein expression (Figure 2-4).  This demonstrates 
that the protein levels themselves are dramatically changing, and not just the active 
phosphorylated quantity. 
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Figure 2-4:  c-KIT protein mRNA expression and protein levels are significantly 
reduced when miR-17-3p levels are high.  A:  messenger RNA levels of c-KIT are 
significantly reduced in P69 cells as compared to the M12 line (p < 0.0001), with further 
reduction when miR-17-3p is overexpressed in M12 cells (p < 0.05).  Data is the 
average of 3 independent experiments. B: Western blot analysis and C: Densitometry of 
c-KIT protein expression in the P69, M12, and M12 overexpressing miR-17-3p.  Blot is 
representative of 3 independent experiments; quantitation is compiled data from the 3 
experiments (p < 0.05 for P69 to M12, and M12 to M12+miR-17-3p c-KIT). 
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 Review of the major microRNA-Target prediction software platforms (DIANA88, 
MiRDB89, TargetMiner90, RNA2291) showed that only RNA22 andTargetMiner included 
targeting of miR-17-3p to c-KIT in a list of the top 40 candidate target genes for miR-17-
3p.  TargetScan predicted binding, but at a lower confidence level.  Analysis of the c-
KIT 3’-UTR using TargetScan revealed multiple highly conserved potential candidate 
sites where miR-17-3p might bind (Figure 2-5)92-94.  Analysis of those sites using 
RNAHybrid yielded the top two candidates, based on the best binding of the microRNA 
seed, with large, equal predicted free energy values (Figure 2-6)86,87. 
To validate the predicted binding of miR-17-3p to the c-KIT 3’-UTR, a 612 base 
pair portion of the 3’-UTR of c-KIT containing both potential binding sites was amplified 
and inserted downstream of the firefly luciferase gene in the Dual-Luciferase miRNA 
Target Expression vector pmiR-Glo® (Promega Corporation).  The cloning preparation 
resulted in not only a pmiR-Glo® vector with a single copy of the c-KIT 3’-UTR, but also 
a second clone with two tandem copies inserted downstream of the luciferase gene.  
Comparison of luciferase activity (relative to Renilla luciferase activtiy) showed that 
expression was suppressed with a single copy of the cloned portion of the 3’-UTR, and 
that 2 tandem copies of that portion suppressed activity even further in M12 cells.  
Evaluation in the M12 + miR-17-3p overexpressing cell line showed even greater effect, 
substantiating that miR-17-3p is directly responsible for at least a portion of suppression 
of c-KIT expression (Figure 2-7).   
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Figure 2-5:  In-silico evaluation of the top two miR-17-3p binding sites in the c-KIT 
3’-UTR region show high conservation.  Nucleotides 959-1075 of the 3’-UTR region 
of c-KIT show two potential binding sites for miR-17-3p.  Red and brown fonts outline 
entire miR-binding region, and red and brown boxes denote the miR seed-pairing region 
wherein canonical miR binding is best. (hsa: homo sapiens ptr: chimpanzee mml: 
rhesus monkey oga: bushbaby tbe: tree shrew mmu: mouse laf: elephant eca: horse) 
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Figure 2-6:  Predicted binding of miR-17-3p to 2 c-KIT 3’-UTR region binding sites.  
The two binding sites with highest free energy are within 100 nucelotides of each other.  
Green is the sequence of miR-17-3p, and red is the complementary region of the 3’-
UTR of c-KIT.  (Adapted from RNAHybrid86,87). 
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Figure 2-7:  c-KIT expression is suppressed by miR-17-3p.  M12 cells and M12 cells 
stably transformed with a vector expressing miR-17-3p were transiently transfected with 
a luciferase reporter construct containing a single or double tandem copy of a portion of 
the c-KIT 3’-UTR.  Firefly luciferase expression is reported normalized to renilla 
luciferase activity and relative to empty vector expression.  Results are the mean of 3 
independent experiments, each performed in triplicate. 
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 Subcloning efforts to isolate and mutate both miR-17-3p binding sites individually 
through synthesized 3’-UTR fragments revealed through luciferase 3’-UTR constructs 
that both binding sites have a minor but significant impact on c-KIT expression, 
suggesting that the additive effect of the two could allow for significant repression of 
translation (Figure 2-8). 
c-KIT expression affects many downstream pathways, including the AKT, ERK, 
and JAK/STAT pathways.   Through RPMA analysis, we found that neither p-AKT, p-
STAT3, nor p-ERK were significantly affected by the addition of miR-17-3p into the M12 
cell line (Figure 2-9).   
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Figure 2-8:  Suppression of each binding site in the c-KIT 3’-UTR contributes to 
mRNA translation suppression.  M12 cells expressing miR-17-3p were transiently 
transfected with wild type (WT) or mutated (MUT) sequence of each of the two binding 
sites for miR-17-3p within a 612 bp portion of the the c-KIT 3’-UTR.  Firefly luciferase 
expression is reported normalized to renilla luciferase activity and relative to mutant 
expression.  Results are the mean of 2 independent experiments, each performed in 
triplicate. 
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Figure 2-9:  miR-17-3p does not significantly affect downstream levels of c-KIT 
pathways.  RPMA analysis was conducted on 3 sequential passages of each cell line.  
Serial dilutions of each replicate were probed for the phosphorylated antibodies shown.  
Data is represented as average expression normalized by the global phosphoprotein 
mean and relative to M12 cell line expression levels. 
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DISCUSSION 
c-KIT is a oncoprotein that is well-characterized in a variety of cancers including 
breast, gastrointestinal, non small-cell lung carcinomas, and oral squamous cell 
carcinomas82,95-97.  While initial reports in prostate cancer were conflicting in their 
determination of c-KIT expression, the current literature indicates that c-KIT expression 
is found in more aggressive, metastatic prostatic neoplasias, but not in early tumours, 
and has some role in promoting establishment of bone metastases84. 
In this report, previous RPMA analysis work that identified c-KIT as a modulated 
protein between the P69 and M12 cell lines was confirmed, showing consequent loss of 
expression in the M12 cells transformed with a miR-17-3p expression construct67.  
Western blot analysis showed that while only slightly detectable in the P69 cell line, c-
KIT was highly expressed in the M12 cells, and subsequently lost in the M12 cells 
overexpressing miR-17-3p.  This analysis provided not only confirmation of differences 
as seen with RPMA, but also showed that protein levels themselves are changing, and 
not just the amount of active, phosphorylated c-KIT protein as indicated by the RPMA 
analysis.  Interestingly, messenger RNA levels of c-KIT were also modulated by miR-
17-3p.  As miR binding to the 3’-UTR of a target mRNA typically results in translational 
repression, and only results in cleavage when the seed pairing is a perfect match and in 
complex with Argonaute 234,51,55, mRNA modulation indicates at least one perfectly 
matching seed region and cleavage of the message by Argonaute 2.   
Subsequently, two strong potential binding sites for miR-17-3p in the 3’-UTR of c-
KIT were identified, and through reporter luciferase assays determined that: 
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1. The 3’-UTR is bound and translation suppressed by miR-17-3p.   
2. Comparison of reporter activity using wild type and mutated potential binding 
sites showed that both had modest suppressive activity.  Thus, we suggest that 
the additive effect of the two miR-17-3p binding sites contributes to the overall 
suppression of translation for the c-KIT protein in our model cell lines. 
 There is some concern that even the additive effects of the two identified miR-17-
3p binding sites in the 3’-UTR may not be sufficient to completely ablate protein levels in 
the P69 and M12+miR-17-3p cell lines.  Further analysis of the c-KIT gene identified two 
additional potential binding sites for mIR-17-3p within the c-KIT gene.  These potential 
sites were not previously identified because they are located within the coding regions 
of the message itself, and not the 3’-UTR, which is canonically the location for miR-
target binding.  However, there is a growing body of evidence that miRs can bind and 
suppress translation of their target mRNAs not only in the 3’-UTR, but also within the 5’-
UTR and coding regions of the messenger RNA98,99.  One example in particular is 
interesting and similar to our c-KIT evaluation – miR-34a has been proven to target 
Diacylglycerol Kinase ζ in T-cells through binding sites in both the 3’-UTR and the 
coding region99. 
The binding for the two sites within the cKIT mRNA is particularly strong, and are 
the only two potential sites in c-KIT that are stronger in free energy than the two 3’-UTR 
sites that were identified and modulated here (Figures 2-10 A&B).  Binding site CD-A is 
a strong match, with full complementarity in the 3-7 nt seed region of miR-17-3p, and 
interestingly, the binding begins at nucleotide 1 in the c-KIT messenger RNA, even prior 
to the signal peptide sequence.  Binding site CD-B is found in exon 13, which is part of  
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Figure 2-10:  Additional potential binding sites for c-KIT can be found in regions 
other than the 3’-UTR.  CD-A is found at the 5’ end of the message, starting at 
nucleotide 1.  CD-B is found in exon 13 of the c-KIT message.  Green is the sequence 
of miR-17-3p, and red is the complementary region of the c-KIT mRNA.  (Adapted from 
RNAHybrid86,87). 
CD-A 
CD-B 
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the intracellular domain of the protein77 and is found in 3 of the 6 alternative splicing 
forms of the c-KIT protein. 
 As an important primary signal transduction initiator, c-KIT is naturally heavily 
regulated, not only at the transcriptional level, but growing evidence indicates that 
multiple microRNAs are important for regulation at the translational level.  miR-221 has 
been shown to regulate c-KIT levels in erythroleukemic cells100, but was within the 
normal range in our evaluations and thus was not pursued.  MiR-34a has recently been 
shown to directly target c-KIT levels in a colorectal cancer cell line, with two binding 
sites in the 3’-UTR101.  miR-34a was evaluated by other work in the laboratory and 
shown to be an oncomiR in both the cell line progression model as well as in patient 
LCM analyses67.  An interesting observation from the compilation of unpublished data 
show that while miR-34a is dramatically upregulated in the P69 cells as compared to the 
M12, this seems to have no effect on the c-KIT levels.  It may be that miR-34a is 
involved in regulation of other tumour suppressor mRNAs, and the c-KIT message is not 
efficiently targeted in the prostate cancer system. 
 A particularly interesting microRNA:c-KIT interaction case is that of miR-494.  
This miR was proven to downregulate c-KIT expression levels in gastrointestinal stromal 
tumour cells (GIST) through multiple binding targets within the c-KIT 3’-UTR82.  
Proliferation was affected via the c-KIT downstream pathways.  Interestingly, in the 
panel analysis (Chapter 3), miR-494 was undetected in both the P69 and M12 cell lines 
by RT-qPCR analyses, and thus is not a likely player in c-KIT modulation in prostate 
cancer.  Thus, this discovery of miR-17-3p’s regulation of c-KIT presents an interesting 
parallel case to the miR-494 in the GIST report, wherein different microRNAs through 
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tissue-specific expression fulfill a similar tumour suppressing role.  Loss of expression in 
their respective tissues results in uncontrolled growth through loss of suppression of an 
oncogene. 
 c-KIT positive cancers from a variety of origins are commonly treated with 
Imatinib and other growth factor receptor chemotherapeutics.  Imatinib directly blocks c-
KIT activation at the ATP-binding pocket82.  However, constitutively activated mutations 
for c-KIT are well known, and blocking therapeutics are not effective for those mutants.  
A method that blocks translation of the mutated protein could be a very effective 
therapeutic tool.  Given that c-KIT has been so well-established as a rapidly cycling 
protein78, its translational repression could have an almost immediate effect on the 
reception of growth signals and downstream proliferative signaling to tumour cells 
resulting in the ultimate attenuation of growth and cell cycling, as was shown in the 
study evaluating miR-494 inhibition82.  A combination of miRs shown to target the c-KIT 
mRNA, but without additional known pro-growth effects (such as miR-34a) could 
potentially work to attenuate the growth and chemotaxis of neoplasias through 
suppression of the initiator of those signal transduction processes. 
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Chapter 3: 
Identification of modulated microRNAs through a sequential analysis of prostate 
cancer cell lines and patient samples 
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 Most researchers approach miR discovery in a single approach.  Some have a 
protein or pathway that encompasses their entire research, while others are interested 
in identifying microRNAs on a global scale that affect diseases and conditions such as 
cancer.  While our laboratory initially began working on microRNAs through the 
discovery of miR-17-3p as an attenuator of vimentin protein levels, we have continued 
to work in microRNA discovery in prostate cancer in a search for additional microRNAs 
that could be serving as oncomiRs or tumour suppressors.  And while we begin this 
research on a global scale, we are interested in not only identifying those miRs, but 
determining their mechanism of action through target mRNA identification and 
connection with a signaling pathway that progresses the carcinoma. 
 The previously described progression cell lines P69 and M12 are a unique model 
for prostate cancer, in that P69, having been immortalized from a human non-neoplastic 
prostate epithelium section60,61, is poorly tumorigenic and non-metastatic in nature.  In 
contrast, the M12 cell line, which was derived from 3 sequential injections into nude 
athymic mice, is highly tumorigenic and highly metastatic.  This set of cell lines serves 
as an excellent model for prostate cancer research, in that the M12 cells are derived 
from the P69 cells and therefore share a common basic genetic complement.   
 As the M12 and P69 cell lines are not readily available to other researchers, 
several cell lines are commonly used as models for prostate cancer (Table 3-1).  The 
PC3 cell line is a line that was derived from a vertebral bone metastasis in a 62-year old 
male, and is androgen-insensitive102.  It no longer expresses PSA or the androgen 
receptor103 and is highly tumorigenic and metastatic, and thus is commonly used to 
evaluate prostate cancer therapeutic targets for advanced cancers.  The other canonical 
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prostate cell line is the Dunnings-145 (DU-145), which was derived from the brain of a 
69-year old white male with both CaP and lymphocytic leukemia, is only moderately 
metastatic but also androgen-insensitive103,104.  DU145, like PC3, also does not express 
PSA or the androgen receptor.  A non-tumorigenic cell line known as BPH-01 is a 
SV40T immortalized line derived from a human benign prostatic hypertrophic (BPH) 
biopsy23,105.  While there is some disagreement among researchers as to whether BPH 
always ultimately develops into neoplasia in-vivo, in-vitro, the BPH-01 cell line has only 
been shown to form adenocarcinomas when injected with carcinoma-associated 
fibroblasts24. WMPY-1 is a stromal myofibroblast line that is sometimes referred to in 
CaP research, but since it is not endothelial in nature, it is not as relevant as the other 
lines are to the progression of CaP105. 
The only publicly available progression model for prostate cancer is the LNCaP series 
of cell lines.  The original LNCaP cell line was derived in 1977 from a metastatic 
supraclavicular lymph node in a 50-year-old male106,107.  It is unique from the other cell 
line models in that tumour development is androgen-sensitive.  The C4 and C5 sublines 
were derived through the injection of the LNCaP cells into male nude athymic mice, 
followed by subsequent castration after 8 weeks108.  Tumours that were maintained 
after castration exhibited hormone independence, and thus formed the basis of the C4 
and C5 sublines.  Subsequent reinjection of the C4 cells into nude athymic mice in 
combination with human marrow stromal (MS) fibroblasts generated an even more 
androgen-refractory cell line designated LNCaP-C4-2108.  Interestingly, the C4, C5, and 
C4-2 sublines have lost the Y-chromosome, continue to express PSA and have a lower  
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Table 3-1: Cell line models used in prostate cancer research 
Cell Line Metastatic Potential Androgen Sensitivity 
Stand-Alone Cell Lines 
PC3 High No 
DU-145 Moderate No 
BPH-01 None – benign hyperplastic epithelium 
   
Progressive Models 
P69 Negligible No 
M12 High No 
   
LNCaP Very Low yes 
LNCaP-C4/C5 Low Moderate 
LNCaP-C4-2 Moderate No 
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level of the androgen receptor, all trademarks of hormone-refractory CaP in humans109.  
Thus, the LNCaP progression set of cell lines is a well-established progression model 
for studying prostate cancer.  Additionally, the series is an accurate model for metastatic 
potential, as the sublines form osteoblastic lesions32, the canonical mechanism for 
human prostate cancer metastases to bone, in contrast to the PC3 and DU-145 lines, 
which form osteolytic lesions similar to the bone lesions seen in breast and other 
cancers105. 
While each of the described cell lines can act as good models for prostate cancer, any 
one cell line alone should not be used as a discovery tool for identifying novel 
modulated species, including microRNAs.  Any balanced discovery should include not 
only the easily obtainable cell lines, but also patient samples.  In this way, confirmation 
of the preliminary results obtained from the cell-line work can be confirmed as also 
occurring in the prostate cancer patient, and thus will be more relevant not only in 
identifying new markers, but also in developing new therapeutics against prostate 
cancer.  In this study, we proposed to identify microRNAs that have been modulated in 
prostate cancer through a progressive, sequential analysis that begins at the global 
miRNA level, proceeds through single-miR confirmatory analysis, followed by evaluation 
of miR expression in multiple additional prostate cancer cell lines and finally analysis of 
modulated microRNAs through laser-capture microdissection (LCM) of benign, stromal, 
and tumour tissue from human patient biopsies. 
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Project Aims: 
1. Identify miRs that are dysregulated in prostate cancer through RT-qPCR analysis of 
the P69 and M12 cell lines of a human panel of over 700 miRNAs.  This will serve to 
identify microRNAs as potential oncomiRs when overexpressed in M12 vs. P69, and 
as potential tumour suppressors when lost in M12 vs. P69. 
2. Confirm miRs identified in Aim 1 through single-miR RT-qPCR analysis in the entire 
P69 cell line progression model.  Evaluate any differences between results seen with 
panels as compared to the single-miR analysis. 
3. Evaluate those modulated miRs that continue to act as oncomiRs and tumour 
suppressors through analysis of additional prostate cell lines.  This will serve to 
narrow the field to those miRs that are more indicative of CaP through gain or loss of 
expression. 
4. Using CaP patient biopsies, perform laser-capture microdissection in order to 
separate benign from tumour tissue within the same biopsy slice, and compare miR 
expression between benign and tumour, thus confirming (or eliminating) the 
proposed miRs as modulated in prostate carcinomas.   
 
METHODS & MATERIALS 
Cell Culture 
P69, LNCaP and sublines, BPH-01, PC-3, and DU-145 cells were previously cultured 
and pellets stored at -80°C until RNA isolation.  Adherent M12 cells were cultured in 75 
cm2 flasks using RPMI 1640 supplemented with L-Glutamine (Caisson Labs, North 
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Logan, UT), 5% fetal bovine serum, 5 µg/mL insulin, 5 µg/mL transferrin, 5 µg/mL 
selenium (ITS, Collaborative Research, Bedford, MA).  Gentamycin (0.05 mg/mL) was 
used to prevent bacterial contamination.  Cells were passaged when 50-65% confluent, 
and maintained for no longer than 20 passages.  Passaging was accomplished by 
incubating with 0.25% Trypsin-EDTA (Gibco-Life Technologies, Carlsbad, CA) for 5 
minutes at 37°C, after which the trypsin was inactivated by washing the cells in serum-
containing media.  The cells were then pelleted through centrifugation at 1500xg for 5 
minutes and either passaged, plated, or pellets preserved.  Cell pellets for analysis were 
produced by washing the pellet in PBS, centrifugation at 1500xg for 5 minutes, removal 
of the supernatant, and flash freezing in liquid nitrogen.  Pellets were stored at -20°C or 
-80°C for at least 24 hours.   
RNA Isolation 
 RNA was isolated from cell pellets using the miRVanaTM RNA isolation method 
according to the manufacturer’s protocol (Ambion-Life Technologies, Carlsbad, CA), 
eluted in 50 µL of Elution Buffer, and stored at -80°C.  RNA concentration was 
estimated using either the Smart SpecTM 3000 Spectrophotometer (Bio-Rad 
Laboratories, Hercules, CA) or the NanoDrop ND-2000 Spectrophotometer (Thermo-
Fisher Scientific, Inc., Waltham, MA). 
Laser-Capture Microdissection 
Frozen radical prostatectomy samples were obtained from VCU’s Tissue and 
Data Acquisition and Analysis Core, which obtained all samples following approved 
institutional review board (IRB) protocols.  Each sample was reviewed and scored by a 
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board certified pathologist with expertise in prostate cancer diagnosis.  8 μm tissue 
slices from the biopsy cores were placed on uncharged glass slides, and stained with 
hematoxylin and eosin (H&E) using a standard protocol.  Laser capture microdissection 
(LCM) was performed using the Arcturus Veritas™ laser capture microdissection 
system (Life Technologies). Each tissue type (benign, stroma, venous, tumour) was 
separately captured onto CapSure® Macro LCM caps (LifeTechnologies). At least ten 
slides were captured for each patient included in the study. 
RNA extraction of LCM samples 
Total RNA was isolated from LCM caps using the ARCTURUS® PicoPure® RNA 
Isolation Kit (Life Technologies), following the manufacturers protocol.  Briefly, the LCM 
caps were incubated for 30 minutes at 42°C in 50μl of extraction buffer.  This extract 
was then stored at -20°C until similar cell extracts from successive slides were pooled 
into a single tube and mixed with 1 volume of 70% ethanol.  The precipitated RNA 
solution was loaded onto a MiraCol™ column, centrifuged, washed, and total RNA 
eluted in 11 µL.  RNA quality and quantity were estimated using an Agilent RNA 6000 
Pico chip with the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) using the 
manufacturer’s recommendations. 
Locked-Nucleic Acid miR Panel Analysis 
 M12 and P69 RNA (50 ng) were subjected to the miRCURY LNA™ Universal RT 
microRNA PCR reaction (Exiqon A/S, Denmark) according to the manufacturer’s 
recommended protocol.  Briefly, 4 µL of 5X Reaction buffer and 2 µL of reverse 
transcriptase enzyme mix were combined with appropriately diluted RNA and brought to 
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20 µL volume with RNase-free H2O.  The RNA was reverse transcribed for 60 minutes 
at 42°C, followed by heat inactivation for 5 minutes at 95°C.  The cDNA was diluted and 
aliquotted across Exiqon miRCURY LNA™ Universal RT microRNA PCR Panels I and II 
(Verson 2.M) 384-well plates according to protocol, and qPCR was undertaken in an 
Applied Biosystems 7900HT fast real-time PCR instrument (Life Technologies, 
Carlsbad, CA) using recommended cycling conditions.  Threshold and baseline settings 
were set according to protocol recommendations.  The data was corrected for interplate 
variability using on-plate calibrators, and normalized against the global mean using 
Exiqon GenEx software.  Expression changes were calculated in Microsoft Excel® using 
the 2Δ ΔCT method and recorded as M12 expression relative to P69.   
RT-qPCR (Exiqon) 
Single-miR RT-qPCR analysis was conducted using the LNA platform as well.  
RNA (40 or 50 ng (LCM and cell lines, respectively)) was reverse transcribed using the 
miRCURY LNA™ Universal reverse transcription reaction as described for the Panel 
analysis.  The cDNA was diluted 1:10 and qPCR mix prepared by adding 5 µL of 2X 
Sybr® Green PCR master mix (Exiqon A/S), 1 µL of appropriate primer mix, and 4 µL of 
diluted cDNA.  qPCR was undertaken in an Applied Biosystems 7300 real-time  PCR 
instrument (Life Technologies) using recommended cycling conditions.  Data was 
analyzed using SDS software v1.3.1 (Life Technologies).  Threshhold and baseline 
settings were set according to protocol recommendations, with baseline correction 
between cycles 3 and 12 and an automatic threshold.  Each miR was analyzed against 
a cell line with a minimum of one biological and three technical replicates. 
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RESULTS 
Microarray Panel Analysis of M12 and P69 cell lines 
 Locked-nucleic acid (LNA) RT-qPCR panel analysis of the M12 versus the P69 
cell line was the starting point in a search for microRNAs that are truly modulated, not 
only in cell-line models, but also in human tumours.  Analysis of both Panels 1 and 2 
allowed for analysis of known human miRs as of 2011.  Out of 736 microRNAs assayed, 
231 were found to be oncomiRs (≥2 fold increase in M12 vs. P69 cell lines), 150 were 
found to be tumour suppressors (≤.5 fold decrease in M12 vs. P69 cell lines), with the 
remaining microRNAs within the normal range (Figure 3-1).  Even though the majority of 
microRNAs remained within the normal range, this still left many potential tumour 
suppressors and oncomiRs to evaluate (Tables 3-2a and b, respectively). 
 The choice of which microRNAs to investigate further was accomplished through 
an evaluation of not only the expression level difference between P69 and M12, but also 
initial literature reviews and analysis of potential targets using microRNA-target 
databases including TargetScan, DIANA, and miRDB86-89,92,93,110.  Literature searches 
were conducted in order to determine whether the microRNAs in question had been 
previously identified as modulated in prostate or any other neoplasias.  The microRNAs 
that were selected for further examination comprised the spectrum of both gain and loss 
of expression (Table 3-3).  While most selected miRs have some demonstrated 
evidence promoting carcinoma progression, whether in the form of proven targets or 
previous literature in other neoplasias, in some cases, the expression level difference  
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Figure 3-1:  Analysis of microRNA expression (fold difference in M12 vs. P69 cell 
lines).  Cultured cells were pelleted, RNA isolated, and subjected to Exiqon miRCURY 
LNA™ microRNA system Human panels I and II (version 2.M).  Panel I was performed 
in duplicate using 20 and 50 ng of RNA; Panel II was performed once, using 50 ng of 
RNA.  Data was normalized using the global mean, and fold difference calculated.  
Values greater than 1 represent higher expression in M12 as compared to the P69 cell 
line. 
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Table 3-2a: Tumour suppressor microRNAs identified through miRcury RT-qPCR 
panel analysis of M12 vs P69 cell lines panels I and II (Version 2.M).  Data is sorted 
by expression level, and values are fold expression difference in M12 from P69. 
microRNA 
Expression 
Difference 
microRNA 
Expression 
Difference 
microRNA 
Expression 
Difference 
hsa-miR-548m 0.002 hsa-miR-135b* 0.146 hsa-miR-500 0.319 
hsa-miR-127-3p 0.002 hsa-miR-132* 0.155 hsa-miR-2113 0.320 
hsa-miR-411 0.005 hsa-miR-520a-5p 0.156 hsa-miR-1227 0.329 
hsa-miR-138-1* 0.005 hsa-miR-29c* 0.158 hsa-miR-425* 0.333 
hsa-miR-891b 0.007 hsa-miR-514 0.160 hsa-miR-146b-5p 0.334 
hsa-miRPlus-C1089 0.009 hsa-miR-489 0.161 hsa-miR-140-3p 0.338 
hsa-miR-1248 0.017 hsa-miR-145* 0.162 hsa-miR-127-5p 0.344 
hsa-miR-299-5p 0.020 hsa-miR-342-5p 0.165 hsa-miR-1181 0.349 
hsa-miR-379 0.020 hsa-miR-23b* 0.169 hsa-miR-587 0.353 
hsa-miR-889 0.025 hsa-miR-556-3p 0.173 hsa-miR-379* 0.358 
hsa-miR-548a-5p 0.028 hsa-miR-23a* 0.178 hsa-miR-1182 0.359 
hsa-miR-323-3p 0.031 hsa-miR-1265 0.187 hsa-miR-876-3p 0.365 
hsa-miRPlus-D1061 0.036 hsa-miR-148a* 0.189 hsa-miR-296-3p 0.370 
hsa-miR-34b* 0.037 hsa-miR-143* 0.191 hsa-let-7a-2* 0.371 
hsa-miR-487b 0.039 hsa-miR-1267 0.193 hsa-miR-603 0.372 
hsa-miR-1238 0.039 hsa-miR-376a* 0.198 hsa-miR-411* 0.374 
hsa-miR-409-3p 0.042 hsa-miR-105* 0.199 hsa-miR-144 0.374 
hsa-miR-135b 0.043 hsa-miR-1260 0.210 hsa-miR-1538 0.378 
hsa-miR-614 0.043 hsa-miR-27a 0.210 hsa-miR-323-5p 0.382 
hsa-miR-504 0.044 hsa-miR-125b-1* 0.212 hsa-miR-758 0.386 
hsa-miR-1914* 0.045 hsa-miR-380 0.212 hsa-miR-770-5p 0.392 
hsa-miR-520d-3p 0.047 hsa-miR-369-5p 0.214 hsa-miR-15b 0.392 
hsa-miR-382 0.048 hsa-miR-572 0.215 hsa-miR-27b 0.395 
hsa-miR-1185 0.050 hsa-miR-100 0.222 SNORD38B 0.398 
hsa-miR-579 0.051 hsa-miR-1206 0.225 hsa-miR-1270 0.400 
hsa-miR-659 0.051 hsa-miR-19b-2* 0.230 hsa-miR-339-5p 0.403 
hsa-miR-136 0.055 hsa-miR-138-2* 0.232 hsa-miR-654-5p 0.404 
hsa-miR-452* 0.057 hsa-miR-598 0.234 hsa-miR-19b 0.405 
hsa-miR-377 0.058 hsa-miR-376c 0.235 hsa-miR-630 0.408 
hsa-miR-490-5p 0.059 hsa-miR-31 0.237 hsa-miR-449b* 0.413 
hsa-miR-936 0.064 hsa-miR-376b 0.241 hsa-miR-1256 0.415 
hsa-miR-362-3p 0.072 hsa-miR-1258 0.242 hsa-miR-378* 0.416 
hsa-miR-616 0.080 hsa-miR-543 0.256 hsa-miR-212 0.428 
hsa-miR-432 0.085 hsa-miR-191 0.258 hsa-miR-142-5p 0.431 
hsa-miR-619 0.086 hsa-miR-432* 0.267 hsa-miR-302d* 0.446 
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hsa-miR-509-3p 0.091 hsa-miR-181a-2* 0.267 hsa-miR-100* 0.448 
hsa-miR-1237 0.095 hsa-miR-302e 0.267 hsa-miR-555 0.454 
hsa-miR-541* 0.096 hsa-miR-448 0.272 hsa-miR-23b 0.455 
hsa-miR-1179 0.098 hsa-miR-376a 0.273 hsa-miR-146a 0.459 
hsa-miR-1236 0.100 hsa-miR-1245 0.275 hsa-miR-769-3p 0.460 
hsa-miR-640 0.105 hsa-miR-493* 0.275 hsa-miR-125a-3p 0.469 
hsa-miR-135a 0.122 hsa-miR-649 0.276 hsa-miR-1253 0.471 
hsa-miR-888* 0.124 hsa-miR-924 0.278 hsa-miR-34c-5p 0.472 
hsa-miR-342-3p 0.127 hsa-miR-191* 0.291 hsa-miR-224* 0.475 
hsa-miR-588 0.130 hsa-miR-875-3p 0.305 hsa-miR-591 0.479 
hsa-miR-527 0.132 hsa-miR-218-1* 0.306 hsa-miR-450b-5p 0.487 
hsa-miR-141* 0.135 hsa-miR-526b* 0.306 hsa-miR-636 0.489 
hsa-miR-196b* 0.137 hsa-miR-138 0.310 hsa-miR-720 0.490 
hsa-miR-125b 0.145 hsa-miR-21 0.312 hsa-miR-1914 0.492 
hsa-miR-516b* 0.146 hsa-miR-1913 0.316 hsa-miR-203 0.493 
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Table 3-2b: OncomiR microRNAs identified through miRcury microarray analysis 
of M12 vs P69 cell lines panels I and II (Version 2.M).  Data is sorted by expression 
level, and values are fold expression difference in M12 from P69. 
microRNA 
Expression 
Difference 
microRNA 
Expression 
Difference 
microRNA 
Expression 
Difference 
hsa-miRPlus-
A1027 
2.003 hsa-miR-200c* 3.487 hsa-miR-486-5p 9.078 
hsa-miR-126 2.004 hsa-miR-188-5p 3.557 hsa-miR-570 9.152 
hsa-miR-34c-3p 2.006 hsa-miR-642 3.597 hsa-miR-195* 9.307 
hsa-miR-515-3p 2.007 hsa-miR-326 3.606 hsa-miR-933 9.341 
hsa-miR-621 2.012 hsa-miR-490-3p 3.612 hsa-miR-663b 9.506 
hsa-miR-34a* 2.015 hsa-miR-193b* 3.617 hsa-miR-337-5p 9.977 
hsa-miR-22 2.026 hsa-miR-450a 3.620 hsa-miR-551a 10.377 
hsa-miR-365 2.042 hsa-miR-181c 3.650 hsa-miR-592 10.486 
hsa-miR-491-5p 2.071 hsa-miR-208b 3.741 hsa-miR-513c 10.656 
hsa-miR-96* 2.084 hsa-miR-628-5p 3.746 hsa-miR-211 10.954 
hsa-miR-1264 2.092 hsa-miR-154* 3.751 hsa-miR-299-3p 11.371 
hsa-miR-141 2.093 hsa-miR-7-1* 3.787 hsa-miR-623 11.895 
hsa-miR-589 2.094 hsa-miR-942 3.830 hsa-miR-508-3p 12.437 
hsa-miR-26b 2.105 hsa-miR-187 3.830 hsa-miR-19b-1* 12.583 
hsa-miR-187* 2.157 hsa-miR-135a* 3.855 hsa-miR-517* 12.739 
hsa-miR-330-3p 2.168 hsa-miR-595 3.858 hsa-miR-767-3p 12.925 
hsa-miR-32 2.175 hsa-miR-1244 3.885 hsa-miR-363* 13.280 
hsa-miR-885-3p 2.211 hsa-miR-558 3.986 hsa-miR-662 13.298 
hsa-miR-346 2.219 hsa-miR-647 4.044 hsa-miR-520b 13.474 
hsa-miR-28-3p 2.227 hsa-miR-943 4.137 hsa-miR-196a 13.480 
hsa-miR-30a* 2.277 hsa-miR-34a 4.183 hsa-miR-620 13.515 
hsa-miR-668 2.285 hsa-let-7d 4.191 hsa-miR-518c* 13.620 
hsa-miR-628-3p 2.295 hsa-miR-429 4.224 hsa-miR-3180-3p 13.753 
hsa-miR-1205 2.307 hsa-miR-675* 4.326 hsa-miR-562 15.051 
hsa-miR-1296 2.322 hsa-miR-548k 4.433 hsa-miR-767-5p 15.266 
hsa-miR-30e 2.327 hsa-miR-370 4.444 hsa-miR-501-3p 15.480 
hsa-miR-200b* 2.340 hsa-miR-519e 4.471 hsa-miR-486-3p 16.750 
hsa-miR-125b-2* 2.352 hsa-miR-520f 4.509 hsa-miR-371-5p 16.886 
hsa-miR-526b 2.391 hsa-miR-130a 4.531 hsa-miR-106a* 17.100 
hsa-miR-502-5p 2.396 hsa-miR-580 4.630 hsa-miR-338-5p 17.177 
hsa-miR-137 2.417 hsa-miR-548i 4.639 hsa-miR-33b 17.468 
hsa-miR-214 2.435 hsa-miR-890 4.692 hsa-miR-616* 17.628 
hsa-miR-223 2.437 hsa-miR-146a* 4.810 hsa-miR-374b* 17.749 
hsa-miR-744 2.443 hsa-miR-583 5.012 hsa-miRPlus-
A1031 
17.818 
hsa-miR-325 2.483 hsa-miR-188-3p 5.021 hsa-miR-1269 17.957 
hsa-miR-7 2.490 hsa-miR-222* 5.023 hsa-miR-372 18.745 
hsa-miR-210 2.497 hsa-miR-518b 5.143 hsa-miR-557 18.817 
hsa-miR-33b* 2.499 hsa-miR-548o 5.164 hsa-miR-512-5p 19.327 
hsa-miR-518e 2.514 hsa-miR-124 5.174 hsa-miR-202 19.695 
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hsa-miR-1249 2.515 hsa-miR-885-5p 5.175 hsa-miR-18b* 20.163 
hsa-miR-339-3p 2.528 hsa-miR-146b-3p 5.355 hsa-miRPlus-
D1033 
21.296 
hsa-miR-760 2.529 hsa-miR-600 5.403 hsa-miR-675b 21.361 
hsa-miR-30d 2.555 hsa-miR-597 5.554 hsa-miR-873 21.467 
hsa-miR-1911* 2.561 hsa-miR-15b* 5.574 hsa-miR-1 23.538 
hsa-miR-605 2.583 hsa-miR-381 5.729 hsa-miR-412 23.833 
hsa-miR-148b 2.601 hsa-miR-99a 5.742 hsa-miR-491-3p 24.610 
hsa-miR-877* 2.603 hsa-miR-223* 5.753 hsa-miR-498 25.427 
hsa-miR-200a 2.655 hsa-miR-634 5.801 hsa-miR-937 26.513 
hsa-miR-421 2.664 hsa-miR-518a-3p 5.860 hsa-miR-451 27.084 
hsa-miR-499-5p 2.731 hsa-miR-596 5.881 hsa-miR-520d-5p 27.591 
hsa-miR-1263 2.741 hsa-miR-30c-1* 5.921 hsa-miR-556-5p 27.696 
hsa-miR-26a-1* 2.751 hsa-miR-516a-5p 6.019 hsa-miR-147 27.998 
hsa-miR-25* 2.777 hsa-miR-335* 6.032 hsa-miR-92b* 28.949 
hsa-miR-564 2.805 hsa-miR-554 6.091 hsa-miR-515-5p 30.258 
hsa-miR-545 2.807 hsa-miR-150 6.103 hsa-miR-517c 31.942 
hsa-miR-22* 2.811 hsa-miR-521 6.140 hsa-miR-373* 34.484 
hsa-miR-548d-5p 2.836 hsa-miR-615-3p 6.170 hsa-miR-524-3p 34.725 
hsa-miR-891a 2.840 hsa-miR-551b* 6.242 hsa-miR-454* 35.910 
hsa-miR-26a-2* 2.880 hsa-miR-199a-3p 6.426 hsa-miR-133a 37.907 
hsa-let-7c 2.932 hsa-miR-10a* 6.566 hsa-miR-133b 38.930 
hsa-miR-200a* 2.943 hsa-miR-497 6.572 hsa-miR-181c* 42.935 
hsa-miR-30c-2* 3.050 hsa-miR-9 6.676 hsa-miR-373 45.111 
hsa-miR-184 3.077 hsa-miR-516b 6.816 hsa-miR-518f 47.556 
hsa-miR-1271 3.082 hsa-miR-525-3p 6.817 hsa-miR-921 69.187 
hsa-miR-302a 3.167 hsa-miR-541 7.187 hsa-miR-548l 76.180 
hsa-miR-149* 3.175 hsa-miR-139-5p 7.456 hsa-miR-375 81.495 
hsa-miR-552 3.302 hsa-miR-129-3p 7.465 hsa-miR-143 83.063 
hsa-miR-510 3.344 hsa-miR-362-5p 7.488 hsa-miR-631 85.097 
hsa-miR-10a 3.349 hsa-miR-217 7.616 hsa-miR-153 100.736 
hsa-miR-130b 3.361 hsa-miR-888 7.620 hsa-miR-105 131.645 
hsa-miR-96 3.388 hsa-miR-301b 7.815 hsa-miR-622 147.739 
hsa-miR-608 3.404 hsa-miR-1224-3p 7.950 hsa-miR-122 198.567 
hsa-miR-485-3p 3.414 hsa-miR-519a 8.064 hsa-miR-147b 201.357 
hsa-miR-615-5p 3.421 hsa-miR-338-3p 8.159 hsa-miR-551b 264.961 
hsa-miR-149 3.432 hsa-miR-198 8.234 hsa-miRPlus-
C1076 
1046.216 
hsa-miR-302c 3.435 hsa-miR-610 8.235    
hsa-miR-130b* 3.448 hsa-miR-517a 8.245     
hsa-miR-1255b 3.461 hsa-miR-10b 8.885     
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Table 3-3: microRNAs selected for further analysis 
microRNA 
Expression 
difference 
(M12 vs. P69) 
Proven 
Targets 
Reported in cancer: 
9 6.68 
CDH1, REST, 
CDKN1A, BCL6, 
FOXO1, NF-kB1, 
ETS-1, CD34, 
OncomiR in glioblastoma, lung, hepatocellular, 
prostate, gastric, bladder, mesothelioma 
Tumour suppressor in ovarian 
144 0.374 PLAG1, FGA, FGB 
OncomiR in lung, prostate, esophageal, 
nasopharyngeal 
Tumour suppressor in bladder, bone, colorectal 
133a 37.91 
FSCN1, TAGLN2, 
GSTP1, COL1A1, 
LASP1 
Tumour suppressor in ovarian, colorectal, 
breast, bone, bladder 
133b 38.93 
FSCN1, PTBP2, 
ERG, HCN2, MET 
Tumour suppressor in bladder, uterine, gastric, 
prostate 
146a 0.459 --- 
OncomiR in bone, liver, ovarian, prostate 
SNP mutation confers oncomiR in breast, 
colorectal, ALL, pancreatic 
Tumour suppressor in lung 
147b 201.4 --- Tumour suppressor in rectal 
199a-3p 6.43 
MAPK8, MET, 
CD44, MAPK1, 
AKT1, MET 
OncomiR in colon, gastric, biliary 
Tumour suprressor in testicular, bladder, 
endometrial, bone, liver 
221 0.783 
CDKN1B, c-KIT, 
CDKN1C, DDIT4, 
p27, ZEB2, TBK1 
OncomiR in breast, melanoma, pancreatic, 
glioblastoma multiforme, AML, prostate, cervical, 
ALL 
Tumour suppressor in gastric 
299-3p 11.37 --- --- 
299-5p 0.02 OPN Tumour suppressor in breast 
147 27.9 VEGFA 
OncomiR in liver, lung, gastric, squamous cell 
carcinoma of the tongue 
Tumour suppressor in breast 
488 0.526 AR none 
622 147.7 ING1, K-Ras 
OncomiR in colorectal 
Tumour suppressor in gastric 
127-3p 0.002 MAPK4 
Tumour suppressor in gastric, B-cell non-
Hodgkins lymphoma, renal, bone 
127-5p 0.344 MMP13 
OncomiR in thyroid, cervical 
Tumour suppressor in hepatocellular, colon 
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was so compelling that miRs were chosen without any known targets or previous 
association with cancer.   
Analysis of selected miRs using prostate cell lines 
 The next phase of miR selection was undertaken through single-miR RT-qPCR 
analysis of the subset of miRs selected for further investigation (Table 3-3).  Through 
this work, we hoped to accomplish a two-fold goal:  first of all, to confirm the miRcury 
microarray data through single-miR analysis of RNA from additional passages of M12 
and P69 cell line RNA; secondly, to ascertain whether our initial classification of the 
selected miRs as tumour suppressors or oncomiRs was genuine through analysis of 
additional model cell lines.  This two-fold approach would allow for elimination of those 
miRs that did not follow through as initially expected.  Narrowing of the candidates could 
be important, as the quantity of RNA extracted through laser-capture microdissection of 
patient samples was expected to be low, and the number of miRs that could be 
analyzed was finite.  As was suspected, confirmatory single-miR RT-qPCR analysis of 
the selected miRs showed correlative results in fold expression differences from P69 to 
M12 for most, but not all, microRNAs selected (Table 3-4 and Appendix 1:Table 1).  
While the results were mostly correlative in that oncomiRs typically were overexpressed 
and tumour suppressors lost as compared to P69 levels, the level of those differences 
was often highly variable.  miRs 622, 221, and 299-3p were found to be so different that 
they were opposite in expression as originally observed.  These findings in particular 
were repeated and confirmed with at least one additional RNA extraction.  The 
differences may have been due to the normalization parameters, as the panel data was  
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Table 3-4:  Expression differences are typically observed between Panel and 
single miR “confirmatory” RT-qPCR analysis.  RNA was isolated from different 
passages of M12 and P69 cells than those used for the panel analysis, and subjected to 
individual probing for selected miRs using LNA RT-qPCR.  In both panel and single-miR 
analysis, data was normalized (against the global mean in the panel, and against 
RNU48 for single-miR analysis), and the expression level in M12 calculated relative to 
the P69 cell line.  Each sample was analyzed a minimum of three times.  299-5p results 
appeared correlative, but the RNU48 amplification was atypical.  miR-144 was 
undetected for both P69 and M12 in single-miR analysis. 
Expression differences between panel and single-miR analysis 
 133a 133b 9 622 199a-3p 147b 147  
Panel 37.9 38.9 6.7 147.7 6.43 201.4 27.9  
Single-miR 6.7 2.5 43.3 0.374 1.514 16.9 0.138  
         
 146a 488 221 127-3p 127-5p 299-3p 299-5p 144 
Panel 0.459 0.526 0.783 0.002 0.344 11.4 0.02 0.374 
Single-miR 0.021 0.039 1.39 0.003 0.164 0.035 --- --- 
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normalized to the global mean, while single-miR analyses were normalized to RNU48.  
This could be expected to result in minor differences, but major discrepancies such as 
those seen in miRs 622, 221, and 299-3p cannot be attributed to the normalization 
method. 
 Each of the selected miRs was then further analyzed using the remainder of the 
P69 progression model, as well as additional prostate cancer cell lines, in an effort to 
determine which microRNAs warrant further investigation through modulation and target 
confirmation.  Through analyzing multiple prostate cancer and associated cell lines, we 
hoped to gain confidence in our chosen miRs prior to using precious patient laser-
capture microdissected RNA.  Through this analysis, we chose those miRs that were 
the most consistently expressed among the cell lines (depending on the nature of the 
cell line), and/or those miRs that continued to intrigue us based on their targets or 
known roles in carcinogenicity (Figures 3-2, 3-3, and 3-4, Appendix 1-Table 2). 
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Figure 3-2:  Relative Expression of oncomiR microRNAs in P69-M12 progression 
model.  miR levels were normalized to RNU48, and expression level calculated relative 
to the P69 cell line.  Each sample was analyzed in triplicate at minimum. 
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Figure 3-3:  Relative Expression of Tumour suppressor microRNAs in P69-M12 
progression model.  miR levels were normalized to RNU48, and expression level 
calculated relative to the P69 cell line.  Each sample was analyzed in triplicate at 
minimum.  M12 data for miR-299-5p was not included due to a discrepancy in RNU48. 
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Figure  3-4:  Relative Expression of microRNAs in additional prostate cell lines.  
miR-levels were normalized to RNU48, and are expressed as the dCT (CT(miR) – 
CT(RNU48)).  A lower CT indicates higher expression.  Each sample was analyzed in 
triplicate at minimum. 
 
 
 
 
0.0
5.0
10.0
15.0
20.0
25.0
d
C
T
WPMY1, DU145, M12, PC3 P69
75 
 
miR analysis of Laser-Capture Microdissected (LCM) prostate samples 
 Laser-captured microdissected samples were captured from 5 patient biopsies at 
varying stage of prostate cancer.  The majority of the tumours analyzed were classified 
as Gleason 3, 4, or 5, and in some cases, it was only possible to isolate not only benign 
and tumour tissue, but also stroma, lymphocyte, and/or venous tissue.  miR LNA RT-
qPCR analysis of the 5 sets of patient samples revealed that, as expected, there is 
considerable variability in the nature of the individual patient sample.  A majority of the 
miRs tested varied wildly from tumour to tumour; however, a few miRs assayed showed 
consistency with their predicted role compared to the model cell lines (Figure 3-5, 
Appendix 1: Table 3).  In particular, miR-9 and miR-147b were strongly and consistently 
oncomiRs in tumour samples, and miRs 299-3p and 199a-3p were consistently lower in 
tumour samples than benign, and thus classified as potential tumour suppressors. 
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Figure 3-5:  Relative expression of microRNAs in laser capture microdissected 
tissue samples.  miR levels were normalized to RNU48, and expression level 
calculated relative to the benign tissue of the same patient.  Each sample was analyzed 
in triplicate.   
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DISCUSSION 
Array analysis 
 Array analyses of cell lines, while they should not be used as the sole method for 
identifying miRs that are modulated in neoplasias, can be an excellent launching point 
for narrowing the potential candidates, provided that the cell line model is accurate to in-
vivo processes.  In prostate cancer work, some cell lines serve different purposes.  For 
example, the LNCaP series is an excellent model for identifying miRs that could 
contribute to the pathways required for androgen independence.  However, since the 
LNCaP cell lines require coinjection with MS fibroblast cells for tumorigenesis and 
metastasis in the later lines, they are not a good model for initial tumour development.  
The P69/M12 progression model is the best model for human prostate cancer 
tumorigenesis, and thus we felt that a miR array comparing those cell lines would best 
catalogue modulated miRs in a manner most faithful to human tumorigenesis.  Of the 15 
miRs selected for further analysis, 10 of the 15 (67%) maintained their oncomiR or 
tumour suppressor status in single miR analysis (Table 3-4).  Unfortunately, that 
indicates a relatively high (23%) incorrect read rate for miR analysis using panels.  
There are a variety of technical reasons as to why panel analysis is more subject to 
errors or inaccuracies, but one likely reason is that of stochastic effects.  Splitting one 
reverse transcription reaction across 768 wells is a dilution factor far above that used for 
single-miR analysis, and the sheer chance of an accurate representation of all miRs in 
the sample getting into each of those wells can be a factor in expression level variation.  
Because of that concern, we ran technical duplicates of both M12 and P69 for Panel 1.  
We found that there was high variability between the duplicate runs of Panel 1, and thus 
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the miRs chosen from Panel 1 were those that were consistently modulated (up or 
down) in both plates. 
 Variation between technical duplicates is well-known in miR microarray analysis; 
a study evaluating and comparing locked-nucleic acid (LNA) arrays to bead-based and 
Taqman low-density arrays found that the LNA inter-plate reproducibility was higher 
than the other methods, at approximately 75%111, consistent with the findings presented 
here.  An additional study comparing microarray data to single-miR analysis found 
anywhere from 0 to 10-fold differences in expression between the two platforms112, 
similar to differences observed in this study. 
miR 9 
 As a well-established miR involved in multiple cancers, miR-9 was not a 
surprising find.  miR-9 was overexpressed in all CaP cell lines analyzed, and in 3 of the 
5 patient samples.  Overexpression was dramatic, in the thousand-fold range for the 
DU145 and PC3 cell lines, and a more reasonable overexpression level in M12 and 
patient samples (2.5-78 fold higher than benign).  There are only two reports on miR-9 
in prostate cancer, one being a microarray study and the other focused on the 
Androgen Receptor (AR).  The microarray study found that miR-9 was the most 
dramatic and consistently upregulated miR in prostate cancer, and was expressed as 
an oncomiR in both low and high-grade regions within the same tumour113.   
 miR-9 has many well-established protein targets, in particular, e-cadherin, NF-
ĸB, SOCS5 and ETS-1.  A modest but consistent decrease in the androgen receptor 
level has been shown when miR-9 was overexpressed in-vitro113, which could allow for 
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an eventual switch from the early androgen-dependent tumour to a hormone-refractory 
state. 
miR-144 
 miR-144 has been well-characterized as a modulated microRNA in multiple 
cancers.  However, it seems to have different roles depending on tissue type, and as 
such can be either an oncomiR (lung, esophageal, nasopharyngeal) or tumour 
suppressor (bladder, bone, colorectal), depending on the cancer type.  While our initial 
panel analysis showed miR-144 as a tumour suppressor (0.37-fold downregulated in 
M12 vs. P69), it was undetected in both P69 and M12 single-miR analyses, but highly 
expressed in the M2182 and F6 lines.  To further complicate the picture, patient LCM 
samples showed significant upregulation in tumour compared to benign tissue from the 
same patient, correlative with a recent microarray study reporting miR-144 as a 
potential oncomiR for prostate cancer113.  While the LNA technology used for miR 
analysis in this study is highly specific for the miR in question, recent work in our 
laboratory has found other miR RT-qPCR platforms to be more sensitive in detection, 
and perhaps clarification of the P69 vs. M12 cell line analysis could be further 
investigated using a different platform.  This particular example highlights the need for a 
thorough and balanced approach to miR discovery, using not only cell lines, but also 
patient samples.  Given the consistency in patient samples, miR-144 could be an 
oncomiR in prostate cancer and warrants further investigation, although it would not be 
recommended to use the P69/M12 progression line for miR-144 work. 
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miR-221 
 miR-221 was highly inconsistent in CaP samples, both in cell line analysis and 
patient samples.  Initial panel analysis showed miR-221 to be slightly tumour 
suppressive, with an average expression difference of 0.783 in M12 vs. P69 cells.  
Single-miR analysis showed a 1.38-fold upregulation in the M12 line.  Given known 
error levels in miR panel analysis, this expression difference could be considered to be 
within the range of error.  Analysis of miR-221 in other cell lines and patient samples 
was likewise inconsistent, the only exception being patient 09-362, who had 
overexpression of miR-221 in not only tumour, but also stroma and lymphatic tissue 
(Appendix 1, Table 3).  Thus, miR-221 cannot be considered as an indicator miR for 
prostate carcinoma, but may in fact still be a player in advanced prostate cancer:  while 
several studies report that miR-221 is lost in prostate cancer, others have shown that in 
highly metastatic cancers, miR-221 is overexpressed in association with high-risk 
carcinomas114 and plays a role in androgen independence17. 
miR-488 
 The loss of miR-488 expression was even more impressive in single-miR 
analysis as compared to the panel analysis (0.039 vs. 0.526-fold drop in expression in 
M12 vs. P69).  Similar expression levels to the metastatic M12 cell line were noted in 
the PC3, DU145, and other prostate cell lines, which led us to believe that miR-488 
could be a substantial tumour suppressor.  Unfortunately, it was undetected in both 
benign and tumour samples of all patients (Appendix 1, Table 3).  Exiqon LNA RT-
qPCR is highly specific, but not as sensitive as other applications.  Thus, evaluation with 
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a different platform for miR RT-qPCR analysis could yield results.  Additionally, a study 
in 2011 was unable to detect miR-488 in the prostate cell lines (DU145, PC3, LNCaP), 
but evaluated the miR regardless and found that it is able to affect androgen receptor 
translation directly.  They also found that when they added back miR-488, proliferation 
and viability decreased, and apoptosis was enhanced115.  Unfortunately, the literature 
shows no correlation of miR-488 with any cancer, and expression is mainly seen in 
neural development.  miR-488 levels have also been shown to be so consistent in lung 
cancer patient samples when comparing benign to tumour that it was proposed as a 
potential normalization control116.   
miRs-299-3p & 5p 
 miRs 299-3p and 5p were cast via panel analysis as opposite in expression, with 
miR-299-3p an oncomiR and 299-5p as a tumour suppressor.  This possibility was 
rather intriguing, as it indicated that a shift in strand selection at the miR maturation 
level.  Unfortunately, the high relative level of expression for miR-299-3p did not 
correlate under single-miR analysis, and multiple replicates of miR-299-3p analyzed in 
P69 and M12 showed miR-299-3p expression lost in M12 as compared to P69.  
Similarly, miR-299-3p was lost in PC3 cells as well.  Of the five patients tested for miR-
299-3p, two had detectable levels in benign, with lost or lower expression of miR-299-3p 
in tumour samples.  The remaining 3 samples were undetected in tumour and benign 
tissues.  Thus, miR-299-3p appears to be consistently acting as a tumour suppressor, in 
contrast to its originally perceived role as an oncomiR from the panel analysis.  There is 
no literature or proven targets for miR-299-3p, but many potential binding target 
mRNAs, as predicted by miR prediction platforms86,87,89,117. 
82 
 
 miR-299-5p was identified as a tumour suppressor in the panel analysis, which 
was confirmed by the single-miR analysis.  Expression was similar between M2 and 
PC3 cells, but the miR was undetected in DU145 cells.  Patient analysis found that of 
the 5 patients tested for miR-299-5p, two showed overexpression, in direct contrast to 
that observed by the cell line analyses.  Three patients had undetected levels of miR-
299-5p in both tumour and benign samples.  Of the limited literature available for miR-
299-5p, it has been shown to act as a tumour suppressor in breast cancer, as loss of 
miR-299-5p allows relief of suppression for the Osteopontin protein118, which is known 
to play an important role in inflammation, tissue remodeling, invasion, migration, and 
angiogenesis119.  Osteopontin is also well-characterized as surging in expression during 
the preosteoblast stage of bone cell development, which could parallel the CaP cell 
integration in to bone metastases; moreover, increased osteopontin levels have been 
observed in the LNCaP C4/C5/C4-2 androgen-independent sublines32.  Given its 
bimodal observed role in cell lines and patient samples, it is possible that analysis of 
miR-299-5p with the LNCaP series could illuminate a potential hormone-dependent 
switch. 
miR-147 
 There is not a lot of literature regarding the expression of mIR-147 (also known 
as miR-147a) in cancer, but it has been shown to act as both a tumour suppressor and 
as an oncomiR in different cancers.  Only one mRNA target has been proven, VEGFA, 
which has been shown to stimulate angiogenesis, wound healing and tumour 
development120.  In our analyses, while the panel identified miR-147 as a potential 
oncomiR (27.9-fold increased expression), single-miR analysis showed the opposite 
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pattern, with M12 cells expressing 0.138 fold the level of the P69 cells.  Because of this 
inconsistency, we did not analyze the additional cell lines, and only tested one set of 
patient LCM samples, in which miR-147 levels were undetected in both benign and 
patient. Consequently, we do not consider miR-147 to have a consistent role in prostate 
cancer. 
miR-147b 
 miR-147b is one of the most consistent and promising potential oncomiRs to 
develop from this study.  Panel and single-miR confirmation showed this miR to be 
highly upregulated (201 and 16-fold, respectively), and this high expression was 
duplicated in other prostate cell lines, in a pattern consistent with the neoplastic and 
metastatic nature of the cell lines tested (Figure 3-3).  In particular, the levels of miR-
147b in PC3 cells were exceptionally high.  Through patient LCM sample analysis, 4 of 
the 5 patients showed significant upregulation, with an average of 11.1-fold 
overexpression as compared to paired benign tissue (Appendix 1, Table 3).  This miR is 
relatively uncharacterized; it has not been described in any cancers, and has no known, 
proven targets, although one study did some preliminary work using luciferase 3’-UTR 
constructs and showed some modulation for a few target mRNAs44.  However, the focus 
was less on proving target binding and consequent effects and more on comparing 
seed functionality to other miRs; thus, those targets have not been conclusively shown 
as miR-147b targets.  As a relatively unresearched microRNA, miR-147b will require 
considerable research effort to hammer out its oncogenic mechanism. 
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miR-622 
While there is not a lot of literature regarding miR-622 in neoplasias, the literature 
does agree that miR-622 is upregulated in some rectal cancers, particularly those 
responsive to specific chemotherapeutics121 and those associated with Lynch 
Syndrome122.  However, one report showed that miR-622 acts as a tumour suppressor 
in gastric cancer, with ING1 as a proven target, a component of the p53 pathway 
involved in cell cycle arrest and apoptosis123.  While expression of miR-622 in the panel 
RT-qPCR was not replicated in single-miR analysis, PC3 and DU145 expressions were 
relatively high, but so was the benign stromal line WMPY-1.  Additionally, only 2 of the 5 
patients sampled showed upregulation of miR-622; thus, unless additional patients are 
sampled, it can’t be concluded with confidence that miR-622 is an oncomiR in CaP. 
miRs-127-3p and 5p 
miRs 127-3p and 5p expression levels were lower in M12 cells as compared to 
P69, which was confirmed in single-miR analysis.   They were not tested against the 
additional prostate lines, but were tested against the patient LCM samples.  three out of 
five patients showed loss of expression in miR-127-3p in tumour compared to adjacent 
benign tissue, as did three out of five for 127-5p (though not the same three patients for 
both miRs).  miR-127 deregulation has been shown in gastric and hepatocellular 
cancer, specifically through epigenetic methylation silencing124,125.  This silencing would 
in fact silence both strands, thus making it more difficult to clarify which is having a more 
pronounced effect on tumorigenesis or metastatic behavior.   
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miR-127-3p has at least one proven target, MAPK4, which has already been 
shown to be pivotal in gastric cancer invasion and metastasis124.  miR-127-5p was 
shown to attenuate MMP13 through 3’-UTR and western analysis, which moderately 
promotes invasion and migration125.  miR-127-5p and -3p certainly warrant further 
investigation as a potential tumour suppressor set of microRNAs. 
miRs-133a and b 
miR-133a upregulation was consistent in single-miR analysis, but this 
upregulation did not correlate with the other prostate cell lines tested, and only 2 of the 
5 patient samples showed overexpression of miR-133a.  While miR-133b yielded a 
predictable cell line pattern, in that it was overexpressed in the benign hypertrophic cell 
line BPH-04, as well as in the M12 cells (Appendix 1, Table 1), there was not an 
appreciable overexpression in either DU145 or PC3 cells.  Thus, this miR was not 
analyzed with the limited cDNA created from the patient LCM samples.  Both miRs have 
been well-studied in other cancers as tumour suppressor miRs, and have several 
proven and defined targets in the tumour suppression pathway, and thus they are 
worthy of further research to clarify what is occurring in prostate samples. 
miR-146a 
 Several studies have shown miR-146a as an oncomiR in prostate cancer, but 
one report has shown that overexpression of miR-146a is associated with early stage, 
androgen-dependent neoplasias, while a loss of function of miR-146a is essential for 
androgen independent invasion and metastasis126.  Single-miR analysis confirmed the 
panel-identified loss of expression in M12 as compared to the benign P69, and so initial 
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findings identified miR-146a as a tumour suppressor in cell line analysis.  Unexpectedly, 
only one patient’s tumour had detectable levels of miR-146a.  The miR was 
undetectable in the remaining 4 patient benign and tumour tissues. 
miR-199a-3p 
 While miR-199a-3p was initially identified and confirmed as an oncomiR in the 
P69/M12 progression model, in the 2 patients tested, it consistently showed a ~0.5 fold 
loss of expression in tumour as compared to benign.  The only tissue that it was 
dramatically overexpressed was the stroma of one patient.  miR-199a-3p has been 
shown to act as both oncomiR and tumour suppressor in various cancers, and has 
multiple proven targets to promote both natures; additional work may need to be 
conducted to further evaluate miR-199a-3p’s role towards the progression of CaP, if 
any. 
Overall Conclusions & Future Directions 
 Analysis of a panel of over 700 miRs certainly generates a great deal of 
information, such that one research laboratory couldn’t begin to track down each of the 
modulated microRNAs.  Based on bioinformatics analysis and literature research, 15 
microRNAs were chosen that showed promise through the panel comparison of the 
highly tumorigenic, metastatic M12s to the non-tumourigenic parental P69 line.  This 
comparison is the first of its kind in prostate cancer cell line research; only the P69/M12 
progression can compare a poorly tumorigenic parental line to its metastatic, 
tumorigenic subline that requires no coinjections to generate tumours in mice.  Based 
on the results of these analyses, a balanced approach including not only cell-line but 
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also patient sample analysis allowed elimination of several candidates that appeared to 
be dysresgulated.  Of the 15 candidate miRs chosen for further analysis, 5 did not 
correlate with single-miR analysis.  Of the 14 miRs analyzed using patient LCM tissues, 
only 5 (miR-9, miR-147b, miR-299-3p, miR-127-3p and miR-127-5p) showed sufficient 
consistency between cell-line analyses and between patients to warrant further 
investigation.  Thus, a 33% success rate was achieved based on initially identified 
dyseregulated microRNAs.  The majority of the miRs selected for further investigation 
are, for the most part, not well-described in prostate cancer, and the challenge will be to 
identify those mRNA targets that lead to tumour progression through either a tumour 
suppressor or oncomiR role. 
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Chapter 4 
miR-147b is an oncomiR in prostate cancer and suppresses AATF 
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INTRODUCTION 
 Previous work identified miR-147b as being up-regulated in not only prostate 
cancer cell lines (Figure 4-1), but also in prostate cancer biopsy tumour samples as 
compared to the benign laser-capture microdissected samples (Figure 4-2).   
 miR-147b is not well-studied, having been neither identified as an oncomiR or 
tumour suppressor miR, nor has significant work been reported in proving potential 
mRNA targets.  miR-147b has a similar mature sequence to that of miR-147a38-41, 
differing by only one base in the seed region (miR-147b – UGUGCG, miR-147a -- 
UGUGUG).  While miR-147a has a proven target in vascular endothelial growth factor A 
(VEGFA), a protein known to be pro-angiogenic and pro-migration, there are no proven 
targets for miR-147b.   
Previously, mIR-147b has been  labeled as miR-147 in some reports127, and is 
found on chromosome 15q21.1128, specifically in the 3’-UTR of the normal mucosa of 
esophagus-specific gene 1 protein (NMES1) (Figure 4-3).  Interestingly, NMES1 siRNA 
does not inhibit mature miR-147 levels in mice127.  While there are several targets that 
are predicted by various prediction software platforms (Table 4-1), none have been 
proven thus far, and very few show potential as downregulated tumour suppressors. 
 miR-147b has an identical seed region to that of miR-210 (UGUGCG), and while 
the two miRs have been shown to have some similarity in target effectiveness, they are 
not completely duplicative in their target selection (Figure 4-4)44.  While miR-210, 147a 
and 147b have been shown to have some overlapping predicted targets, each also has 
targets unique to the individual miR.  Interestingly, the number of predicted targets for 
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miR-147a is much higher than the sum of the miR-147b and miR-210 targets.  It is 
assumed that the remainder of the miR sequence has a role in target mRNA selection 
as well, and thus this finding is not surprising.  In our panel analysis of microRNA 
expression in the P69-M12 cell lines, we found miR-210 to be overexpressed 
approximately 2-fold in M12 cells as compared to P69.  Given that miR-147b showed an 
almost 17-fold overexpression, it is doing the bulk of the target repression in the M12 
model if in fact miR-147b and miR-210 have similar regulatory objectives. 
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Figure 4-1 (Adapted from Chapter 3):  miR-147b levels are upregulated in all 
prostate cancer cell line models.  A: miR-147b levels were measured in P69, M2182, 
M12, and F6 cells.  Data was normalized to RNU48 and expressed relative to P69 using 
the comparative CT method.   P69 and M12 cells were analyzed using 3 separate 
extractions (p<0.05).  B: miR-147b levels were measured in M12, DU145, and PC3 
cells.  Data was normalized to RNU48 (dCT) and expressed as a box plot.  The dCT for 
the P69 cell line is visualized as the red box. 
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Figure 4-2 (Adapted from Chapter 3):  miR-147b expression is upregulated in 80% 
of tested patient tumours.  miR-147b levels were measured in tumour and benign 
tissue separated from prostate biopsies using laser-captured microdissection (LCM).  
Data was normalized to RNU48 and expressed relative to the benign tissue using the 
comparative CT method. 
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Figure 4-3:  The pre-miR-147b is located in the 3’-UTR of the NMES1 primary 
transcript on chr15q21.1.  NF-ĸB and STAT1α bind upstream of the pre-miRNA, and 
activate expression.  Mature miR-147b has been shown to develop from cloned primary 
transcripts of NMES1, as well as being independently transcribed127.  Blue represents 
the untranslated regions (UTRs) of the NMES1 mRNA, shades of green represent the 
exons, and yellow indicates the relative position of the miR-147b transcript. 
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microRNA Sequence 
hsa-miR-147a guguguggaaaugcuucugc 
hsa-miR-147b gugugcggaaaugcuucugcua 
hsa-miR-210 cugugcgugugacagcggcuga 
  
                          
 
Figure 4-4:  Similarities between miRs-147a, -147b, and -210.  A:  Table of miR 
sequences.  The seed region is highlighted in green.  B: Targetscan analysis of 
potential targets for miRs 147a, 147b, and 210.  While 62 potential targets are in 
common for all three miRs, each also has unique as well as overlapping mRNA targets.  
(from Bertero et al.44) 
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It is difficult to tease out early (2012 and previous) literature on the miR-147 
family.  Previous incarnations of the commonly used microRNA RT-qPCR arrays 
(Applied Biosytems, Qiagen) had only “miR-147”, with no indication of sequence or A/B 
specificity.  In one instance, miR-147 was designated as such, but the Methods & 
Materials section confirmed it to be miR-147b.  In this report, Toll-like Receptor 2 
(TLR2) and Type 1 Interferon (IFN) stimulation in mice induced miR-147b expression 
through activation and subsequent binding of NF-ĸB and STAT1α to the miR-147 
promoter.  Inflammatory cytokine expression was subsequently attenuated through a 
negative feedback loop127.  This same study reported 3 potential NF-ĸB binding sites in 
the mouse miR-147 promoter, two of which were shown through luciferase activity 
assays to be responsive to NF-ĸB binding.   
Given the remarkable consistency in upregulation of miR-147b in our work, not 
only in prostate cancer cell lines, but also in patient samples, it was important to 
evaluate how inhibition of miR-147b could impact the tumorigenicity of a prostate cancer 
cell line model, and to identify potential tumour suppressor mRNA targets for miR-147b. 
Project Aims 
1.  Inhibit miR-147b levels in the M12 cell line and evaluate any changes in 
proliferation, tumorigenicity, or invasive potential. 
2. Identify potential targets and pathways for a mechanism of miR-147b action. 
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Methods and Materials 
Cell Culture 
 Adherent cells were cultured in 75 cm2 flasks using RPMI 1640 supplemented 
with L-Glutamine (Caisson Labs, North Logan, UT), 5% fetal bovine serum, 5 µg/mL 
insulin, 5 µg/mL transferrin, 5 µg/mL selenium (ITS, Collaborative Research, Bedford, 
MA).  Gentamycin (0.05 mg/mL) was used to prevent bacterial contamination. Cells 
were passaged when 50-65% confluent, and maintained for no longer than 20 
passages.  Passaging was accomplished by incubating with 0.25% Trypsin-EDTA 
(Gibco-Life Technologies, Carlsbad, CA) for 5 minutes at 37°C, after which the trypsin 
was inactivated by washing the cells in serum-containing media.  The cells were then 
pelleted through centrifugation at 1500xg for 5 minutes and either passaged, plated, or 
pellets preserved.  Cell pellets for analysis were produced by washing the pellet in 10 
mL PBS, centrifugation at 1500xg for 5 minutes, removal of the supernatant, and flash 
freezing in liquid nitrogen.  Pellets were stored at -80°C for at least 24 hours. 
Transfection 
Stable transformations of an early passage of the M12 cell line with a vector 
containing a miR-147b inhibiting sequence or scrambled control (pEZX-AM03, 
Geneocopeia Inc., Rockville, MD) were performed using TransIT®-LT1 Transfection 
Reagent (Mirus BIO LLC, Madison, WI, USA).  Briefly, 1.5 x 105 cells were plated in a 
25 cm2 flask in appropriate serum-containing media for 24 hours.  The cells were then 
rinsed with PBS, and serum-containing media replaced.  The plasmid (6.5 µg) was 
mixed with 650 µL of RPMI media with no serum or additives and 19.5 µL of TransIT®-
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LT1 reagent at room temperature for 15-30 minutes.  The solution was added dropwise 
to each flask, and gently rocked back and forth.  The transfections were incubated for 
48 hours under standard cell culture conditions, and then selected for stable 
transformants using 200 ng/mL of Puromycin or 300 ng/mL of Hygromycin for two 
weeks.  After the selection die-off, the cells were maintained using Puromycin (100 
ng/mL) or Hygromycin (150 ng/mL).   
RNA Isolation 
 RNA was isolated from cell pellets using the miRVanaTM RNA isolation method 
according to the manufacturer’s protocol (Ambion-Life Technologies, Carlsbad, CA), 
eluted in 50 µL of Elution Buffer, and stored at -80°C.  RNA concentration was 
estimated using either the Smart SpecTM 3000 Spectrophotometer (Bio-Rad 
Laboratories, Hercules, CA) or the NanoDrop ND-2000 Spectrophotometer (Thermo-
Fisher Scientific, Inc., Waltham, MA). 
Messenger RNA Analysis 
Messenger RNA was quantified using reverse transcription-quantitative PCR 
(RT-qPCR).  Reverse transcription was accomplished using the iScriptTM cDNA 
Synthesis kit (Bio-Rad Laboratories).  Briefly, 50 ng of RNA was mixed with 4 µL of the 
5X iScript reaction mix, 1 µL of the iScript Reverse Transcriptase, and the volume 
brought to 20 µL with nuclease-free water.  The reaction mix was incubated for 5 
minutes at 25°C, followed by 30 minutes at 42°C, and heat inactivation for 5 minutes at 
85°C.  Reactions were stored at -20°C until analysis.  The qPCR reactions were 
prepared by adding 3 µL of the prepared cDNA, 10 µM primer pairs for the relevant 
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mRNA target (GAPDH:  Forward:  5’-ACCACAGTCCATGCCATCAC; Reverse: 5’-
TCCACCACCCTGTTGCTGTA.  AATF:  Forward:  5’-
GACACGGACAAAAGGTATTGCG; Reverse: 5’-CCGGTGTTTTTGCAGAGTGG), 1X 
FastStart Universal SYBR Green Master Mix (Roche Diagnostics, Indianapolis, IN), and 
brought to 20 µL volume with nuclease-free water.  qPCR was conducted in an Applied 
Biosystems 7300 real-time  PCR instrument (Life Technologies) using the following 
conditions:  50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for 
15 seconds, 55°C for 35 seconds, and 68°C for 35 seconds.  Data was analyzed using 
SDS software v1.3.1 (Life Technologies), using automatic threshold and baseline 
settings.  Each mRNA evaluated was analyzed in triplicate using a minimum of three 
separate cell passage RNA extractions.  GAPDH was used as a normalization control, 
and relative expression was calculated using the comparative CT method85. 
Western Blotting 
Cultured cell pellets were lysed in 4% sodium dodecyl sulfate (SDS) in 
phosphate-buffered saline (PBS) with 1X PhosSTOP phosphatase inhibitor (Roche 
Diagnostics) and COMplete protease inhibitor (Roche Diagnostics), followed by 
sonication for five minutes at 4°C.  Protein concentration was calculated using the Dc 
Protein Assay (Bio-Rad Laboratories), and absorbance read at 750 nm on the Smart 
SpecTM 3000 Spectrophotometer (Bio-Rad Laboratories). 
For western blotting, equal quantities of cell lysate (30-40 µg) were loaded onto a 
Novex® 4-12% Tris-Glycine SDS polyacrylamide gel (Life Technologies), under 
denaturing conditions using a loading buffer with 2% SDS, 5% β-Mercaptoethanol, 20% 
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glycerol and 0.004% bromophenol blue in 0.125M Tris-HCl, and electrophoresed in a 25 
mM Tris, 190 nM glycine, 0.1% SDS running buffer for approximately 90 minutes at 140 
volts.  The samples were transferred onto a Trans-Blot® nitrocellulose membrane (Bio-
Rad Laboratories) for 90 minutes at 200 mA and 4°C in a 48 mM Tris, 39 mM glycine, 
0.04% SDS transfer buffer.  Nonspecific binding was prevented by washing the blot for 
30 minutes at room temperature in 5% nonfat dry milk in Tris-buffered saline with 0.05% 
Tween-20 (TBST).    The blot was rinsed briefly in TBST, and incubated overnight (14-
20 hours) at 4°C in primary IgG antibody in 5% BSA in TBST.  Primary antibodies used 
were 1:1000 α-β-actin (C4) produced in mouse (Santa Cruz Biotechnologies, Inc., 
Santa Cruz, CA), 1:100 α-NF-kB produced in rabbit (Santa Cruz Biotechnologies, Inc) 
and 1:500 α-AATF produced in mouse (Abnova, Tapiei, Taiwan),.  After incubation in 
primary antibody, the blot was washed with TBST four times for 5 minutes, followed by 
incubation in secondary antibody (1:1000 α-mouse IgG-HRP produced in goat (Santa 
Cruz Biotechnologies)) for 1 hour at room temperature.  The blot was again washed 
with TBST four times for 5 minutes, and luminol reaction developed using the Western 
Lightning® chemiluminescent reagents (Perkin Elmer, Boston, MA).  Western blots were 
exposed and bands quantified using the ODYSSEY® Fc Imaging System (LI-COR 
Biosciences, Lincoln, NE). 
Proliferation Assay 
 M12 and M12 cells transformed with the miR-147b inhibitor plasmid (5,000 cells) 
were plated into each well of a 24-well plate in triplicate.  The adherent cells were 
released by incubating with 0.25% Trypsin-EDTA (Gibco-Life Technologies) for 5 
minutes at 37°C, after which the trypsin was inactivated by washing the cells in serum-
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containing media.  The cells were then pelleted through centrifugation at 1500xg for 5 
minutes and the pellets resuspended in 1 mL of PBS, and counted using a Coulter 
Counter® Analyzer (Beckman Coulter, Inc., Brea, CA) or Vi-Cell™ XR Cell Viability 
Analyzer (Beckman Coulter, Inc) using a trypan blue solution.  Cells were >90% live 
when analyzed in this fashion. 
Migration and Invasion Assays 
 For evaluation of migratory capabilities, M12 cells stably transformed with either 
a scrambled control or miR-147b inhibitor were diluted in serum-free RPMI 1640 
medium and 5 x 104 cells added to a ThinCert™ TC membrane support insert (Greiner 
Bio-one BVBA/SPRL, Belgium) placed in the well of a 24-well plate.  For invasion 
assays, 30 µL of a 10% solution of Cultrex® Basement Membrane Extract (Growth 
Factor Reduced), (R&D Systems®, Minneapolis, MN) in RPMI 1640 was pipetted onto 
the membrane support insert, and incubated at 37°C for 1 hour prior to adding 1.25 x 
106 cells to the upper chamber.  For both assays, 1 mL of RPMI 1640 medium 
containing 5% FBS and 10 ng/mL EGF was pipetted into the lower chamber of the well 
as the chemoattractant.  The unit was incubated for 24 hours.  Media was aspirated and 
cells were fixed by adding 0.025% of gluteraldehyde in ddH2O to the bottom chamber 
for 20 minutes, followed by staining with 0.1% leucocrystal violet in 10% EtOH and PBS 
for a minimum of 30 minutes.  The membranes were excised and mounted to a 
microscope slide using Permount® (Fisher Scientific, Waltham, MA).  Cell counts 
representing migratory or invasive cells were performed in 5 random fields for each 
replicate, averaged, and expressed as relative to the control.  Data was the result of a 
minimum of 3 independent experiments, each performed in triplicate.   
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In-Vivo studies 
M12 and M12 cells stably transformed with the miR-147b inhibitor plasmid 
(1x106) were subcutaneously (SC) injected into 10 (5 for each treatment) male athymic 
nude mice (Harlan Laboratories, Inc., Indianapolis, IN) to assess tumorigenicity.  
Tumour growth was monitored with caliper measurement and tumour volume calculated 
as length x width2/2 (mm3) over a period of 45 days until sacrifice.  All experiments were 
conducted under a protocol approved by the Institution Animal Care and Use 
Committee of Virginia Commonwealth University (VCU). 
Data Analysis 
 Data were presented as the mean ± standard deviation.  Statistical analyses 
were conducted in the Microsoft® Excel software platform, using the independent 
Student's t-test, assuming equal variance between the two groups. Statistical 
significance was defined as p ≤ 0.05. 
Results 
Inhibition of miR-147b in the M12 cells had significant effects on migratory and 
invasive potential of the highly metastatic cell line (p <0.001 for both assays) (Figure 4-
5).  Additionally, stable transfection with a miR-147b inhibitor inhibited proliferation in 
M12 cells by an average of 58.5% (p <0.03) (Figure 4-6).  This inhibition is uncommon 
in our experience in this cell line progression model, as the cells have been 
immortalized via SV40T, which is known to bind to the Rb protein and prevent the Rb-
mediated cell-cycle stop at G1129 (reviewed in Dick et al.130). Thus, we would predict 
that a target of miR-147b would be a tumour suppressor protein involved in cell cycle 
102 
 
progression.  Inhibition of miR-147b results in loss of translation suppression of that 
tumour suppressor, which can then act on the cell cycle as a stop signal, and 
consequently, cell doubling times are reduced. 
Cells (1x106) were injected subcutaneously into the flanks of nude athymic mice 
and monitored for tumour volume for up to 47 days after injection.  M12 cells with the 
miR-147b inhibitor showed a significantly lower level of tumour growth (p=.085) (Figure 
4-7).  All mice (with the exception of one M12 injected mouse) developed tumours. 
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Figure 4-5:  Inhibition of miR-147b significantly reduces migratory and invasive 
potential.  M12 cells were stably transformed with scrambled control or miR-147b 
inhibitor, plated on a ThinCert transwell membrane (with basement membrane added 
for invasion assay) and assessed for (A) migratory (p < 0.001) and (B) invasive potential 
(p < 0.001).  Data is the mean of 3 independent experiments, each performed in 
triplicate. 
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Figure 4-6:  Cell proliferation is impacted by miR-147b inhibition.  Inhibition 
resulted in a 58.5% reduction in proliferation (p < 0.03).  Results are representative of 4 
independent experiments, each performed in triplicate. 
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Figure 4-7:  Tumour growth is significantly reduced upon miR-147b 
inhibition.  Subcutaneous injections of the respective cell lines into the flank of nude 
athymic mice.  Tumour reduction was consistently observed (p = .085).  Results are 
reported as the average ratio of tumour volume to the final average M12 tumour 
volume.  N=5 mice for each treatment. 
 
 
 
 
-10.0
10.0
30.0
50.0
70.0
90.0
110.0
14 21 28-30 35-37 38-40 41-43 45-47
A
v
e
ra
g
e
 t
u
m
o
u
r 
s
iz
e
 (
%
 o
f 
M
1
2
)
Days post-injection
M12
M12 + miR-147b Inhibitor
106 
 
 Given our observations of the difference in oncogenic potential when miR-147b is 
inhibited, we felt confident that this miR has at least one significant target that would 
prevent tumour progression when released from suppression.  We therefore focused 
our efforts on identifying potential targets for activation. 
NF-ĸB is one of the potential activators of miR-147b transcription and thus we 
were interested in determining if it was upregulated, and the consequent cause of the 
observed increase in miR-147b levels.  However, western blot analysis did not indicate 
a change in NF-ĸB levels (Figure 4-8).  Thus, we do not view it as the source of the 
miR-147b upregulation.   
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Figure 4-8: NF-kB levels are not increased in M12 cells, and thus likely not 
contributing to increased miR-147b expression.  Western blot analysis of NF-kB and 
β-Actin as loading control.  Blot is representative of 2 independent experiments. 
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 As there are no absolutely proven targets for miR-147b, a search for potential 
targets is literally a fishing expedition.  While the majority of miR binding events occur in 
the 3’-UTR of the messenger RNA, a growing body of literature has shown that miRs 
can bind and modulate mRNA translation throughout the message, including the 5’-UTR 
and coding regions98,99.  This certainly complicates the search, as the majority of miR-
target prediction software platforms search the 3’-UTRs of genes alone.  We first turned 
to miR-prediction software platforms for identification of potential targets.  Review of the 
most commonly identified, highest confidence mRNA targets using TargetScan92-94,110, 
TargetMiner90, miRDB86,87,89,117, and Diana88 resulted in a large list.  Upon identifying 
targets, we reviewed the seed-pairing potential between miR and mRNA, and 
performed a literature search to determine each protein’s known role, possible 
correlations to malignancy.  The majority of proteins identified as having high seed-
pairing capability to mIR-147b were either not previously shown to be modulated in 
cancers, or were in fact being upregulated in tumours and thus would not likely be 
active targets for translation suppression by miR-147b in the prostate.  The only protein 
identified that had a known tumour-suppressive role in cancers was AATF, or apoptosis-
antagonizing transcription factor. 
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Table 4-1:  Top predicted targets for miR-147b by bioinformatic analysis.  
Evaluation of the top potential mRNA candidates from 3 different miRNA target mining 
software programs, DIANA, miRDB, and TargetScanHuman, release 6.2, revealed that 
with the exception of AATF, none of the top targets have known tumour suppressive 
function. 
Protein Abbreviation Function Role in Carcinogenicity? 
Predicted 
by: 
NADH 
dehydrogenase 
(ubiquinone) 1 
alpha subcomplex, 
4 
NDUFA4 
NADH dehydrogenase activity and 
oxidoreductase activity – transfers 
NADH to ubiquinone; 
mitochondrial respiratory chain, 
complex I 
Unknown 
DIANA, 
miRDB 
TargetScan 
scavenger receptor 
class A, member 3 
SCARA3 
macrophage scavenger receptor-
like protein which deplete reactive 
oxygen species; induced by 
oxidative stress.  
mRNA up in ovarian tumours compared 
to breast131 DIANA 
insulin-like growth 
factor 2 
(somatomedin A) 
IGF2 
insulin family of growth factors, 
the predominant growth factor in 
adults. 
Tumour progression through initiation of 
steroidogenesis132,133 
High levels in many cancers through loss 
of epigenetic control, including prostate 
DIANA 
apoptosis 
antagonizing 
transcription factor 
AATF 
interacts with c-Jun in the 
apoptotic pathway 
Overexpression induces apoptosis 
May stimulate Androgen Receptor (REF) 
DIANA 
polymerase (RNA) 
III (DNA directed) 
polypeptide F 
POLR3F 
Subunit of RNA Polymerase III, 
transcribes ribosomal and tRNA 
genes 
Unknown 
DIANA, 
miRDB 
zinc finger protein 3 
homolog (mouse) 
ZFP3 
May be involved in transcriptional 
regulation 
unknown miRDB 
potassium voltage-
gated channel, 
shaker-related 
subfamily, member 
3 
KCNA3 
Voltage-gated potassium channel, 
essential in T-Cell proliferation and 
activation 
Upregulated in rat prostate cancer cell 
lines 
miRDB 
Homeobox C6 HOXC6 
Transcription factor involved in 
development 
Upregulated in gastric cancer 
Deregulated in head and neck squamous 
cell carcinoma 
Upregulated in prostate cancer134 
TargetScan 
Zinc finger protein 
148 
ZNF148 
Transcriptional effector involved in 
cell growth and death 
Upregulated in colorectal cancer 
Effector of Vimentin 
TargetScan 
Brain-derived 
neuotrophic factor 
BDNF 
Nerve growth factor involved in 
striatal neurons 
Decreased in colorectal cancer pt serum 
Elevated in gastric cancer 
High expression associated with poor 
prognosis in lung cancer 
TargetScan 
Homeobox A9 HOXA9 
Trancription factor involved in 
morphogenesis and differentiation 
Elevated in ovarian, prostate, 
meningioma, oral cancer 
Decreased in bladder cancer 
TargetScan 
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 The Apoptosis-Antagonizing Transcription Factor (AATF) was first isolated in 
rats, and subsequently in humans during a search for TGF-β regulated genes involved 
in the differentiation of intestinal crypt cells135.  It is located on chromosome 17q11.2-
q12, and is also known as Che-1136,137.   The protein contains 560 amino acids, a 
nuclear localization signal, three nuclear hormone receptor LXXLL binding motifs, a 
leucine zipper motif, and several phosphorylation sites for different kinases135,137.  AATF 
is expressed in every tissue, but expression is enriched in brain, heart, thymus, kidney, 
and placenta135.  Interestingly, AATF shares homology with SV40 large T antigen as 
well as with E. coli ς-factor 70, and interacts with the Rb protein in a similar fashion to 
SV40T138.  As an RNA Polymerase-II binding protein, AATF has been shown to have a 
key role in cellular processes including DNA damage response, cell-cycle control, 
chromatin remodeling, and apoptosis139.   
Evaluation of AATF message and protein expression was consistent with it being 
regulated by miR-147b (Figure 4-9).  Western blot analysis indicated that while low in 
abundance, AATF is certainly detectable in P69 and the M12 cells treated with miR-
147b inhibitor.  However, the AATF signal was not visible in the M12 cell lysates.  
Additionally, RT-qPCR analysis showed that AATF messenger RNA levels are also 
being modulated by miR-147b.  As in our evaluation of the c-KIT message (Chapter 3), 
AATF mRNA must be cleaved by the miR-147b/Argonaute 2 complex in order for 
messenger RNA levels to be changed between the cell lines.  While there could be and 
is a considerable level of complexity between the P69 and M12 cells (Chapter 2), 
modulation between the M12 and M12 treated with mIR-147b inhibitor could only be 
caused by miR-147b cleavage.  
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Figure 4-9:  messenger RNA and protein levels are returned to P69 levels by miR-
147b inhibition.  AATF expression in the P69, M12, and M12 stably transformed with 
vector expressing miR-147b inhibitor.  A:  Western blot analysis and B: quantitation.  
Blot and quantitation are representative of 2 independent experiments, normalized to β-
Actin and reported as relative to the M12 cell line.  C:  messenger RNA relative 
quantitation shows that mRNA levels are impacted by miR-147b, and inhibition reverts 
levels to P69 levels (p<0.03 for P69 and miR-147b inhibited lines vs. M12).  mRNA is 
normalized to GAPDH and reported as relative to the M12 cell line.  Results are 
compiled data from two biological replicates, each performed in triplicate. 
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The AATF 3’-UTR is very short, approximately 207 nucleotides long. Analysis of 
the AATF 3’-UTR using TargetScan and RNAHybrid revealed no sites in the 3’-UTR 
where miR-147b might bind.  Analysis of the entire messenger RNA using RNAHybrid 
and Diana identified six excellent potential matches, all with free energy values below -
22 kcal/mol (Table 4-2).    
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Table 4-2:  Top potential binding sites for miR-147b are within the coding regions 
of the mRNA.  Binding sites are ordered by descending free energy values.  Adapted 
from RNAHybrid86,87 analysis of AATF mRNA (NM_012138.3). 
position  665 (Exon 1) 
target 5' G         CAC      AAA  A 3' 
           AGCAGAAGC   UCUGCA   AC     
           UCGUCUUCG   AGGCGU   UG     
miRNA  3' A         UAA      G      5' 
 
mfe: -30.7 kcal/mol 
 
position  190 (5’-UTR) 
target 5' G   C GG GU GGG        U 3' 
           GGC G  G  U   CCGCACAU     
           UCG C  C  A   GGCGUGUG     
miRNA  3' A   U UU GU AA           5' 
 
mfe: -29.2 kcal/mol 
 
position  105 (5’-UTR) 
target 5' G   UGU GG   GCC        G 3' 
           AGC   G  GUG   UCCGCGCG     
           UCG   C  CGU   AGGCGUGU     
miRNA  3' A   U   UU   AA         G 5' 
 
mfe: -27.8 kcal/mol 
 
position  58 (5’-UTR) 
target 5'  C     CCCC  CCCCUC        C 3' 
            GCAGG    GC      CCGCGCGC     
            CGUCU    CG      GGCGUGUG     
miRNA  3' AU     U     UAAA            5' 
 
mfe: -25.2 kcal/mol 
 
position  1305 (Exon 5) 
target 5' A           CUUUGCCGAC   ACAGUCUACAGGAA        U 3' 
           UGGCA AAGCG          UUU              CCGCACAC     
           AUCGU UUCGU          AAA              GGCGUGUG     
miRNA  3'       C                                          5' 
 
mfe: -24.3 kcal/mol 
 
position  507 (Exon 2) 
target 5'    U       GAC        G 3' 
              GGGAGCA   UCUGC CA     
              UCUUCGU   AGGCG GU     
miRNA  3' AUCG       AA      U  G 5' 
 
mfe: -22.9 kcal/mol 
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Discussion 
In this report, we sought to confirm miR-147b’s previously identified status as an 
oncomiR, which was based not only on analysis of the poorly-tumorigenic P69 and its 
highly metastatic subline M12, but also other well-established prostate cancer cell lines, 
and finally through confirmation using human biopsy samples retrieved by laser-capture 
microdissection.  Inhibition of miR-147b in M12 cells resulted in markedly reduced cell 
proliferation, and reduced migratory and invasive potential.  Tumour growth in-vivo was 
also reduced in male nude athymic mice when miR-147b was inhibited.   
We also hoped to identify potential proteins whose mRNAs were targets of miR-
147b, thus elucidating a mechanism for the observed oncogenic effects.  Through a 
combination of bioinformatics analyses and literature reviews of potential targets, we 
identified AATF as a strong candidate for miR-147b targeting.  AATF appears to act 
either as an oncogene or tumour suppressor, and its action is strongly dependent on the 
tumour origin.  It is known to interact with subunit 11 of RNA Polymerase II, and repress 
growth arrest by activation of p21, a cyclin-dependent kinase inhibitor138,140.  The same 
study showed that a significant amount of AATF is complexed with Rb protein, and 
competes with Rb-recruited HDAC1 for binding, which can lead to dysregulation of 
proliferation targets140.  
AATF also has a known role as an oncogene.  In breast cancer and leukemia, 
AATF is known to be upregulated, likely through the c-Myc response element in its 
promoter141.  RNA interference with AATF message results in decreased cell 
proliferation and induction of apoptosis through down-regulation of Bcl2 and up-
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regulation of Bax139.  AATF is also known to interact with the tumour suppressor Rb, 
releasing repression on E2F-mediated transcription137, and is implicated in co-activation 
of the androgen receptor137,142.  Some research has shown that AATF is phosphorylated 
and stabilized upon DNA damage, and in a p53-dependent manner, AATF works to 
modulate the G2/M checkpoint143. 
The low levels observed in the prostate cell lines here described are consistent 
with observed down-regulation in kidney and colon carcinomas140.  In-vitro, 
overexpression of AATF in human colon carcinoma cells caused cell accumulation at 
the G1 checkpoint, and directly stimulated p21 transcription in a p53-independent 
manner140.  Such a block would be consistent with our observations of reduced cell 
proliferation when miR-147b was inhibited (Figure 4-5), and AATF consequently 
upregulated.  This results in competitive binding over HDAC1 for the SP1 binding sites 
of p21, and therefore transcription of the tumour suppressor (Figure 4-10).  Interestingly, 
NMES-1, the gene in which miR-147b is located, has been shown to be downregulated 
in colon and esophageal carcinoma tumour tissues144,145.  If miR-147b levels were found 
to be upregulated in these tissues as well, it would indicate that miR-147b is being 
selectively overexpressed, as compared to being overexpressed during the 
overexpression of NMES1. 
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A: Benign State 
 
B: Tumour State 
 
Figure 4-10:  Proposed mechanism of miR-147b action on cell cycle progression.  
A:  In the benign state, miR-147b is not well-expressed, and thus AATF protein is 
produced and can interact with the SP1 binding sites on the p21 protein, outcompeting 
HDAC1. B:  In the neoplastic cell, miR-147b is overexpressed in prostate, colon, and 
kidney carcinomas, and acts to cleave and reduce AATF message, thus allowing for 
deacetylation of the p21 gene and consequently less transcription, which leads to loss 
of the tumour suppressor protein and an increase in cell cycle progression. 
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 Our results show a significant effect of miR-147b on AATF through mRNA and 
western blot analysis of protein levels.  Thus, there is certainly a tie between miR-147b 
and AATF.  In order to prove that this interaction is a direct effect by miR-147b and not 
suppression through an indirect manner, cloning wild type and mutated versions of each 
of the seven potential binding sites of the miR-147b mRNA into 3’-UTR luciferase 
constructs will need to be undertaken.  This final group of experiments will elucidate the 
manner of action of miR-147b on the AATF protein levels. 
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Chapter 5: 
miR-9 acts as an oncomiR in prostate cancer by regulation of e-cadherin and 
SOCS5 through multiple pathways that drive towards tumour progression and 
metastasis 
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Previous work identified miR-9 as up-regulated in not only prostate cancer cell 
lines (Chapter 3), (Figure 5-1), but also in 3 out of 4 of prostate cancer biopsy tumour 
samples as compared to the benign laser-capture microdissected tissue (Figure 5-2).  
The consistency and high expression of miR-9 in the majority of samples analyzed led 
to an investigation of miR-9’s mode of action in prostate cancer. 
miR-9 has been well characterized in neural tissue development (reviewed in 
Yuva-Aydemir et al.146), but is detectable in a variety of human tissues.  miR-9 is a 
family of three identical sequences (ucuuugguuaucuagcuguauga).  These 3 
homologues are designated as miR-9-1, 9-2, and 9-3.  miR-9-1 is located within an 
open reading frame on chr 1q22, miR-9-2 is located within the reading frame of a LNC-
RNA on chr 5q14.3, and miR-9-3 is located on chr15.26.1. The miR-9-3 locus has Myc 
and MycN binding sites that have been shown to activate miR-9 expression43.  In at 
least one instance, miR-9 has been upregulated through action of Prospero Homeobox 
1 (PROX1)29. 
 While hundreds of putative miR-9 targets have been identified through a variety 
of miR-target prediction programs, only six have been definitely proven as being directly 
targeted by miR-9; i.e., that miR-9 binds to a portion of the mRNA, and that binding 
affects protein levels (Table 5-1). 
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Figure 5-1 (Adapted from Chapter 3):  miR-9 levels are upregulated in all prostate 
cancer cell line models.  A: miR-9 levels were measured in P69, M12, M2182, and F6 
cells.  Data was normalized to RNU48 and expressed relative to P69 using the 
comparative CT method.   B: miR-9 levels were measured in M12, DU145, WMPY1 and 
PC3 cells.  Data was normalized to RNU48 (dCT) and expressed as a box plot.  The dCT 
for the P69 cell line is visualized as the red box. 
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Figure 5-2 (adapted from Chapter 3):  miR-9 expression is upregulated in 60% of 
tested patient tumours.  miR-9 levels were measured in tumour and benign tissue 
separated from prostate biopsies using laser-captured microdissection (LCM).  Data 
was normalized to RNU48 and expressed relative to the benign tissue using 
comparative CT method.  miR-9 was undetected in both benign and tumour  
of Pt 09-225. 
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Table 5-1:  Proven direct targets of miR-9.  The targets listed have been proven 
through both luciferase assay analysis and mutation of the 3’-UTR, as well as at least 
one additional analytical technique (western blot of protein level, microarray, etc.). 
mRNA target Shown in 
e-cadherin Breast cancer 
NF-kB Metastatic melanoma 
CXCR4 Nasopharyngeal carcinoma 
BRCA1 Ovarian Cancer 
Stathmin Human embryonic stem cells
147 
SOCS5 
Non-small cell lung cancer and 
melanoma cell lines 
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E-cadherin has been described as a direct target for miR-9 in multiple instances, 
including colon, hepatocellular, and breast cancer20,148,149.  E-cadherin (CDH1) is a 
transmembrane glycoprotein that forms adherens junctions between adjacent epithelial 
cells. The cytoplasmic tail associates with intracellular proteins, ultimately linking the 
adherens junctions to the actin cytoskeleton24,150,151.  The extracellular domain of e-
cadherin interacts with e-cadherin from neighboring cells to form adherent sheets of 
epithelial cells20,152. 
NF-kB is also known to be a direct target of miR-9.  While NF-kB is known to be 
activated in an inflammatory response and early tumour apoptosis, ultimately many 
neoplasias show constitutive activation of NF-kB and transcription of pro-survival gene 
products153,154.  NF-kB activity as related to miR-9 appears to occur in the cancers 
where miR-9 expression is lost, and NF-kB is consequently upregulated155,156.  Many of 
the cancers describing miR-9 overexpression do not note a change in NF-kB levels, and 
thus competitive binding for miR-9 or promoter elements in NF-kB may be the cause for 
the lack of observed change in miR-9 overexpressing carcinomas. 
Suppressor of Cytokine Signalling, or SOCS5, are a family of proteins that work 
to inhibit downstream JAK/STAT signaling through inhibition of STAT phosphorylation 
by multiple actions.  Some SOCS proteins bind and inhibit JAK kinases, while others 
compete with STATs for phosphotyrosine binding sites on cytokine receptors157.  SOCS 
proteins also interact with the ubiquitination machinery through a motif called the SOCS 
box to ubiqitinate the signaling intermediates and thus reduce signal transduction158.   
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Given the consistent upregulation of miR-9 in prostate cancer cell lines and 
patient samples as described in Chapter 3, it was important to evaluate how inhibition of 
miR-9 could impact the tumorigenicity of a prostate cancer cell line model, and to 
evaluate known targets of miR-9 as affecting tumour progression in prostate cancer. 
Project Aims 
3.  Inhibit miR-9 levels in the M12 cell line and evaluate any changes in proliferation, 
tumorigenicity, or invasive potential. 
4. Evaluate potential target mRNAs in prostate cancer; confirm the mode of action of 
miR-9 as inhibiting e-cadherin and SOCS5 protein expression, thus promoting the 
EMT transition and angiogenesis through multiple pathways. 
 
Methods and Materials 
Cell Culture 
 Adherent cells were cultured in 75 cm2 flasks using RPMI 1640 supplemented 
with L-Glutamine (Caisson Labs, North Logan, UT), 5% fetal bovine serum, 5 µg/mL 
insulin, 5 µg/mL transferrin, 5 µg/mL selenium (ITS, Collaborative Research, Bedford, 
MA).  Gentamycin (0.05 mg/mL) was used to prevent bacterial contamination. Cells 
were passaged when 50-65% confluent, and maintained for no longer than 20 
passages.  Passaging was accomplished by incubating with 0.25% Trypsin-EDTA 
(Gibco-Life Technologies, Carlsbad, CA) for 5 minutes at 37°C, after which the trypsin 
was inactivated by washing the cells in serum-containing media.  The cells were then 
pelleted through centrifugation at 1500xg for 5 minutes and either passaged, plated, or 
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pellets preserved.  Cell pellets for analysis were produced by washing the pellet in 10 
mL PBS, centrifugation at 1500xg for 5 minutes, removal of the supernatant, and flash 
freezing in liquid nitrogen.  Pellets were stored at -80°C for at least 24 hours. 
Transfection 
Stable transformations of an early passage of the M12 cell line with a vector 
containing a miR-9 inhibiting sequence or scrambled control (pEZX-AM03, 
Geneocopeia Inc., Rockville, MD) were performed using TransIT®-LT1 Transfection 
Reagent (Mirus BIO LLC, Madison, WI, USA).  Briefly, 1.5 x 105 cells were plated in a 
25 cm2 flask in appropriate serum-containing media for 24 hours.  The cells were then 
rinsed with PBS, and serum-containing media replaced.  The plasmid (6.5 µg) was 
mixed with 650 µL of RPMI media with no serum or additives and 19.5 µL of TransIT®-
LT1 reagent at room temperature for 15-30 minutes. The solution was added dropwise 
to each flask, and gently rocked back and forth.  The transfections were incubated for 
48 hours under standard cell culture conditions, and then selected for stable 
transformants using 200 ng/mL of Puromycin or 300 ng/mL of Hygromycin for two 
weeks.  After the selection die-off, the cells were maintained using Puromycin (100 
ng/mL) or Hygromycin (150 ng/mL).   
RNA Isolation 
 RNA was isolated from cell pellets using the miRVanaTM RNA isolation method 
according to the manufacturer’s protocol (Ambion-Life Technologies, Carlsbad, CA), 
eluted in 50 µL of Elution Buffer, and stored at -80°C.  RNA concentration was 
estimated using either the Smart SpecTM 3000 Spectrophotometer (Bio-Rad 
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Laboratories, Hercules, CA) or the NanoDrop ND-2000 Spectrophotometer (Thermo-
Fisher Scientific, Inc., Waltham, MA). 
Messenger RNA Analysis 
Messenger RNA was quantified using reverse transcription-quantitative PCR 
(RT-qPCR).  Reverse transcription was accomplished using the iScriptTM cDNA 
Synthesis kit (Bio-Rad Laboratories).  Briefly, 50 ng of RNA was mixed with 4 µL of the 
5X iScript reaction mix, 1 µL of the iScript Reverse Transcriptase, and the volume 
brought to 20 µL with nuclease-free water.  The reaction mix was incubated for 5 
minutes at 25°C, followed by 30 minutes at 42°C, and heat inactivation for 5 minutes at 
85°C.  Reactions were stored at -20°C until analysis.  The qPCR reactions were 
prepared by adding 3 µL of the prepared cDNA, 10 µM primer pairs for the relevant 
mRNA target (GAPDH:  Forward:  5’-ACCACAGTCCATGCCATCAC; Reverse: 5’-
TCCACCACCCTGTTGCTGTA.  E-Cadherin:  Forward:  5’-
GGTGCTCTTCCAGGAACCTC; Reverse: 5’-GAAACTCTCTCGGTCCAGCC.  SOCS5:  
Forward:  5’-CCTCCTTCGGCCTTCACCTA; Reverse: 5’-
TATAAAATCGTGACCAATAGCAGGC), 1X FastStart Universal SYBR Green Master 
Mix (Roche Diagnostics, Indianapolis, IN), and brought to 20 µL volume with nuclease-
free water.  qPCR was conducted in an Applied Biosystems 7300 real-time  PCR 
instrument (Life Technologies) using the following conditions:  50°C for 2 minutes, 95°C 
for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 55°C for 35 seconds, and 
68°C for 35 seconds.  Data was analyzed using SDS software v1.3.1 (Life 
Technologies), using automatic threshold and baseline settings.  Each mRNA evaluated 
was analyzed in triplicate using a minimum of three separate cell passage RNA 
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extractions.  GAPDH was used as a normalization control, and relative expression was 
calculated using the comparative CT method12. 
Western Blotting 
Cultured cell pellets were lysed in 4% sodium dodecyl sulfate (SDS) in 
phosphate-buffered saline (PBS) with 1X PhosSTOP phosphatase inhibitor (Roche 
Diagnostics) and COMplete protease inhibitor (Roche Diagnostics), followed by 
sonication for five minutes at 4°C.  Protein concentration was calculated using the Dc 
Protein Assay (Bio-Rad Laboratories), and absorbance read at 750 nm on the Smart 
SpecTM 3000 Spectrophotometer (Bio-Rad Laboratories). 
For western blotting, equal quantities of cell lysate (30-40 µg) were loaded onto a 
Novex® 4-12% Tris-Glycine SDS polyacrylamide gel (Life Technologies), under 
denaturing conditions using a loading buffer with 2% SDS, 5% β-Mercaptoethanol, 20% 
glycerol and 0.004% bromophenol blue in 0.125M Tris-HCl, and electrophoresed in a 25 
mM Tris, 190 nM glycine, 0.1% SDS running buffer for approximately 90 minutes at 140 
volts.  The samples were transferred onto a Trans-Blot® nitrocellulose membrane (Bio-
Rad Laboratories) for 90 minutes at 200 mA and 4°C in a 48 mM Tris, 39 mM glycine, 
0.04% SDS transfer buffer.  Nonspecific binding was prevented by washing the blot for 
30 minutes at room temperature in 5% nonfat dry milk in Tris-buffered saline with 0.05% 
Tween-20 (TBST).    The blot was rinsed briefly in TBST, and incubated overnight (14-
20 hours) at 4°C in primary IgG antibody in 5% BSA in TBST.  Primary antibodies used 
were 1:1000 α-β-actin (C4) produced in mouse (Santa Cruz Biotechnologies, Inc., 
Santa Cruz, CA), 1:2500 α-e-cadherin (CDH1) produced in mouse (Sigma Aldrich, St. 
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Louis, MO), 1:100 α-NF-kB produced in rabbit (Santa Cruz Biotechnologies, Inc), and 
1:500 α-SOCS5 (M-300) produced in rabbit (Santa Cruz Biotechnologies),.  After 
incubation in primary antibody, the blot was washed with TBST four times for 5 minutes, 
followed by incubation in secondary antibody (1:1000 α-mouse IgG-HRP produced in 
goat (Santa Cruz Biotechnologies) and/or 1:1000 α-rabbit IgG-HRP produced in goat 
(Cell Signalling Technology, Danvers, MA),  for 1 hour at room temperature.  The blot 
was again washed with TBST four times for 5 minutes, and luminol reaction developed 
using the Western Lightning® chemiluminescent reagents (Perkin Elmer, Boston, MA).  
Western blots were exposed and bands quantified using the ODYSSEY® Fc Imaging 
System (LI-COR Biosciences, Lincoln, NE). 
Proliferation Assay 
 M12 and M12 cells transformed with the miR-9 inhibitor plasmid were plated 
(5,000 cells) onto a 24-well plate in triplicate.  The adherent cells were released by 
incubating with 0.25% Trypsin-EDTA (Gibco-Life Technologies) for 5 minutes at 37°C, 
after which the trypsin was inactivated by washing the cells in serum-containing media.  
The cells were then pelleted through centrifugation at 1500xg for 5 minutes and the 
pellets resuspended in 1 mL of PBS, and counted using a Coulter Counter® Analyzer 
(Beckman Coulter, Inc., Brea, CA) or Vi-Cell™ XR Cell Viability Analyzer (Beckman 
Coulter, Inc) using a trypan blue solution.  Cells were >90% live when analyzed in this 
fashion. 
Migration and Invasion Assays 
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 For evaluation of migratory capabilities, M12 cells stably transformed with either 
a scrambled control or miR-9 inhibitor were diluted in serum-free RPMI 1640 medium 
and 5 x 104 cells added to a ThinCert™ TC membrane support insert (Greiner Bio-one 
BVBA/SPRL, Belgium) placed in the well of a 24-well plate.  For invasion assays, 30 µL 
of a 10% solution of Cultrex® Basement Membrane Extract (Growth Factor Reduced), 
(R&D Systems®, Minneapolis, MN) in RPMI 1640 was pipetted onto the membrane 
support insert, and incubated at 37°C for 1 hour prior to adding 1.25 x 106 cells to the 
upper chamber.  For both assays, 1 mL of RPMI 1640 medium containing 5% FBS and 
10 ng/mL EGF was pipetted into the lower chamber of the well as the chemoattractant.  
The unit was incubated for 24 hours.  Media was aspirated and cells were fixed by 
adding 0.025% of gluteraldehyde in ddH2O to the bottom chamber for 20 minutes, 
followed by staining with 0.1% leucocrystal violet in 10% EtOH and PBS for a minimum 
of 30 minutes.  The membranes were excised and mounted to a microscope slide using 
Permount® (Fisher Scientific, Waltham, MA).  Cell counts representing migratory or 
invasive cells were performed in 5 random fields for each replicate, averaged, and 
expressed as relative to the control.  Data was the result of a minimum of 3 independent 
experiments, each performed in triplicate.   
In-Vivo studies 
M12 and M12 cells transformed with the miR-9 inhibitor plasmid (1x106 cells) 
were subcutaneously (SC) injected into 10 (5 for each treatment) male nude athymic 
mice (Harlan Laboratories, Inc., Indianapolis, IN) to assess tumorigenicity.  Tumour 
growth was monitored with caliper measurement and tumour volume calculated as 
length x width2/2 (mm3) over a period of 45 days until sacrifice.  To assess metastatic 
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potential, three male athymic nude mice were orthotopically injected with (1x106 cells) of 
M12 or M12 cells transformed with the miR-9 inhibitor plasmid.  The mice were 
sacrificed at 76 days, and peritoneal metastatic sites were counted.   All experiments 
were conducted under a protocol approved by the Institution Animal Care and Use 
Committee of Virginia Commonwealth University (VCU). 
3’-UTR constructs 
A portion of the 3’-UTR of e-cadherin was previously cloned into pmiR-Report, 
the seed region subsequently mutagenized8 and both clones were obtained through 
Addgene (Plasmids 25038 and 25039; http://www.addgene.org) (Table 5-2). 
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Table 5-2:  E-Cadherin 3’-UTR fragment constructs.  miR-9 binding site is highlighted 
in yellow, the seed region is highlighted in green, and mutated nucleotides are 
highlighted in red. 
Clone ID Sequence 
WT 
 
CAGGACTTAGAATAGTGCCTAAAGTGCTGCAGCCAAAGACAGAGCGGAACTATGAAAAGTGGGCTTA 
Mutated binding site 
CAGGACTTAGAATAGTGCCTAAAGTGCTGCAGCGTTTCTCAGAGCGGAACTATGAAAAGTGGGCTTA 
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Transfection & Luciferase Activity Analysis 
 Transient co-transfections of the 3’-UTR fragments cloned into a luciferase 
reporter vector along with a renilla luciferase vector for normalization were performed 
using TransIT®-LT1 Transfection Reagent (Mirus BIO LLC, Madison, WI, USA).  Briefly, 
cells were plated such that they would reach approximately 50% density in appropriate 
serum-containing media after 24 hours (2.5x104 cells/well in a 24-well plate).   The cells 
were allowed to adhere for 24 hours, rinsed with 0.5 mL PBS, and serum-containing 
media replaced.  0.5 µg of the cloned UTR:vector was mixed with 50 µL of RPMI media 
and 1 µg of Renilla plasmid with no serum or additives and 1.5 µL of TransIT®-LT1 
reagent at room temperature for 15 minutes.  The solution was added dropwise to each 
well, and gently rocked back and forth.  The transfections were incubated for 24 hours 
under standard cell culture conditions.   
 Cell lysis and luciferase assays were conducted using the Dual-Luciferase 
Reporter Assay System (Promega Corporation).  The transfection media in each well 
was suctioned off, wells rinsed in PBS, and 100 µL of 1X Passive Lysis Buffer (Promega 
Corporation) was pipetted into each well.  The samples were rocked for 15 minutes at 
room temperature, and the lysate transferred to 1.5 mL microcentrifuge tubes and 
frozen at -20°C until analysis.  Luciferase and Renilla measurements were taken in a 
GloMax® 20/20 luminometer (Promega Corporation).  Lysate (20 µL) was added to a 
1.5 mL microcentrifuge tube, and 30 µL of firefly Luciferase Assay Reagent II added to 
the lysate and luciferase activity measured at a wavelength of 560 nm.  Subsequently, 
30 µL of Stop & Glo was added, the solution mixed, and renilla luciferase activity was 
measured at the 480 nm wavelength. 
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Data Analysis 
 Data were presented as the mean ± standard deviation.  Statistical analyses 
were conducted in the Microsoft® Excel software platform, using the independent 
Student's t-test, assuming equal variance between the two groups. Statistical 
significance was defined as p ≤ 0.05. 
Results 
Evaluation of miR-9’s effect on the tumorigenic potential of the M12 cells was 
performed through stable expression of a specific miR-9 inhibitor.  Inhibition of miR-9 
had significant effects on migratory and invasive potential of the highly metastatic cell 
line as compared to the scrambled control (p <0.0001 for both assays) (Figure 5-3); 
however, miR-9 inhibition did not affect cell proliferation rates (data not shown).  This is 
not surprising, given that the M12 cell line is immortalized with the SV40T antigen, 
which binds Rb, a tumour suppressor protein that halts cell cycle progression61,130. 
M12 or M12 + miR-9 inhibitor cells (1x106 cells) were subcutaneously injected 
into the flanks of nude athymic mice and monitored for tumour volume for up to 47 days.  
M12 cells with the miR-9 inhibitor showed a significantly lower level of tumour growth (p 
<0.0001) (Figure 5-4).  Four of the five M12 injected mice developed tumours, but only 
two of the five M12+miR-9 inhibited mice developed tumours, which grew at a slower 
rate, resulting in a smaller tumour volume.  Intraprostatic injection resulted in 7 
metastatic sites for M12-injected mice, while neither of the M12+miR-9 inhibited mice 
had any observed metastatic sites by 76 days after injection. 
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Figure 5-3:  Inhibition of miR-9 significantly reduces migratory and invasive 
potential.  M12 cells were stably transformed with scrambled control or miR-9 inhibitor, 
plated on a ThinCert transwell membrane (with basement membrane added for invasion 
assay) and assessed for (A) migratory (p < 0.0001) and (B) invasive potential (p < 
0.0001).  Data is the mean of 3 independent experiments, each performed in triplicate. 
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B        IP injected mice Metastatic Lesions 
M12 (n=1) 7 
M12+miR-9 Inh (n=2) 0 
Figure 5-4:  Tumour growth and metastasis is reduced upon miR-9 inhibition.  A:  
Subcutaneous injections of the respective cell lines into the flank of nude athymic mice.  
Tumour reduction was significantly reduced in mice injected with M12 cells stably 
expressing the miR-9 inhibitor (p < .0001).  Results are reported as the average percent 
of tumour volume to the final average M12 tumour volume.  N=5 mice for each 
treatment.  B:  Intraprostatic (IP) injection into nude athymic mice resulted in 0 
metastatic lesions when miR-9 was inhibited, as compared to 7 lesions in the mouse 
injected with M12 cells alone. 
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 Given the strong evidence for miR-9’s contribution to oncogenic potential in the 
inhibition studies, we felt confident that miR-9 must have at least one significant target 
that would prevent tumour progression when released from suppression.  We therefore 
focused our efforts on evaluating miR-9’s proven targets in prostate cancer using the 
P69 and M12 progression model. 
As a known effector of the epithelial to mesenchymal transition, we were first 
interested in evaluating e-cadherin, one of the proven targets for miR-9 (Table 5-1).  In 
the early tumour cell’s transition from an affixed epithelial cell to a motile phenotype, the 
transition in expression from e-cadherin to vimentin is well known and 
described22,24,43,152.  Previous work in the P69 and M12 cell lines showed that vimentin 
is upregulated in the M12 cell line as compared to P69, and that vimentin upregulation 
is caused in part by miR-17-3p loss in the M12 cell line (Figure 2-1)25.   
Evaluation of E-cadherin message and protein expression was consistent with 
being regulated by miR-9 (Figure 5-5).  Western blot analysis indicated that e-cadherin 
is highly expressed in P69 cells, and considerably lost in the M12 cells.  Inhibition of 
miR-9 results in a corresponding increase in CDH1 levels.  Additionally, RT-qPCR 
analysis showed that CDH1 messenger RNA levels are also significantly modulated by 
miR-9 (p < 0.03).  As in our evaluation of the c-KIT message (Chapter 3), CDH1 
messenger RNA must be cleaved by the miR-9/Argonaute 2 complex in order for mRNA 
levels to be changed between the cell lines.  While there could be and is a considerable 
level of complexity between the P69 and M12 cells (Chapter 2), modulation of CDH1 
message between the M12 and M12 + mIR-9 inhibitor could be caused by miR-9 
cleavage.     
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Figure 5-5:  messenger RNA and protein levels of CDH1 are increased upon miR-9 
inhibition.  CDH1 expression in the P69, M12, and M12 stably transformed with vector 
expressing miR-9 inhibitor.  A:  Western blot analysis and B: quantitation.  Blot and 
quantitation are representative of 5 independent experiments, normalized to β-Actin and 
reported as relative to the M12 cell line.  C:  messenger RNA relative quantitation shows 
that mRNA levels are impacted by miR-9, and miR-9 inhibition relieves messenger RNA 
and protein levels (p<0.03 for P69 and miR-9 inhibited lines vs. M12).  mRNA is 
normalized to GAPDH and reported as relative to the M12 cell line.  Results are 
compiled data from two biological replicates, each performed in triplicate. 
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One miR-9 binding site in e-cadherin was identified through an RNAHybrid 
analysis of the entire mRNA.  This site, found in the 3’-UTR, has been proven to be 
directly bound by miR-9 thereby impacting translation21,43. (Figure 5-6).   Interestingly, 
based on a TargetScan92-94,110 analysis, miR-9 is the only conserved microRNA that 
binds to e-cadherin’s 3’-UTR.  Transient transfections of luciferase constructs containing 
the CDH1 3’-UTR wild type or mutated seed region target (Table 5-2) resulted in loss of 
suppression as observed through luciferase activity (Figure 5-7). 
 As another proven target of miR-9, NF-kB is typically only shown as modulated 
when miR-9 suppression is lost, as is seen in carcinomas that show a loss of miR-9 
expression153-156,159.  In these instances, relief of suppression of NF-kB results in 
initiation of transcription of a variety of pro-oncogenic and angiogenic genes.  However, 
a concomitant decrease in NF-kB is not observed in the cancers in which miR-9 is 
overexpressed.  Similarly, no difference between NF-kB levels were observed between 
the M12 and M12+miR-9 inhibited cells (Figure 5-8).  Thus, control of NF-kB was not 
pursued further. 
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position  1320 
target 5'    A GU    C           C 3' 
              A  GCUG   AGCCAAAGA     
              U  CGAU   UUGGUUUCU     
miRNA  3' AGUA GU    CUA           5' 
 
mfe: -21.2 kcal/mol 
 
 
              
Figure 5-6:  Proven binding site for miR-9 in e-cadherin.  Adapted from 
RNAHybrid86,87 analysis of CDH1 mRNA (NM_004360.3).   Green is the sequence of 
miR-9, and red is the complementary region of the 3’-UTR of CDH1. 
 
Seed 
Region 
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Figure 5-7:  e-cadherin expression is suppressed by miR-9.  M12 cells were 
transiently transfected with a firefly luciferase reporter construct containing a portion of 
the CDH1 3’-UTR, with the wild type or mutated miR-9 binding seed region (Table 5-3) 
along with a renilla luciferase plasmid.  Firefly luciferase expression is reported as 
normalized to renilla luciferase activity and relative to mutated seed region expression.  
Results are the mean of 2 independent experiments, each performed in triplicate. (p 
<0.01) 
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Figure 5-8:  NF-kB levels are not modulated by miR-9.  Western blot analysis shows 
that NF-kB levels do not change significantly between M12 or M12 cells plus miR-9 
inhibitor. Β-Actin included as a loading control.  Blot is representative of 3 independent 
experiments. 
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As a negative regulator of EGFR and JAK signaling pathway, SOCS5, recently 
identified as a direct target of miR-9, could attentuate signal transduction and ultimately 
transcription of a variety of pro-oncogenic, pro-angiogenic genes157,180.  Evaluation of 
messenger RNA showed no significant difference in levels between P69, M12, and M12 
cells transfected with miR-9 inhibitor; however, western blot analysis indicated a strong 
difference in SOCS5 protein levels between the different cell types (Figure 5-9).  
Messenger RNA levels do not always change in targets, as perfect seed matches to the 
miR and Argonaute 2 are required for cleavage of the message55. 
 An evaluation of the SOCS5 mRNA sequence in RNAHybrid against the miR-9 
sequence revealed four potential binding sites for miR-9, two of which are located in the 
3’-UTR (one proven165), and two located within coding regions of the mRNA (Table 5-3), 
all with significant free energy values. 
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Figure 5-9:  While protein levels of SOCS5 are increased upon miR-9 inhibition, 
messenger RNA levels are not significantly different.  SOCS5 expression in the 
P69, M12, and M12 stably transformed with vector expressing miR-9 inhibitor.  A:  
Western blot analysis and B: quantitation show that miR-9 inhibition results in increased 
levels of SOCS5.  Blot and quantitation are representative of 6 independent 
experiments, normalized to β-Actin and reported as relative to the M12 cell line.  C:  
messenger RNA relative quantitation shows that mRNA levels are not significantly 
impacted by miR-9.  mRNA is normalized to GAPDH and reported as relative to the 
M12 cell line.  Results are compiled data from three biological replicates, each 
performed in triplicate. 
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Table 5-3:  Potential and proven binding sites for miR-9 in SOCS5.  Adapted from 
RNAHybrid13,14 analysis of SOCS5 mRNA (NM_014011.4).   Green is the sequence of 
miR-9, and red is the complementary region of the 3’-UTR of SOCS5.  Two of the 
potential binding sites are within the 3’-UTR, one of which (shaded in aqua) has been 
proven through luciferase 3’-UTR assays and western blot analysis of SOCS515. 
position  1180 
target 5'    A     GUC     U       C 3' 
              GCAGC   AGAUA CUGGAGA     
              UGUCG   UCUAU GGUUUCU     
miRNA  3' AGUA     A       U         5' 
 
mfe: -23.6 kcal/mol 
 
 
 
position  3101 (UTR) 
target 5'   C        UU         C 3' 
             UAUGGCUA    GCCAAGG     
             AUGUCGAU    UGGUUUC     
miRNA  3' AGU        CUAU       U 5' 
 
mfe: -20.7 kcal/mol 
 
 
 
position  3696 (UTR) 
target 5'  A      AACUU          C 3' 
            AUGUAG     UAACCAAAGA     
            UAUGUC     AUUGGUUUCU     
miRNA  3' AG      GAUCU            5' 
 
mfe: -20.1 kcal/mol 
 
  
position  967 
target 5'    G     U   U          A 3' 
              GCGGC UAG   AUUGAAGA     
              UGUCG AUC   UGGUUUCU     
miRNA  3' AGUA         UAU          5' 
 
mfe: -19.7 kcal/mol 
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Discussion 
In this report, we sought to confirm miR-9’s previously identified status as an 
oncomiR, which was based on not only a comparison between the poorly-tumorigenic 
P69 and its highly metastatic subline M12, but also other well-established prostate 
cancer cell lines, and finally through confirmation using human biopsy samples through 
laser-capture microdissection.  Inhibition of miR-9 in M12 cells resulted in significantly 
reduced migratory and invasive potential in-vitro, as well as reduced tumour growth in-
vivo with no metastatic sites observed in nude athymic mice.  Evaluation of the 
expression signatures of known miR-9 targets indicated that while NF-kB is not 
modulated in this model, e-cadherin and SOCS5 are both regulated by miR-9, resulting 
in increased levels when miR-9 is inhibited in M12 cells.  Luciferase constructs 
containing the e-cadherin 3’-UTR showed that miR-9 suppression of the mRNA is 
effective in the prostate cancer model.   
E-Cadherin message and protein levels are suppressed by miR-9 
Dysregulation of miR-9, although initially assumed as being overexpressed in 
carcinoma in general, has been shown through recent literature to be cancer type-
specific.  In breast cancer, neuroblastoma and prostate cancer, miR-9 is observed to be 
up-regulated843, whereas it is downregulated in metastatic melanomas.  In these cell 
types, miR-9 suppresses expression of NF-ĸB, which results in increased levels of 
Snail1 and subsequent activation of e-cadherin160.  Interestingly, higher levels of miR-9 
have been associated with a better outcome in ovarian cancer, where it was shown to 
directly target BRCA1159.   
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The difference in miR-9 expression by cancer type could be due to promoter 
activity of miR-9, whether through PROX1, Snail1, or hypermethylation.  miR-9 is also 
down-regulated in nasopharyngeal carcinoma (NPC),  where it is implicated in the 
inflammatory response, specifically for Interferon-induced genes161.  In this case, 
hypermethylation of the miR-9 promoter results in reduced transcription, resulting in loss 
of CXCR suppression, a chemokine receptor that has been shown to be expressed in a 
number of different tumour types162.  Recently, a second report showing the direct effect 
of miR-9 on CXCR identified that this loss of suppression resulted in the accumulation 
of β-catenin through the Wnt pathway22,163, and the subsequent transcriptional 
activation of JAK/STAT proliferative pathways164.   
E-cadherin is known to sequester β-catenin, which also works to assist in 
dynamically connecting the adherens junctions to the cytoskeleton21,22,151.  Loss of e-
cadherin through miR-9 suppression would free β-catenin from the adherens complex, 
permitting its movement into the nucleus, where it can interact with the zinc finger 
transcriptional factors of the Tcf/Lef family to activate transcription of pro-metastatic, 
pro-angiogenic genes including VEGFA, Siamois, c-Myc and cyclin D122,43 (Figure 5-
10).  Loss of e-cadherin has also been shown to reduce phosphorylation of β-catenin, 
which results in increased stability by blocking movement to the proteasome for 
degradation152.   
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Figure 5-10:  miR-9’s mode of action on tumour progression through e-cadherin.  
In the presence of miR-9 (upper panel), e-cadherin message is cleaved and 
suppressed, resulting in less protein production.  This allows for accumulation of β-
catenin (green “L”), which can then diffuse into the nucleus, activate transcription factors 
and drive transcription of pro-survival, pro-proliferation genes including c-Myc and 
Cyclin D1.  c-Myc then initiates additional miR-9 message through a positive feedback 
signal.  In the noncancerous tissue (lower panel), e-cadherin is produced and 
sequesters β-catenin, preventing activation of downstream transcriptional events. 
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SOCS5 protein levels are suppressed by miR-9 
As a recently identified direct target for miR-9, loss of the tumour suppressor 
SOCS5 results in increased and prolonged activation of JAK/STAT pathways.  The full 
function and target RTKs and JAK/STATS for SOCS5 is still unknown.  However, it 
shares strong homology with the other members of the SOCS family, which are known 
to interfere with both JAK kinase and STAT protein activity, as well as promote their 
degradation through ubiquitination157,158.  In the original report identifying miR-9 as a 
regulator for SOCS5 when overexpressed, SOCS5 expression was shown to be down-
regulated concomitant with increased JAK1, STAT1 and STAT3 phosphorylation 
levels165.  SOCS transcription is also known to be part of a negative feedback loop, in 
that STAT binding sites activate SOCS5 transcription for ultimate suppression of signal 
transduction157,158.  Even though the JAK/STAT pathway has been shown to be 
activated in M12 cells60,61,67, the negative feedback loop that would ultimately attenuate 
JAK/STAT signaling is being prevented through suppression of SOCS5, as we have 
shown that both SOCS5 mRNA and protein levels are reduced in M12 cells compared 
to the parental P69 (Figure 5-11). 
Conclusions 
 This report has confirmed our previous work identifying miR-9 as an oncomiR in 
prostate cancer.  The action of miR-9 is multifaceted; through suppression of miR-9, the 
e-cadherin that makes up the cell-cell interactions characteristic of an epithelial lineage 
is suppressed; thus, promotion from a stationary, embedded cell to a more motile 
phenotype is stimulated, as is readily observed in the EMT transition for a variety of  
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Figure 5-11:  miR-9 overexpression inhibits SOCS5, causing increased signal 
transduction through the JAK/STAT pathways.  In the presence of miR-9 (left), 
SOCS5 message is cleaved and translation suppressed, resulting in less protein 
production.  This allows phosphorylation and signal transduction, resulting in p-STAT 
transcriptional activation of pro-survival, proliferation, and invasion/mestatasis 
oncogenes.  In the normal tissue without miR-9 overexpression (right), SOCS5 is 
produced and reduces or blocks phosphorylation of JAK kinase and STAT while also 
promoting ubiquitination, thus attenuating the JAK/STAT signaling cascade, and 
lowering activation of transcriptional events. 
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cancers.  Loss of e-cadherin also results in release and stabilization of β-catenin, which 
can then move to the nucleus and activate transcription of VEGFA, c-Myc, Cyclin D1, 
and other pro-angiogenesis, proliferative genes.  Given that c-Myc is a known activator 
of miR-9-3, this too represents a feedback loop that could further induce even more 
miR-9 expression.  Finally, action of miR-9 on SOCS5 results in loss of attenuation of 
the JAK/STAT pathways, which ultimately transduces growth signals to promote cell 
survival and proliferation.  This is the first report to show a multi-targeted mode of action 
of miR-9 in a cancer.  Moreover, results observed in-vivo indicate that both tumour 
growth and metastases are severely impacted by miR-9 inhibition (Figure 5-4).  For 
those carcinomas in which miR-9 is overexpressed, inhibition of miR-9 could be a very 
effective therapeutic target, both in early neoplasias to prevent the EMT transition, but 
also in advanced, aggressive cancers to reduce proliferation and combat metastasis. 
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Chapter 6: 
Summary and Future Directions 
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Dysregulation of microRNAs to drive tumour progression and metastasis is 
receiving a great deal of attention, as canonical pathways are seen to be regulated at 
key protein nodes through miR suppression67.  This can result in either suppression of a 
tumour suppressor protein through overexpression of the miR (oncomiR), or activation 
of a previously suppressed oncogene through loss of a tumour suppressor miR. 
 The prostate cancer cell line progression model developed by Dr. Joy Ware is 
valuable for identifying modulated miRs and downstream pathways in prostate cancer, 
as the normal epithelial SV40T immortalized P69 cell line is poorly tumorigenic and not 
metastatic61.  The M12 subline, produced by three subsequent injections of tumour cells 
into nude athymic mice, is highly tumorigenic and metastatic in nature60.  These two cell 
lines constitute a unique model in prostate cancer research, in that they have a common 
genetic background, and presumably selection of the M12 subline mimics a human 
tumour progression pathway. 
 Using the P69 and M12 progression model, our laboratory has been able to 
identify a variety of dysregulated microRNAs and their corresponding target mRNAs, 
and identify key impacted pathways that progress the neoplasia.  These findings have 
been confirmed through in-vitro modulation of the miRs, showing changes in 
tumorigenesis, for the most part, metastases, and migratory capabilities, but also 
through in-vivo work in mice.  Moreover, their dysregulation was confirmed in analysis of 
prostate cancer biopsies.   
 In this dissertation, we performed a global miR analysis to identify dysregulated 
miRs between the P69 and M12 cell line, and then confirmed those expression 
differences in other well-used prostate cancer cell lines as well as laser-capture 
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microdissected samples from prostate biopsies (Chapter 3).  miRs 9 and 147b were 
identified for further analysis based on their consistently high level of expression.   
miR-147b was identified as a potential oncomiR through this work.  Inhibition of 
miR-147b was found to affect not only proliferative, migratory and invasive capabilities 
of M12 cells, but also reduced tumour growth in male nude athymic mice.  AATF was 
identified as a potential target through western blot and mRNA analysis, along with 
identification of potential miR-147b binding sites within the mRNA.  AATF has been 
well-established as being involved in cell-cycle progression139,143.  Its loss has 
previously been shown to activate p21 transcription, which is a known inhibitor of cell-
cycle progression136.   
Similarly, miR-9 was found to be overexpressed in prostate samples and to 
function as an oncomiR by affecting the epithelial to mesenchymal transition through 
suppression of e-cadherin.  As e-cadherin assists in maintaining the integrity of the 
epithelial cell to cell contact, loss of e-cadherin would result in destabilization of the cell 
from the rest of the tissue.  Loss of e-cadherin results in increased levels of free β-
catenin.  β-catenin can then translocate to the nucleus and assist in activation of 
transcription of proliferative genes, including Cyclin D1 and c-Myc21,22,43 (Chapter 5).  
Inhibition of miR-9 resulted in not only reduction of migratory and invasive potential, but 
significant reduction of tumorigenesis and metastases, as evaluated through in-vivo 
work with male nude athymic mice.   
Building on previous work on miR-17-3p, reverse phase microarray analysis 
(RPMA) comparing the parental P69 and M12 subline showed a dramatic increase in c-  
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Table 6-1:  dysregulated microRNAs identified in prostate cancer through the 
P69-M12 progression model 
microRNA Target Protein/mRNA(s) Pathways implicated 
miR-17-3p25 Vimentin, c-KIT 
EMT transition, AKT, ERK, 
JAK/STAT 
miR-125b67 ErbB2 & 3 AKT 
miR-147b AATF Cell Cycle progression, p21 
miR-9 E-cadherin, SOCS5 
EMT transition, cell cycle, 
JAK/STAT, β-catenin, c-Myc 
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Figure 6-1:  Proposed mechanism for a multi-modal effect of dysregulated miR 
effects on tumour progression.  Overexpression of miR-9 results in loss of SOCS5, 
an attenuator of JAK-STAT signal transduction, and of e-cadherin, an adhesion protein 
that maintains epithelial sheet integrity, as well as sequestration of β-catenin, a 
transcriptional activator of c-Myc and Cyclin D1.  Likewise, overexpression of miR-147b 
results in the loss of AATF, and subsequent loss of p21 transcription, an inhibitor of 
CDK/Cyclin activated cell cycle progression.  Loss of miRs-17-3p and 125b both result 
in increased transcription and levels of RTK growth factor receptors c-KIT and 
ERBB2/ERBB3, which increases pro-proliferative and survival signal transduction.  Loss 
of miR-17-3p also promotes the EMT transition through relief of vimentin transcriptional 
suppression, an intermediate filament characteristic of the mesenchymal phenotype. 
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KIT in the M12 cells67.  This increase in c-KIT, a stem cell growth factor receptor 
tyrosine kinase, was ablated in the M12 cells expressing miR-17-3p.  We identified two 
binding sites in c-KIT’s 3’-UTR that we confirmed as being directly targeted by miR-17-
3p (Chapter 2).  Two additional binding sites, one in the 5’-UTR and the other in an 
exon, were identified for further analysis. 
The summation of this laboratory’s work in identifying modulated microRNAs in 
prostate cancer has progressed such that four microRNAs have been identified as 
contributing to the progression of the prostate tumour (Table 6-1).  Evaluation of the 
impacted pathways show that each is vitally connected to key modulators and/or 
pathways known to affect tumour progression or cell proliferation.  While admittedly 
some miRs (miR-9) were chosen based on their known targets and connectivity and 
therefore some bias may be in place there, others (miR-147b) were chosen based on 
their high (or low) consistent expression, with little to no foreknowledge of their target 
proteins. 
Taken together, we know that through both modeling and patient samples, 
prostate cancer has a reduced expression of miR-17-3p25 and miR-125b67.  Loss of 
miR-17-3p causes relief of suppression for vimentin and c-KIT, with a concomitant 
increase in EMT transition, and activation of growth signal transduction pathways, 
thereby enhancing subsequent transcription of proliferation/survival genes (Figure 6-1).  
On the other hand, miRs 147b and 9 are highly upregulated, each also contributing to 
the EMT transition as well as growth and proliferation signaling pathways.  
Consequently, while each miR tends to be evaluated on a case-by-case basis, it is the 
accumulation of all of these dysregulations that contribute to tumour progression and 
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the transition to an invasive phenotype in prostate cancer.  Thus, the sum of the parts 
working synergistically is greater than each component working alone. 
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Chapter 7: 
An evaluation of the stability of microRNAs in forensically relevant  
biological fluids 
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While forensic DNA analysis has reached a level of maturity in the Forensic 
Science field with regards to the sophistication of the techniques and confidence in the 
results, the equally important question of body fluid identification has lagged behind, 
and could still be considered to be in a primitive state. Current crime scene and in-
laboratory methods utilize detection methods that exploit the properties of each 
biological fluid (e.g. phenolphthalin or TMB testing for blood, amylase detection for 
saliva, and urease tests for urine), but validated identifying techniques are largely 
limited to microscopic methods (i.e. identification of spermatozoa) or immunological 
methods, as seen in the widely used immunochromatographic commercial tests for 
blood, semen, and other biological fluids.  Thus, while there is widespread confidence in 
the DNA profile generated, there is often significantly less assurance in the identity of 
the body fluid that the DNA profile was developed from. It is common during trials for 
attorneys to categorically accept the STR analysis, but probe the forensic scientist on 
the source of the DNA that generated the profile.  Because of this dichotomy, significant 
efforts have been made over the past ten years in order to develop forensic serological 
techniques of a more discriminatory nature.  There are three main areas that can be 
exploited for molecular methods for body fluid identification:  the genome, the 
transcriptome, and the proteome.  Each has been subject to a great deal of research.  
 Recently, there has been some work in the forensic science field in regards to 
exploring microRNAs (miRs) for a molecular-based, forensic body fluid identification 
method.  MiRs are small structures that are transcribed as larger precursors (60-100 
nts) that immediately form a stem-loop structure with incomplete base-pairing and 
flanking nucleotides34.  Processing of the immature miR is accomplished through 
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excision of the loop, resulting in a mature miR of 19-23 nucleotides long.  There are no 
known postprocessing modifications, and thus miRs are simpler, and potentially less 
problematic for detection than proteins and mRNAs.  MicroRNAs show distinct promise 
for forensic body fluid identification on several grounds.  There is significant literature 
that some miRs are differentially expressed, and in fact are involved in embryonic stem 
cell development and tissue differentiation35,166,167. They are found in extracellular 
fluids166, and thus the discovery and application of unique miRs to forensically relevant 
body fluids is a distinct possibility.  
 Because of their small size and lack of a poly-A tail, miRs are inherently less 
susceptible to degradation than mRNA.  Additionally, miRs are very hardy, and can be 
recovered from highly compromised samples including formalin-fixed paraffin 
embedded (FFPE) tissue25.  In serum, miRs have been shown to survive harsh 
conditions such as boiling, low or high pH, cycles of freeze-thaw, and extended 
storage56.  In the clinical arena, miRs have been shown in urine, and potential markers 
for bladder cancer have been evaluated168,169.  A recent study evaluated liquid semen, 
kept at room temperature for up to seven days, and frozen and thawed up to eight 
times, and found minimal differences in levels of three miRs evaluated168.  Urine stability 
was evaluated in up to four consecutive freeze-thaw cycles, and no significant 
difference was found in mIR-1 and miR-16 levels170.   
There is considerable evidence that many miRs are encapsulated in an 
exosome, which, depending on the microRNA and the secretion process, could be 
membrane- or protein-based58,171.  Because of this, recent studies have shown that 
samples can even be treated with RNase enzymes and the encapsulated miRs are still 
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detectable56.  This implies a high degree of stability of the species, and therefore, a very 
good possibility that if body-fluid specific miRs are found and described, a very robust 
miR panel for forensic body fluid identification could be developed.   
Recently published studies examining miRs for forensic body fluid ID purposes 
utilized microarray screens and/or RT-qPCR, with varying results167,172-174.  A panel that 
can discriminate between blood, semen, saliva, vaginal secretions, and menstrual blood 
has already been described by Hanson et al172,175.  Further, Zubakov et al found that 
miRs could be detected using qPCR from just picograms of total RNA, far below the 
known detection limit of mRNAs173.  Recent reports have shown that miRs are 
detectable and coextracted in silica-column based DNA extracts at a similar level to 
RNA extracts176,177.  Because of the preliminary results reported from these authors, it is 
clear that miRs are detectable from forensic samples, and that it is an area that should 
be evaluated thoroughly.   The purpose of this work was to evaluate the stability of 
microRNAs in blood, semen, urine, and saliva under the harsh treatment conditions that 
evidence samples could be subjected to at the crime scene. 
Methods & Materials 
Sample Collection & Treatment 
Blood, urine, semen, and saliva were collected from volunteers under an 
approved human subjects research protocol.  One body fluid collection from a single 
individual was used for all treatments, in order to eliminate variation seen in person-to-
person and collection-to-collection miR levels.  Urine, semen, and saliva were deposited 
into sterile collection cups and 50 µL (semen, saliva) or 100 µL (urine) was applied to 
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cotton swabs or cloth.  Blood was collected into a Vacutainer® containing EDTA 
(Beckton, Dickinson & Company, Franklin Lakes, NJ), inverted for 15 seconds, and 50 
µL immediately applied to cotton swabs or cloth.  All samples were allowed to dry for 24 
hours, and swabs or stains cut and placed into 1.5 mL microcentrifuge tubes, and 
stored at -20ºC before and after subjection to treatment.   
 Samples undergoing irradiation were placed on a Bio-Rad 464BR ultraviolet 
transilluminator (Bio-Rad Laboratories, Hercules, CA) for 4 hours. Samples undergoing 
heat treatment were incubated at 55ºC or 95ºC for 0.5, 1, 2, 4, or 24 hours.  For 
samples exposed to chemical conditions, 100 µL of 87 mM or 870 mM sodium 
hypochlorite (1:10 dilution and full-strength household bleach, respectively), glacial 
acetic acid, or household dishwashing detergent were applied to the samples.  The 
microcentrifuge tubes containing the treated samples were left open to air dry for 72 
hours.  The samples were then stored at -20ºC until isolation.   
RNA Isolation and Analysis 
 RNA isolation was conducted using the Qiagen miRNeasy mini kit (Qiagen N.V., 
Venlo, The Netherlands).  Briefly, the entire swab or fabric cutting was placed in 700 µL 
of QIAzol lysis reagent, and incubated for 5 minutes at room temperature, vortexing 
every minute.  The swab or cutting was then placed in a DNA IQ™ Spin Basket 
(Promega, Madison, WI, USA), and centrifuged at 13000xg for 3 minutes.  The resultant 
lysate was then processed according to protocol and total RNA eluted in 30 µL of 
RNase-free water.  RNA was quantified using the NanoDrop ND-2000 UV 
Spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA). 
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 Quantitative reverse transcription was carried out via the qScript™ microRNA 
Quantification System (Quanta Biosciences Inc., Gaithersburg, MD).    Reverse 
transcription was carried out according to the manufacturer’s protocol using 7 µL of 
RNA extract.  qPCR reactions were prepared in triplicate for each sample using a 
modified protocol:  6.25 µL of PerfeCTa SYBR Green SuperMix (2X), 0.25 uL (2.5 µM) 
PerfeCTa microRNA Assay Primer (miR-16, 21, or 24), 2 µL of cDNA reaction, and 4 µL 
of nuclease-free water.  Thermal cycling was conducted on the Life Technologies Prism 
7300 instrument (Life Technologies, Foster City, CA) using the following parameters:  
95ºC for 2 minutes, followed by 40 cycles of 95ºC for 5 seconds, 60ºC for 15 seconds, 
and 70ºC for 30 seconds (data collection). qPCR analysis was conducted using SDS 
software, v1.3.1 (Life Technologies). 
All treatments were performed on a minimum of two treated samples, with 3 
technical (qPCR) replicates for each treated sample, with the exception of the full-
strength bleach, detergent, and acetic acid treatments, which had one biological sample 
with a minimum of 3 technical replicates. 
Data Analysis 
In order to determine relative changes in sample integrity, a dCT was calculated 
in which the CT of the treated sample was subtracted from the CT of the untreated 
control of the same body fluid.  Given that the literature regarding normalization miRs 
for body fluids is variable, and effect on integrity is as yet unknown, this is the most 
discriminating measure.  Using identical RNA extraction, reverse transcription, and 
qPCR parameters provide a consistent comparison of miR quality from treated sample 
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to control.  An unpaired two-tailed t–test was applied to determine significance between 
treated and untreated samples.    
Results & Discussion 
RNA Isolations 
Total RNA yield was not affected by any treatment method (data not shown).  
This is consistent with a previous report by Setzer et al178, in which mRNA stability in 
environmentally challenged samples was evaluated. 
Heat Treatment 
Blood, treated for any length of time at both 55 and 95°C, was highly resistant to 
degradation, with no failed reactions (Figures 7-1a & b).  miR-16 levels are high in 
blood, which resulted in low CT values regardless of treatment.  Saliva too was 
remarkably stable under heat treatment at 55°C (not tested at 95°C) and was always 
detectable.  However, seminal fluid and urine showed themselves to be more 
susceptible to the degradative effects of heat treatment.  Semen had a 92.8% failure 
rate (4 biological replicates, 14 technical replicates) at 30’, 50% failure rate at 1 hour, 
and 0% failure rates at 2 and 24 hours.  This pattern is seen in several instances of 
treatment, and is cause for deliberation, as it too, was seen in multiple biological and 
technical replicates.  Urine, as a high-volume, low cell-content fluid, understandably has 
low levels of miRs to begin with (CT range of positive control miR-16 – 32.4 ± 1.4).  
Thus, any degradation can quickly result in loss of signal.  Thus, sample failure rates at 
1 and 2 hours of 55°C were not unexpected.  What was unexpected, however, were 
excellent amplification of miR-16 in urine at 24 hours at 55°C, and 100% sample 
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success at 1, 2, or 24 hours at 95°C.  As these results are somewhat more variable than 
expected, several biological and technical replicates of the failed treatments were 
repeated; however, results were consistent and since native miR-16 levels are low in 
untreated urine, not statistically significant. 
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Figure 7-1:  microRNA stability under heat conditions over time.  Relative miR-16 
levels as determined by the difference in CT from treated sample to control of the same 
body fluid.  A: 55°C Heat Treatment.  Blood and saliva miR levels did not change 
significantly at 30 and 60 minutes, but differences were significantly higher at 2 and 24 
hours (p<0.05).  Urine and semen had significantly higher dCT levels and failed 
reactions.  N≥2 biological and 6 technical replicates for each treatment.  B: 95°C Heat 
Treatment of blood and urine (semen and saliva not tested).  Differences in urine were 
not statistically significant; however, all differences in blood were statistically significant 
(p<.005). No failed reactions. N=1 biological and minimum 3 technical replicates for 
each treatment. 
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Ultraviolet Treatment 
 All body fluids tested were highly resistant to ultraviolet treatment, yielding 
detectable miR levels.  Blood and semen CTs were statistically higher than the control 
(p<.01), but still detectable with no reaction failures. (Figure 7-2A).  As seen in heat 
treatment, saliva samples actually had a modest increased in miR levels based on CT 
values, but the results were not statistically significant.  While there is very little research 
in the area of UV damage to RNAs, and none for small RNAs, the primary mode of 
action for ultraviolet damage is the fusion of pyrimidine doublets, and ultraviolet 
exposure has been shown to impact RNA in pure extracted form179.  However, this is 
not relevant to the matrix of a dried body fluid sample; ultraviolet light has been shown 
to affect mRNA levels only after 90 and 180 days of exposure from mock forensic 
samples178. 
Chemical Treatment 
Bleach treatment resulted in two widely variant results.  While blood and urine 
were consistently resistant to both diluted and household strength bleach application, 
semen and saliva proved vulnerable, resulting in a majority of sample failures at 10% 
bleach treatment, and 100% failures at full-strength bleach application (Figure 7-2B).  
This is enigmatic, as application with glacial acetic acid (pH ~2.4) yielded minimal 
difference from the control for all body fluids (Figure 7-2C).  Given the fact that RNA is 
more stable under slightly acidic conditions than DNA, it would be interesting to 
evaluate samples that had been exposed to similar conditions for DNA quantity and  
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Figure 7-2:  microRNA stability under various conditions.  Relative miR-16 levels as 
determined by the difference in CT from treated sample to control of the same body 
fluid.  A: Ultraviolet exposure.  miR levels were minimally affected by ultraviolet 
exposure.  Only blood and semen showed statistically significant differences vs. control 
(p <0.01) N=2 biological and ≥5 technical replicates for each treatment.  No failed 
reactions were observed.  B: Bleach treatment.  10% bleach:  Urine miR levels did not 
change significantly (p=0.263), and blood was significantly affected (p<0.001) but still 
readily detectable.  Saliva and semen had mainly failed reactions N≥2 biological and 6 
technical replicates for each body fluid treatment.  Full-strength bleach:  Urine was not 
significantly affected by whole bleach treatment (p=0.483), but blood, semen, and saliva 
were significantly affected (p<0.001).  While blood miR-16 levels were affected by 
treatment, but still detectable, saliva and semen were degraded to the point that miR-16 
was undetected.  N=1 biological and 3 technical replicates for each body fluid treatment.  
C: Acid and Detergent treatment.  Glacial Acetic Acid:  All body fluids were detectable, 
with no significant deviation from positive control detection threshold.  N=1 biological 
and 3 technical replicates for each body fluid treatment.  Dishwashing detergent:  Saliva 
and urine were readily detectable, with no significant deviation from positive control 
detection threshold.  Blood too was easily detectable, but significantly affected (p=0.03).  
Semen had a 50% failure rate with dishwashing detergent application.  N≥1 biological 
and 3 technical replicates for each body fluid treatment.   
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STR profile analysis. Again, saliva seemed to gain miR levels during treatment as 
compared to the control (difference not statistically significant).   
 Application of dish detergent was performed for multiple reasons.  First, it is a 
canonical treatment for forensic samples, given the fact that crime scene cleanup by 
perpetrators are typically attempted using common and convenient household 
chemicals.  Secondly, it stands to reason that because some secreted miRs are 
encapsulated within a microvesicle, which contains large amounts of cell membrane 
lipid components, or co-transported with HDL particles56-59, stability could be affected by 
disrupting such particles and exposing the microRNAs.  Interestingly, blood, urine, and 
saliva were minimally affected by detergent application, with saliva again yielding better 
amplification results than the control (Figure 7-2C).  However, semen yielded only a 
50% success rate (2 biological, 6 technical replicates). 
Overall miR stability (by body fluid, different miRs) 
 Three candidate microRNAs were evaluated for stability purposes; miR-16, 21, 
and 24.  These miRs are commonly detected in tissues and body fluids, were evaluated 
in all body fluids and found to be expressed at high levels.  miR-16 was used for this 
study, but miR-21 and miR-24 were also evaluated in a number of treatment types, and 
were consistent with the results seen in miR-16 (data not shown).  This indicates that 
degradation seen in this study is likely to be representative of the integrity levels of the 
miR population in the body fluids assessed.  In an effort for consistency, miR-16 was 
used across all body fluids; however, highly expressed miRs in each body fluid could be  
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Figure 7-3: Overall Stability Parameters.  Compiled average CT data for all 
treatments, all replicates.  As miR-16 was highly abundant in blood, even severe 
treatment resulted in detectable miR levels.  As the abundance of the miR decreased 
(as determined by CT), treatment resulted in more amplification failures in a 40-cycle 
amplification. 
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found and used as a better indicator, as they would likely result in less failed reactions 
in low-abundance body fluids such as urine.  
Conclusions 
 This study sought to characterize the stability of microRNAs for forensic samples.  
Given the explosion in recent interest in microRNAs, it is important to understand the 
limitations, if any, to the forensic analysis of a new species of nucleic acid.  Overall, the 
microRNAs assayed, as an indicator of the species as a whole, were remarkably stable, 
with detection in the majority of treatments (Figure 7-3).  The microRNAs present in 
blood and saliva were both more abundant and robust, and were detectable throughout 
all treatments.  Urine and semen were more susceptible to treatment, but were 
detectable in the majority of treatment scenarios.   Larger volumes of each body fluid 
could have been used, but it was felt that keeping the volume small was more indicative 
of the sample sizes often seen in forensic evidence.  Given that the miRs tested were 
very readily and consistently detectable in such small samples, it is highly possible that 
stability is even better than seen in these results, once more abundant and indicative 
miRs are identified for each body fluid.  The results from this study underscore the need 
to comprehensively evaluate the miRnome in each forensically relevant body fluid.  
Other researchers have begun to do this through the use of microarray qRT-PCR, but 
there are still inconsistencies between research laboratories in regards to which miRs 
are diagnostic for the primary body fluids.  The secondary, accessory body fluids have 
not been assayed (urine, feces, sweat) in most cases.  Additionally, there is 
disagreement and confusion, not only in the forensic community, but also within the 
analytical and research community, regarding appropriate endogenous markers for 
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miRs in body fluids.  Certainly once there is more standardization and better means of 
normalization, a better evaluation and identification of unique markers for each body 
fluid can be undertaken. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
175 
 
REFERENCES 
 
1. Drake RR, Elschenbroich S, Lopez-Perez O, et al. In-depth proteomic analyses of 
direct expressed prostatic secretions. J Proteome Res. 2010;9(5):2109-2116. 
2. American Cancer Society. Key statistics of prostate cancer. 
http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-
statistics. Accessed 11/01, 2013. 
3. Chen FZ, Zhao XK. Prostate cancer: Current treatment and prevention strategies. 
Iran Red Crescent Med J. 2013;15(4):279-284. 
4. FitzGerald LM, Kwon EM, Conomos MP, et al. Genome-wide association study 
identifies a genetic variant associated with risk for more aggressive prostate cancer. 
Cancer Epidemiol Biomarkers Prev. 2011;20(6):1196-1203. 
5. Ismail MT, Gomella LG. Transrectal prostate biopsy. Urol Clin North Am. 
2013;40(4):457-472. 
6. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin 
North Am. 1997;24(2):275-282. 
7. Gunderson K, Wang CY, Wang R. Global prostate cancer incidence and the 
migration, settlement, and admixture history of the northern europeans. Cancer 
Epidemiol. 2011;35(4):320-327. 
8. Walter LC, Fung KZ, Kirby KA, et al. Five-year downstream outcomes following 
prostate-specific antigen screening in older men. JAMA Intern Med. 2013;173(10):866-
873. 
9. Hugo H, Ackland ML, Blick T, et al. Epithelial--mesenchymal and mesenchymal--
epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213(2):374-383. 
10. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among 
men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 
2004;350(22):2239-2246. 
11. Toles CA. Black men are dying from prostate cancer. ABNF J. 2008;19(3):92-95. 
12. Cnattingius S, Lundberg F, Sandin S, Gronberg H, Iliadou A. Birth characteristics 
and risk of prostate cancer: The contribution of genetic factors. Cancer Epidemiol 
Biomarkers Prev. 2009;18(9):2422-2426. 
176 
 
13. Goh CL, Schumacher FR, Easton D, et al. Genetic variants associated with 
predisposition to prostate cancer and potential clinical implications. J Intern Med. 
2012;271(4):353-365. 
14. Lindberg J, Mills IG, Klevebring D, et al. The mitochondrial and autosomal mutation 
landscapes of prostate cancer. Eur Urol. 2013;63(4):702-708. 
15. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays 
which capture disease progression show activation of pro-survival pathways at the 
cancer invasion front. Oncogene. 2001;20(16):1981-1989. 
16. Epstein JI, Allsbrook WC,Jr, Amin MB, Egevad LL, ISUP Grading Committee. The 
2005 international society of urological pathology (ISUP) consensus conference on 
gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228-1242. 
17. Sun T, Wang X, He HH, et al. MiR-221 promotes the development of androgen 
independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. 
Oncogene. 2013. 
18. Ostling P, Leivonen SK, Aakula A, et al. Systematic analysis of microRNAs targeting 
the androgen receptor in prostate cancer cells. Cancer Res. 2011;71(5):1956-1967. 
19. Nyquist MD, Li Y, Hwang TH, et al. TALEN-engineered AR gene rearrangements 
reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad 
Sci U S A. 2013;110(43):17492-17497. 
20. Frixen UH, Behrens J, Sachs M, et al. E-cadherin-mediated cell-cell adhesion 
prevents invasiveness of human carcinoma cells. J Cell Biol. 1991;113(1):173-185. 
21. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-
cadherin promotes metastasis via multiple downstream transcriptional pathways. 
Cancer Res. 2008;68(10):3645-3654. 
22. Voronkov A, Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors. 
Curr Pharm Des. 2013;19(4):634-664. 
23. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. 
Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic 
epithelium. Cancer Res. 1999;59(19):5002-5011. 
24. Hayward SW, Wang Y, Cao M, et al. Malignant transformation in a nontumorigenic 
human prostatic epithelial cell line. Cancer Res. 2001;61(22):8135-8142. 
25. Zhang X, Ladd A, Dragoescu E, Budd WT, Ware JL, Zehner ZE. MicroRNA-17-3p is 
a prostate tumor suppressor in vitro and in vivo, and is decreased in high grade prostate 
177 
 
tumors analyzed by laser capture microdissection. Clin Exp Metastasis. 2009;26(8):965-
979. 
26. Zhao Y, Yan Q, Long X, Chen X, Wang Y. Vimentin affects the mobility and 
invasiveness of prostate cancer cells. Cell Biochem Funct. 2008;26(5):571-577. 
27. Lynch CC, Vargo-Gogola T, Matrisian LM, Fingleton B. Cleavage of E-cadherin by 
matrix metalloproteinase-7 promotes cellular proliferation in nontransformed cell lines 
via activation of RhoA. J Oncol. 2010;2010:530745. 
28. Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H. Human mast 
cells produce matrix metalloproteinase 9. Eur J Immunol. 1999;29(8):2645-2649. 
29. Lu MH, Huang CC, Pan MR, Chen HH, Hung WC. Prospero homeobox 1 promotes 
epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-
9. Clin Cancer Res. 2012;18(23):6416-6425. 
30. Amankwah EK, Sellers TA, Park JY. Gene variants in the angiogenesis pathway 
and prostate cancer. Carcinogenesis. 2012;33(7):1259-1269. 
31. Kambhampati S, Ray G, Sengupta K, Reddy VP, Banerjee SK, Van Veldhuizen PJ. 
Growth factors involved in prostate carcinogenesis. Front Biosci. 2005;10:1355-1367. 
32. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer 
cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth 
in the bone environment. Prostate. 1999;39(4):246-261. 
33. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes 
small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854. 
34. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. 
Cell. 2009;136(4):642-655. 
35. Zhang L, Stokes N, Polak L, Fuchs E. Specific microRNAs are preferentially 
expressed by skin stem cells to balance self-renewal and early lineage commitment. 
Cell Stem Cell. 2011;8(3):294-308. 
36. Pan Q, Chegini N. MicroRNA signature and regulatory functions in the endometrium 
during normal and disease states. Semin Reprod Med. 2008;26(6):479-493. 
37. Wu S, Huang S, Ding J, et al. Multiple microRNAs modulate p21Cip1/Waf1 
expression by directly targeting its 3' untranslated region. Oncogene. 2010;29(15):2302-
2308. 
38. Kozomara A, Griffiths-Jones S. miRBase: Integrating microRNA annotation and 
deep-sequencing data. Nucleic Acids Res. 2011;39(Database issue):D152-7. 
178 
 
39. Griffiths-Jones S. miRBase: microRNA sequences and annotation. Curr Protoc 
Bioinformatics. 2010;Chapter 12:Unit 12.9.1-10. 
40. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: 
microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 
2006;34(Database issue):D140-4. 
41. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: Tools for 
microRNA genomics. Nucleic Acids Res. 2008;36(Database issue):D154-8. 
42. Thomas M, Lange-Grunweller K, Hartmann D, et al. Analysis of transcriptional 
regulation of the human miR-17-92 cluster; evidence for involvement of pim-1. Int J Mol 
Sci. 2013;14(6):12273-12296. 
43. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, 
regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12(3):247-256. 
44. Bertero T, Grosso S, Robbe-Sermesant K, et al. "Seed-milarity" confers to hsa-miR-
210 and hsa-miR-147b similar functional activity. PLoS One. 2012;7(9):e44919. 
45. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. 
EMBO J. 2004;23(20):4051-4060. 
46. Davis-Dusenbery BN, Hata A. Mechanisms of control of microRNA biogenesis. J 
Biochem. 2010;148(4):381-392. 
47. Zeng Y, Yi R, Cullen BR. Recognition and cleavage of primary microRNA 
precursors by the nuclear processing enzyme drosha. EMBO J. 2005;24(1):138-148. 
48. Gregory RI, Yan KP, Amuthan G, et al. The microprocessor complex mediates the 
genesis of microRNAs. Nature. 2004;432(7014):235-240. 
49. Katahira J, Yoneda Y. Nucleocytoplasmic transport of microRNAs and related small 
RNAs. Traffic. 2011;12(11):1468-1474. 
50. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell 
Biol. 2009;10(2):126-139. 
51. Dueck A, Ziegler C, Eichner A, Berezikov E, Meister G. microRNAs associated with 
the different human argonaute proteins. Nucleic Acids Res. 2012;40(19):9850-9862. 
52. Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the dicer 
complex to Ago2 for microRNA processing and gene silencing. Nature. 
2005;436(7051):740-744. 
179 
 
53. Murphy D, Dancis B, Brown JR. The evolution of core proteins involved in 
microRNA biogenesis. BMC Evol Biol. 2008;8:92-2148-8-92. 
54. Elkayam E, Kuhn CD, Tocilj A, et al. The structure of human argonaute-2 in complex 
with miR-20a. Cell. 2012;150(1):100-110. 
55. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human 
Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 
2004;15(2):185-197. 
56. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: A novel class of 
biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997-
1006. 
57. Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: A new 
source of biomarkers. Mutat Res. 2011;717(1-2):85-90. 
58. Lasser C, Alikhani VS, Ekstrom K, et al. Human saliva, plasma and breast milk 
exosomes contain RNA: Uptake by macrophages. J Transl Med. 2011;9:9-5876-9-9. 
59. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-
mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic 
exchange between cells. Nat Cell Biol. 2007;9(6):654-659. 
60. Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Chen J, Ware JL. 
Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial 
cell line. Prostate. 1998;34(4):275-282. 
61. Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, Ware JL. Tumorigenicity 
of SV40 T antigen immortalized human prostate epithelial cells: Association with 
decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer. 
1994;58(5):721-729. 
62. Jackson-Cook C, Bae V, Edelman W, Brothman A, Ware J. Cytogenetic 
characterization of the human prostate cancer cell line P69SV40T and its novel 
tumorigenic sublines M2182 and M15. Cancer Genet Cytogenet. 1996;87(1):14-23. 
63. Plymate SR, Bae VL, Maddison L, Quinn LS, Ware JL. Reexpression of the type 1 
insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T 
antigen immortalized human prostate epithelial cells. Endocrinology. 1997;138(4):1728-
1735. 
64. Cao Q, Li YY, He WF, et al. Interplay between microRNAs and the STAT3 signaling 
pathway in human cancers. Physiol Genomics. 2013. 
180 
 
65. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. 
Cell. 2008;133(2):217-222. 
66. Astbury C, Jackson-Cook CK, Culp SH, Paisley TE, Ware JL. Suppression of 
tumorigenicity in the human prostate cancer cell line M12 via microcell-mediated 
restoration of chromosome 19. Genes Chromosomes Cancer. 2001;31(2):143-155. 
67. Budd WT. Combinatorial analysis of tumorigenic microRNAs driving prostate 
cancer. [dissertation]. Virginia Commonwealth University; 2012. 
68. Ferracin M, Bassi C, Pedriali M, et al. miR-125b targets erythropoietin and its 
receptor and their expression correlates with metastatic potential and ERBB2/HER2 
expression. Mol Cancer. 2013;12(1):130. 
69. Schneider SA, Sukov WR, Frank I, et al. Outcome of patients with micropapillary 
urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification 
identifies patients with poor outcome. Mod Pathol. 2013. 
70. Wang S, Huang J, Lyu H, et al. Therapeutic targeting of erbB3 with MM-
121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing 
breast cancer. Breast Cancer Res. 2013;15(5):R101. 
71. Yue L, Xiang J, Shen Z, et al. Inhibition of ErbB-2 induces TFF3 downregulation in 
breast cancer cell lines. APMIS. 2013. 
72. Improta G, Zupa A, Fillmore H, et al. Protein pathway activation mapping of brain 
metastasis from lung and breast cancers reveals organ type specific drug target 
activation. J Proteome Res. 2011;10(7):3089-3097. 
73. Mueller C, Liotta LA, Espina V. Reverse phase protein microarrays advance to use 
in clinical trials. Mol Oncol. 2010;4(6):461-481. 
74. Pernas FG, Allen CT, Winters ME, et al. Proteomic signatures of epidermal growth 
factor receptor and survival signal pathways correspond to gefitinib sensitivity in head 
and neck cancer. Clin Cancer Res. 2009;15(7):2361-2372. 
75. Sereni MI, Pierobon M, Angioli R, Petricoin EF,3rd, Frederick MJ. Reverse phase 
protein microarrays and their utility in drug development. Methods Mol Biol. 
2013;986:187-214. 
76. Di Lorenzo G, Autorino R, D'Armiento FP, et al. Expression of proto-oncogene c-kit 
in high risk prostate cancer. Eur J Surg Oncol. 2004;30(9):987-992. 
77. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-kit as targets 
for inflammatory diseases. Eur J Pharmacol. 2006;533(1-3):327-340. 
181 
 
78. Babina M, Rex C, Guhl S, et al. Baseline and stimulated turnover of cell surface c-kit 
expression in different types of human mast cells. Exp Dermatol. 2006;15(7):530-537. 
79. Fett NM, Teng J, Longley BJ. Familial urticaria pigmentosa: Report of a family and 
review of the role of KIT mutations. Am J Dermatopathol. 2013;35(1):113-116. 
80. Ratajczak MZ, Perrotti D, Melotti P, et al. Myb and ets proteins are candidate 
regulators of c-kit expression in human hematopoietic cells. Blood. 1998;91(6):1934-
1946. 
81. Lennartsson J, Ronnstrand L. Stem cell factor receptor/c-kit: From basic science to 
clinical implications. Physiol Rev. 2012;92(4):1619-1649. 
82. Kim WK, Park M, Kim YK, et al. MicroRNA-494 downregulates KIT and inhibits 
gastrointestinal stromal tumor cell proliferation. Clin Cancer Res. 2011;17(24):7584-
7594. 
83. Simak R, Capodieci P, Cohen DW, et al. Expression of c-kit and kit-ligand in benign 
and malignant prostatic tissues. Histol Histopathol. 2000;15(2):365-374. 
84. Wiesner C, Nabha SM, Dos Santos EB, et al. C-kit and its ligand stem cell factor: 
Potential contribution to prostate cancer bone metastasis. Neoplasia. 2008;10(9):996-
1003. 
85. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402-408. 
86. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective 
prediction of microRNA/target duplexes. RNA. 2004;10(10):1507-1517. 
87. Kruger J, Rehmsmeier M. RNAhybrid: microRNA target prediction easy, fast and 
flexible. Nucleic Acids Res. 2006;34(Web Server issue):W451-4. 
88. Vlachos IS, Kostoulas N, Vergoulis T, et al. DIANA miRPath v.2.0: Investigating the 
combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 2012;40(Web 
Server issue):W498-504. 
89. Wang X, El Naqa IM. Prediction of both conserved and nonconserved microRNA 
targets in animals. Bioinformatics. 2008;24(3):325-332. 
90. Bandyopadhyay S, Mitra R. TargetMiner: microRNA target prediction with 
systematic identification of tissue-specific negative examples. Bioinformatics. 
2009;25(20):2625-2631. 
182 
 
91. Miranda KC, Huynh T, Tay Y, et al. A pattern-based method for the identification of 
MicroRNA binding sites and their corresponding heteroduplexes. Cell. 
2006;126(6):1203-1217. 
92. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are 
conserved targets of microRNAs. Genome Res. 2009;19(1):92-105. 
93. Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP. Weak seed-pairing 
stability and high target-site abundance decrease the proficiency of lsy-6 and other 
microRNAs. Nat Struct Mol Biol. 2011;18(10):1139-1146. 
94. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA 
targeting specificity in mammals: Determinants beyond seed pairing. Mol Cell. 
2007;27(1):91-105. 
95. Chee CE, Krishnamurthi S, Nock CJ, et al. Phase II study of dasatinib (BMS-
354825) in patients with metastatic adenocarcinoma of the pancreas. Oncologist. 
2013;18(10):1091-1092. 
96. Salomonsson A, Jonsson M, Isaksson S, et al. Histological specificity of alterations 
and expression of KIT and KITLG in non-small cell lung carcinoma. Genes 
Chromosomes Cancer. 2013;52(11):1088-1096. 
97. Sinha N, Mukhopadhyay S, Das DN, Panda PK, Bhutia SK. Relevance of cancer 
initiating/stem cells in carcinogenesis and therapy resistance in oral cancer. Oral Oncol. 
2013;49(9):854-862. 
98. Maurel M, Dejeans N, Taouji S, Chevet E, Grosset CF. MicroRNA-1291-mediated 
silencing of IRE1alpha enhances glypican-3 expression. RNA. 2013;19(6):778-788. 
99. Shin J, Xie D, Zhong XP. MicroRNA-34a enhances T cell activation by targeting 
diacylglycerol kinase zeta. PLoS One. 2013;8(10):e77983. 
100. Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal 
erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc 
Natl Acad Sci U S A. 2005;102(50):18081-18086. 
101. Siemens H, Jackstadt R, Kaller M, Hermeking H. Repression of c-kit by p53 is 
mediated by miR-34 and is associated with reduced chemoresistance, migration and 
stemness. Oncotarget. 2013;4(9):1399-1415. 
102. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and 
characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 
1979;17(1):16-23. 
183 
 
103. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium 
of old and new lines--part 1. J Urol. 2005;173(2):342-359. 
104. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human 
prostate carcinoma cell line (DU 145). Int J Cancer. 1978;21(3):274-281. 
105. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium 
of old and new lines--part 2. J Urol. 2005;173(2):360-372. 
106. Horoszewicz JS, Leong SS, Chu TM, et al. The LNCaP cell line--a new model for 
studies on human prostatic carcinoma. Prog Clin Biol Res. 1980;37:115-132. 
107. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic 
carcinoma. Cancer Res. 1983;43(4):1809-1818. 
108. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of 
androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone 
stromal cells. Int J Cancer. 1994;57(3):406-412. 
109. Vijayakumar S, Garcia D, Hensel CH, et al. The human Y chromosome 
suppresses the tumorigenicity of PC-3, a human prostate cancer cell line, in athymic 
nude mice. Genes Chromosomes Cancer. 2005;44(4):365-372. 
110. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by 
adenosines, indicates that thousands of human genes are microRNA targets. Cell. 
2005;120(1):15-20. 
111. Wang B, Howel P, Bruheim S, et al. Systematic evaluation of three microRNA 
profiling platforms: Microarray, beads array, and quantitative real-time PCR array. PLoS 
One. 2011;6(2):e17167. 
112. Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human 
breast cancer is associated with advanced clinical stage, lymph node metastasis and 
patient poor prognosis. RNA. 2008;14(11):2348-2360. 
113. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA profiling of 
prostate cancer. J Cancer. 2013;4(5):350-357. 
114. Shen J, Hruby GW, McKiernan JM, et al. Dysregulation of circulating microRNAs 
and prediction of aggressive prostate cancer. Prostate. 2012;72(13):1469-1477. 
115. Sikand K, Slaibi JE, Singh R, Slane SD, Shukla GC. miR 488* inhibits androgen 
receptor expression in prostate carcinoma cells. Int J Cancer. 2011;129(4):810-819. 
184 
 
116. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA 
expression profiles that may predict recurrence of localized stage I non-small cell lung 
cancer after surgical resection. Cancer Res. 2010;70(1):36-45. 
117. Wang X. miRDB: A microRNA target prediction and functional annotation database 
with a wiki interface. RNA. 2008;14(6):1012-1017. 
118. Shevde LA, Metge BJ, Mitra A, et al. Spheroid-forming subpopulation of breast 
cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo 
expression of osteopontin. J Cell Mol Med. 2010;14(6B):1693-1706. 
119. Berge G, Pettersen S, Grotterod I, Bettum IJ, Boye K, Maelandsmo GM. 
Osteopontin--an important downstream effector of S100A4-mediated invasion and 
metastasis. Int J Cancer. 2011;129(4):780-790. 
120. Ye W, Lv Q, Wong CK, et al. The effect of central loops in miRNA:MRE duplexes 
on the efficiency of miRNA-mediated gene regulation. PLoS One. 2008;3(3):e1719. 
121. Della Vittoria Scarpati G, Falcetta F, Carlomagno C, et al. A specific miRNA 
signature correlates with complete pathological response to neoadjuvant 
chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 
2012;83(4):1113-1119. 
122. Balaguer F, Moreira L, Lozano JJ, et al. Colorectal cancers with microsatellite 
instability display unique miRNA profiles. Clin Cancer Res. 2011;17(19):6239-6249. 
123. Guo XB, Jing CQ, Li LP, et al. Down-regulation of miR-622 in gastric cancer 
promotes cellular invasion and tumor metastasis by targeting ING1 gene. World J 
Gastroenterol. 2011;17(14):1895-1902. 
124. Guo LH, Li H, Wang F, Yu J, He JS. The tumor suppressor roles of miR-433 and 
miR-127 in gastric cancer. Int J Mol Sci. 2013;14(7):14171-14184. 
125. Yang Z, Zhang Y, Wang L. A feedback inhibition between miRNA-127 and 
TGFbeta/c-jun cascade in HCC cell migration via MMP13. PLoS One. 
2013;8(6):e65256. 
126. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-
refractory prostate cancer. RNA. 2008;14(3):417-424. 
127. Liu G, Friggeri A, Yang Y, Park YJ, Tsuruta Y, Abraham E. miR-147, a microRNA 
that is induced upon toll-like receptor stimulation, regulates murine macrophage 
inflammatory responses. Proc Natl Acad Sci U S A. 2009;106(37):15819-15824. 
128. Flicek P, Ahmed I, Amode MR, et al. Ensembl 2013. Nucleic Acids Res. 
2013;41(Database issue):D48-55. 
185 
 
129. Bruno T, De Angelis R, De Nicola F, et al. Che-1 affects cell growth by interfering 
with the recruitment of HDAC1 by rb. Cancer Cell. 2002;2(5):387-399. 
130. Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat 
Rev Mol Cell Biol. 2013;14(5):297-306. 
131. Bock AJ, Nymoen DA, Brenne K, Kaern J, Davidson B. SCARA3 mRNA is 
overexpressed in ovarian carcinoma compared with breast carcinoma effusions. Hum 
Pathol. 2012;43(5):669-674. 
132. Comstock C, Knudsen KE. IGF2 revs the steroidogenesis engine. Endocr Relat 
Cancer. 2013. 
133. Belharazem D, Kirchner M, Geissler F, et al. Relaxed imprinting of IGF2 in 
peripheral blood cells of patients with a history of prostate cancer. Endocr Connect. 
2012;1(2):87-94. 
134. Miller GJ, Miller HL, van Bokhoven A, et al. Aberrant HOXC expression 
accompanies the malignant phenotype in human prostate. Cancer Res. 
2003;63(18):5879-5888. 
135. Lindfors K, Halttunen T, Huotari P, et al. Identification of novel transcription factor-
like gene from human intestinal cells. Biochem Biophys Res Commun. 
2000;276(2):660-666. 
136. Di Padova M, Bruno T, De Nicola F, et al. Che-1 arrests human colon carcinoma 
cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter. J Biol Chem. 
2003;278(38):36496-36504. 
137. Burgdorf S, Leister P, Scheidtmann KH. TSG101 interacts with apoptosis-
antagonizing transcription factor and enhances androgen receptor-mediated 
transcription by promoting its monoubiquitination. J Biol Chem. 2004;279(17):17524-
17534. 
138. Fanciulli M, Bruno T, Di Padova M, et al. Identification of a novel partner of RNA 
polymerase II subunit 11, che-1, which interacts with and affects the growth suppression 
function of rb. FASEB J. 2000;14(7):904-912. 
139. Sharma M. Apoptosis-antagonizing transcription factor (AATF) gene silencing: 
Role in induction of apoptosis and down-regulation of estrogen receptor in breast 
cancer cells. Biotechnol Lett. 2013;35(10):1561-1570. 
140. Di Padova M, Bruno T, De Nicola F, et al. Che-1 arrests human colon carcinoma 
cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter. J Biol Chem. 
2003;278(38):36496-36504. 
186 
 
141. Kaul D, Mehrotra A. Functional characterization of AATF transcriptome in human 
leukemic cells. Mol Cell Biochem. 2007;297(1-2):215-220. 
142. Felten A, Brinckmann D, Landsberg G, Scheidtmann KH. Zipper-interacting protein 
kinase is involved in regulation of ubiquitination of the androgen receptor, thereby 
contributing to dynamic transcription complex assembly. Oncogene. 2013;32(41):4981-
4988. 
143. Bruno T, De Nicola F, Iezzi S, et al. Che-1 phosphorylation by ATM/ATR and Chk2 
kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell. 
2006;10(6):473-486. 
144. Spisak S, Kalmar A, Galamb O, et al. Genome-wide screening of genes regulated 
by DNA methylation in colon cancer development. PLoS One. 2012;7(10):e46215. 
145. Zhou J, Wang H, Lu A, et al. A novel gene, NMES1, downregulated in human 
esophageal squamous cell carcinoma. Int J Cancer. 2002;101(4):311-316. 
146. Yuva-Aydemir Y, Simkin A, Gascon E, Gao FB. MicroRNA-9: Functional evolution 
of a conserved small regulatory RNA. RNA Biol. 2011;8(4):557-564. 
147. Delaloy C, Liu L, Lee JA, et al. MicroRNA-9 coordinates proliferation and migration 
of human embryonic stem cell-derived neural progenitors. Cell Stem Cell. 
2010;6(4):323-335. 
148. Sun Z, Han Q, Zhou N, et al. MicroRNA-9 enhances migration and invasion 
through KLF17 in hepatocellular carcinoma. Mol Oncol. 2013;7(5):884-894. 
149. Wang J, Zhao H, Tang D, Wu J, Yao G, Zhang Q. Overexpressions of MicroRNA-9 
and MicroRNA-200c in human breast cancers are associated with lymph node 
metastasis. Cancer Biother Radiopharm. 2013. 
150. Liu M, Zhu H, Yang S, Wang Z, Bai J, Xu N. C-myc suppressed E-cadherin 
through miR-9 at the post-transcriptional level. Cell Biol Int. 2013;37(3):197-202. 
151. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents 
beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J 
Cell Sci. 1999;112 ( Pt 8)(Pt 8):1237-1245. 
152. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-
cadherin promotes metastasis via multiple downstream transcriptional pathways. 
Cancer Res. 2008;68(10):3645-3654. 
153. Huber MA, Azoitei N, Baumann B, et al. NF-kappaB is essential for epithelial-
mesenchymal transition and metastasis in a model of breast cancer progression. J Clin 
Invest. 2004;114(4):569-581. 
187 
 
154. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and 
cancer. Mol Cancer. 2013;12:86-4598-12-86. 
155. Guo LM, Pu Y, Han Z, et al. MicroRNA-9 inhibits ovarian cancer cell growth 
through regulation of NF-kappaB1. FEBS J. 2009;276(19):5537-5546. 
156. Wan HY, Guo LM, Liu T, Liu M, Li X, Tang H. Regulation of the transcription factor 
NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer. 2010;9:16-
4598-9-16. 
157. Krebs DL, Hilton DJ. SOCS proteins: Negative regulators of cytokine signaling. 
Stem Cells. 2001;19(5):378-387. 
158. Babon JJ, Sabo JK, Zhang JG, Nicola NA, Norton RS. The SOCS box encodes a 
hierarchy of affinities for Cullin5: Implications for ubiquitin ligase formation and cytokine 
signalling suppression. J Mol Biol. 2009;387(1):162-174. 
159. Sun C, Li N, Yang Z, et al. miR-9 regulation of BRCA1 and ovarian cancer 
sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst. 2013. 
160. Liu S, Kumar SM, Lu H, et al. MicroRNA-9 up-regulates E-cadherin through 
inhibition of NF-kappaB1-Snail1 pathway in melanoma. J Pathol. 2012;226(1):61-72. 
161. Gao F, Zhao ZL, Zhao WT, et al. miR-9 modulates the expression of interferon-
regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells. 
Biochem Biophys Res Commun. 2013;431(3):610-616. 
162. Lu J, Luo H, Liu X, et al. miR-9 targets CXCR4 and functions as a potential tumor 
suppressor in nasopharyngeal carcinoma. Carcinogenesis. 2013. 
163. Jin Z, Zhao C, Han X, Han Y. Wnt5a promotes ewing sarcoma cell migration 
through upregulating CXCR4 expression. BMC Cancer. 2012;12:480-2407-12-480. 
164. Yu T, Liu K, Wu Y, et al. MicroRNA-9 inhibits the proliferation of oral squamous cell 
carcinoma cells by suppressing expression of CXCR4 via the wnt/beta-catenin signaling 
pathway. Oncogene. 2013. 
165. Zhuang G, Wu X, Jiang Z, et al. Tumour-secreted miR-9 promotes endothelial cell 
migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 
2012;31(17):3513-3523. 
166. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. 
Clin Chem. 2010;56(11):1733-1741. 
167. Courts C, Madea B. Specific micro-RNA signatures for the detection of saliva and 
blood in forensic body-fluid identification. J Forensic Sci. 2011;56(6):1464-1470. 
188 
 
168. Wang C, Yang C, Chen X, et al. Altered profile of seminal plasma microRNAs in 
the molecular diagnosis of male infertility. Clin Chem. 2011;57(12):1722-1731. 
169. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA 
as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder 
cancer. Urol Oncol. 2010;28(6):655-661. 
170. Gidlof O, Andersson P, van der Pals J, Gotberg M, Erlinge D. Cardiospecific 
microRNA plasma levels correlate with troponin and cardiac function in patients with ST 
elevation myocardial infarction, are selectively dependent on renal elimination, and can 
be detected in urine samples. Cardiology. 2011;118(4):217-226. 
171. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and 
microRNA-protective protein by mammalian cells. Nucleic Acids Res. 
2010;38(20):7248-7259. 
172. Hanson EK, Lubenow H, Ballantyne J. Identification of forensically relevant body 
fluids using a panel of differentially expressed microRNAs. Anal Biochem. 
2009;387(2):303-314. 
173. Zubakov D, Boersma AW, Choi Y, van Kuijk PF, Wiemer EA, Kayser M. MicroRNA 
markers for forensic body fluid identification obtained from microarray screening and 
quantitative RT-PCR confirmation. Int J Legal Med. 2010;124(3):217-226. 
174. Wang Z, Luo H, Pan X, Liao M, Hou Y. A model for data analysis of microRNA 
expression in forensic body fluid identification. Forensic Sci Int Genet. 2012;6(3):419-
423. 
175. Hanson EK, Ballantyne J. Circulating microRNA for the identification of forensically 
relevant body fluids. Methods Mol Biol. 2013;1024:221-234. 
176. Omelia EJ, Uchimoto ML, Williams G. Quantitative PCR analysis of blood- and 
saliva-specific microRNA markers following solid-phase DNA extraction. Anal Biochem. 
2013;435(2):120-122. 
177. van der Meer D, Uchimoto ML, Williams G. Simultaneous analysis of micro-RNA 
and DNA for determining the body fluid origin of DNA profiles. J Forensic Sci. 
2013;58(4):967-971. 
178. Setzer M, Juusola J, Ballantyne J. Recovery and stability of RNA in vaginal swabs 
and blood, semen, and saliva stains. J Forensic Sci. 2008;53(2):296-305. 
179. Kladwang W, Hum J, Das R. Ultraviolet shadowing of RNA can cause significant 
chemical damage in seconds. Sci Rep. 2012;2:517. 
189 
 
180. Linossi EM, Chandrashekaran IR, Kolesnik TB, et al. Suppressor of cytokine 
signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with 
the adaptor protein shc-1. PLoS One. 2013;8(8):e70536. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
190 
 
 
 
APPENDIX 1: Expression Analysis of modulated microRNAs 
Table 1:  Average CT values of miR RT-qPCR selected for further analysis in 
prostate cell lines.  Further processing included normalization of all CT values using 
RNU48, which reached the cycle threshold consistently around 19-20 in the RNA of all 
cell lines tested.  Each value is the average of a minimum of one biological replicate 
with technical triplicates.  Undet = undetected to 40 amplification cycles.  *For the miR-
299-5p M12 evaluation, RNU48 had an atypical amplification plot (CT of ~24). 
cell line 133a 133b 9 622 146a 
199a-
3p 147b 488 
P69 36.217 34.750 37.587 34.667 32.780 34.177 35.560 35.997 
WPM1 undet 36.093 33.270 35.567 --- --- 33.365 undet 
BPH-04 35.605 31.603 --- --- --- --- --- undet 
M2182 undet 34.823 34.670 34.430 27.200 33.640 33.977 undet 
M12 34.110 32.053 30.777 36.577 38.860 34.070 31.977 undet 
F6 undet 34.703 35.770 36.990 36.625 32.845 33.010 undet 
DU145 --- 32.397 25.647 36.320 --- --- 30.967 undet 
PC3 37.430 33.910 27.210 34.370 --- --- 27.960 undet 
LnCaP-L --- --- --- --- --- --- --- 29.580 
LnCaP-C4 --- --- --- --- --- --- --- 30.960 
LnCaP-C4-2 undet --- --- --- --- --- --- 29.485 
LnCaP-P4 --- --- --- --- --- --- --- 32.785 
 
cell line 
299-
3p 221 127-5p 127-3p 299-5p 147 144 
P69 34.670 21.210 33.800 27.960 31.877 36.650 undet 
WPM1 34.460 --- --- --- 26.327 --- --- 
BPH-04 --- --- --- --- --- --- --- 
M2182 36.747 --- 37.390 36.880 34.990 35.830 37.563 
M12 undet 21.453 undet undet 34.375* undet undet 
F6 undet 25.047 undet 35.500 35.625 37.695 34.885 
DU145 undet --- --- --- undet --- --- 
PC3 undet --- --- --- 34.190 --- --- 
LnCaP-L --- --- --- --- --- --- --- 
LnCaP-C4 --- --- --- --- --- --- --- 
LnCaP-C4-2 --- --- --- --- --- --- --- 
LnCaP-P4 --- --- --- --- --- --- --- 
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Table 2:  miR expression of all cell lines analyzed.  miR-levels were normalized to 
RNU48 (dCT).  ---: not tested 
cell line 133a 133b 9 622 146a 199a-3p 147b 488 
P69 17.04 13.73 16.57 15.51 13.63 15.02 16.41 16.82 
WPM1 21.14 15.92 12.79 15.08 --- --- 12.88 21.14 
BPH-04 16.42 11.78 --- --- --- --- --- 20.82 
M2182 20.41 14.70 15.24 15.00 7.77 14.21 14.54 20.41 
M12 11.99 12.41 11.13 16.93 19.21 14.42 12.33 21.52 
F6 21.03 14.30 15.53 16.75 16.38 12.60 12.77 21.03 
DU145 --- 13.71 5.23 15.90 --- --- 10.55 20.86 
PC3 16.32 13.36 5.99 13.15 --- --- 6.74 18.89 
LnCaP-L --- --- --- --- --- --- --- 11.02 
LnCaP-C4 20.86 --- --- --- --- --- --- 11.82 
LnCaP-C4-2 21.77 --- --- --- --- --- --- 11.26 
LnCaP-P4 --- --- --- --- --- --- --- 13.45 
         
cell line 
299-
3p 221 127-5p 127-3p 299-5p 147 144  
P69 15.52 2.03 14.30 8.46 12.38 17.50 20.50  
WPM1 13.98 --- --- --- 5.84 --- ---  
BPH-04 --- --- --- --- --- --- ---  
M2182 17.31 --- 17.96 17.45 15.56 16.40 18.13  
M12 20.35 1.64 16.92 16.92 --- 20.35 15.96  
F6 19.76 6.07 19.76 15.26 15.32 17.45 14.64  
DU145 19.58 --- --- --- 19.58 --- ---  
PC3 18.78 --- --- --- 12.97 --- ---  
LnCaP-L --- --- --- --- --- --- ---  
LnCaP-C4 --- --- --- --- --- --- ---  
LnCaP-C4-2 --- --- --- --- --- --- ---  
LnCaP-P4 --- --- --- --- --- --- ---  
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Table 3:  Relative miR expression of laser-captured microdissected tissues from 5 
patients.  miR-levels were normalized to RNU48, and expression level calculated 
relative to the benign tissue of the same patient.  Undet = both benign and the tissue 
were undetected to 40 amplification cycles.  Red shading indicates that the miR in 
question was undetected in the benign sample to 40 cycles, and green indicates that 
miR in question was undetected in the tissue type being tested.  miR-133b was not 
examined due to inconsistent readings in the cell line analysis. 
Patient Notes on sample 9 144 221 488 299-3p 299-5p 199a-3p 
7     Tumour 2.622 nt 0.245 Undet. Undet. 3.726 nt 
09-225   G4+/G6 Tumour Undet. Undet. 0.4454 Undet. 0.4070 Undet. 0.4983 
09-362   G3/G4 
Tumour 0.295 Undet. 3.031 Undet. Undet. Undet. 0.578 
Stroma 0.551 Undet. 26.446 Undet. Undet. Undet. 25.194 
Lymph 0.547 34.416 9.514 Undet. Undet. Undet. 0.809 
10-014-
V002   
  
Tumour 78.339 Undet. 1.939 Undet. Undet. 22.445 nt 
Stroma nt nt 6.119 nt nt nt nt 
Lymph nt Undet. 1.063 nt nt nt nt 
10-036-
V001 
early 
stage 
Tumour 3.873 Undet. 0.364 nt 0.833 Undet. nt 
Venous Undet. 214.277 nt nt nt nt nt 
          
          
Patient Notes on sample 622 127-3p 127-5p 133a 146a 147b 147 
7     Tumour 0.341 0.477 0.009 0.585 nt 0.416 nt 
09-225   G4+/G6 Tumour 0.1504 0.2803 0.5430 0.8878 0.4132 4.6000 nt 
09-362   G3/G4 
Tumour 6.521 2.868 1.000 5.816 Undet. 3.482 Undet. 
Stroma 1.167 0.288 1.000 40.317 Undet. Undet. Undet. 
Lymph 1.320 0.186 1.000 0.658 Undet. Undet. Undet. 
10-014-
V002   
  
Tumour 1.495 2.845 0.017 2.959 nt 16.507 nt 
Stroma nt 2.809 nt 4.713 nt nt nt 
Lymph nt nt nt nt nt nt nt 
10-036-
V001 
early 
stage 
Tumour 2.621 0.331 Undet. 1.067 nt 19.973 nt 
Venous nt 1.382 Undet. 2.508 nt Undet. nt 
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